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FIBRINOGEN 
Fibrinogen is a soluble plasma glycoprotein that, under normal circumstances, is 
present in human plasma at a concentration of 2-4 mg/ml (6-12 I'M). The plasma 
half-life is 3-4 days in humans and about 10-25 % of the total body fibrinogen is 
extravascularl. Fibrinogen is composed of two sets of three polypeptide chains (AOI, 
86 . and 'Y) that are interconnected by disulphide bridges (figure I). The 
aminoterminal segments of all six chains form a central domain from which the AOI 
and 86 chains protrude'. These aminotermini are the target of thrombin and small 
peptides (FPA and FP8) can be cleaved off. 
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Figure 1. Mouel of the human fibrinogen molecule showing structural characteristicsl 
Three main molecular forms of fibrinogen have been identified in plasma"'. 
Fibrinogen is assumed to be synthesized in the high molecular weight form 
(HMW)iO, with two intact carboxyl ends of the OI-chain. In plasma two groups of 
degraded forms of fibrinogen can be distinguished. One group has one degraded AOI-
chain carboxyl end and is called the low molecular weight (LMW) form, in the other 
form both AOI-chains are degraded and this is called the LMW' form. In a normal, 
average plasma 70% of fibrinogen is HMW, 26% is LMW and only 4% is LMW'. 
The LMW and LMW' forms are heterogenous due to different lengths of their 
residual AOI-chain. The enzymes responsible for the degradation have not yet been 
identifiedll. ll . Recently, it has also been described that ± 3% of the natural 
occurring fibrinogen molecules have a globular C-termin31 extension on both 
carboxy terminal ends which shares C-terminal homology with the 6 and 'Y chains. 
The molecular weight of the fibrinogen molecules with the extended 01 chains is 
12 intrndul'Iion 
420.000". The extended A,,-chains of this fibrinogen are more resistant to 
degradation than the normal forms. 
The main function of fibrinogen IS In the clotting process. After thrombin has 
cleaved off the fibrinopeptides A from the N-terminal end of the A,,-chain the 
molecule changes its conformation and, via intermediate stages, polymerizes into an 
insoluble fibrin network. Somewhat delayed, the fibrinopeptides B are also cleaved 
off the BB-chain, initiating the lateral polymerization of the fibrin fibres. This fibrin 
network is normally constmcted of fibres that are about one {till in diameter, which 
means a width of several hundred molecules. Approximately 80% of the blood clot 
volume consists of solvent and the relative mass of' fibrin in the clot is not more than 
0.3%. The remainder includes blood elements like platelets and red and white blood 
cells. 
A HIGH PLASMA FIBRINOGEN LEVEL - AN INDEPENDENT RISK 
INDICATOR FOR CARDIOVASCULAR EVENTS 
Only about 30% of all cardiovascular events can be predicted by the established risk 
factors like hypercholesterolemia, smoking, overweight, diabetes, age, gender and 
hypertension i4 , This suggests the existence of more risk factors. In recent years the 
relation between plasma fibrinogen levels and cardiovascular risk has been evaluated 
in a number of epidemiological studies. 
The Northwick Park Heart Study was the first large-scale prospective longitudinal 
study that described the association between plasma fibrinogen levels and the risk for 
cardiac events lS • An increase of the plasma fibrinogen with one standard deviation of 
the mean (about 15%) gave almost a doubling of the risk for cardiac events in the 
next five years. After 10 years follow-up, approximately half of the coronary events 
had occurred in the upper terti Ie of the plasma fibrinogen levels. The prognostic 
value of fibrinogen is at least equal and probably greater than that of cholesterol 
(figure 2). 
The association between the plasma level and cardiac events has since then been 
confirmed in a number of other studies, including the Gothenburg/fl, the 
Framingham", Leigh", PROCAM'9, Scottish Heart Health"', Caerphilly-
Speedwell"''', the GRIPS" and the ECAT-Angina pectoris'" studies (table I). 
Elevated pJasma fibrinogen levels have also been associated with an increased risk of 
myocardial infarction in patients with unstable angina25 and in patients that had 
experienced a stroke26 or a previous infarction27.28, Even though these studies 
differed in design and procedures they all identified fibrinogen as an independent 
risk indicator. The predictive value of elevated plasma tibrinogcn levels for the 
incidence of fatal and nonfatal myocardial infarctions and cerebrovascular events 
were independent of the prevalence and distribution of other, established 
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Figure 2. Relation hetween plasma fibrinogen and cholesterol levels and the incidence of cardiac 
events (in the 5 year follow up period) in the Northwick Park Heart Studyl~ 
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Figure 3. Relation hetween incidem:e of coronary events (events per 1000 patient years in Leigh 
SIU(Jy and events in 6 years/lPOO in the PROCAM Study) and plasma levels of fihrinogen and 
cholesterol in the Leigh Studyl8 and the PROCAM Sluclyl9 
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cardiovascular risk factors. 
Interactions between high plasma fibrinogen levels and other risk factors 
are repeatedly observed. In the PROCAM and the Leigh study it was shown that 
individuals with both high fibrinogen and high cholesterol had the highest cardiac 
risk, which was more than additive (figure 3), similar to individuals with high 
fibrinogen and high blood pressure (figure 4). Also, several gender differences were 
observed in the Framingham and the ECAT-angina pectoris studies which examined 
both men and women. For example, in the Framingham Study, it was shown that the 
magnitude of the fibrinogen-mediated risk in women declined with age. Also, in 
women elevated fibrinogen levels were not associated with risk of stroke17 , figure 5). 
EFFECTS OF INCREASED PLASMA FIBRINOGEN LEVELS THAT MAKE 
A DillECT RELATION WITH CORONARY ARTERY DISEASE PLAUSIBLE 
It has been established in several epidemiological studies that elevated plasma 
fibrinogen levels represent an increased risk for the development of cardiovascular 
incidents (table I). Even though the background of this relation has not yet been 
elucidated it is plausible that increased fibrinogen levels can give a causal 
contribution to cardiovascular disease: a) fibrinogen influences the formation and 
growth of the arteriosclerotic lesion29 , b) fibrinogen is the principal component of 
gelatinous and fibrous pJaques30, c) there is interaction between many cell types and 
fibrinogen: the proliferation30 and migrationJI of smooth muscle cells is stimulated by 
fragments of fibrinogen, d) fibrinogen is an important promoter of the aggregation 
of activated plateletsreview: 32, e) it also interacts with endothelial ceJlsJ3.3~, rnonocylesJ~ 
and macrophages36,31, 1) as part of the extracellular matrix fibrinogen is also involved 
in tumor growth, although not for melastases i , 
A direct contribution of fibrinogen to risk might also be through the plasma 
viscosity, which is mainly determined by the plasma fibrinogen level.l~, An increased 
plasma viscosity can induce microcirculatory disorders, like reduced oxygen release, 
in poststenotic vascular segments39 , 
Relation between plasma fibrinogen levels and the severity of vascular disease 
The relation between plasma fibrinogen levels and vascular thrombotic events is 
further strengthened by the correlations between plasma fibrinogen levels and the 
degree of coronary artery disease29.4{4.4 and peripheral arterial disease45 , 
Table L Prospective epidemiological investigations. 
Study sample size mean age length of method endpoint number of 
(range) follow up events 
(years) 
NPHS" 1511 white men 52 10.0 gravimetric (I) IHD death (1) 68 
(40-64) (2). non-fatal 
,"'" 
(2) 60 
Gothenburg" 792 men all 54 13.5 spectra- (1) MI (1) 92 
photometric (2) stroke (2) 38 
Leigh1S 297 men 52 7.3 nephelometric MI 40 
(40-69) 
Framingham l ? 554 men >55 12 spectro- (1) IHD (1) 312 
761 women 47-79 photometric (2) stroke (2) 92 
Caerphilly/Speedwell" 4860 men (45-49) 5.1/3.2 nephelometric IHD 251 
(2 cohorts) Clauss 
PROCAM 19 2116 men 48 6 Clauss MI 82 
(40-65) 
GRIPS" 5239 men (40-60) 5 Clauss MI 107 
ECAT-angina pectoris2-l 2587 men 56 2 Clauss coronary 106 
456 women events 
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Figure 4. Relation between incidence of coronary events (incidence/lOOO patient years), plasma 
fibrinogen levels alld systolic blood pressure ill the Goteborg Study16 
MEASUREMENT OF PLASMA FlllRINOGEN LEVELS 
The measurement of fibrinogen levels can be based on several different 
principles"''', The first group is formed by the clotting rate assays, that give a 
functional fibrinogen JeveI48-SO • -The second group of assays measures the amount of 
protein that can be clotted with thrombin~", The third group are the methods based 
on heat- and salt precipitation of fibrinogen", Finally, there are the immunological 
methods!i6.57, in which the interest has grown since the introduction of specific 
monoclonal antibodies that will make it possible to assay specific fractions of 
fibrinogenS8 • 
In studies where the different fibrinogen assays are compared, the agreements 
between the methods were acceplable"''', However, because of the different 
characteristics of the assays it is expected that the different assays are not equally 
valuable for the use of fibrinogen as a risk indicator. This needs further attention in 
the future and has not been addressed systematically, 
VARIATIONS IN PLASMA FlllRINOGEN LEVELS 
physiological variation 
The plasma levels of fibrinogen are related to several environmental, life-style and 
physiological factors (table 2), Smoking"''', age"''', gender"'1O, body weight7l , 
race72 , stress71 ,7l,15, social class7J,74,76, alcohol intake, season77,78. exercise79 • 
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pregnancy80, contraceplives7o,81,~2, and menopause70 have repeatedly been shown to 
affect the fibrinogen levelsovervkw: 69,83,M, 
acute phase reaction 
A part of the human defence system against tissue injury or infection is a change in 
the synthesis rate and possibly also the clearing rate of a group of proteins, named 
the acute phase proteins. Plasma fibrinogen levels can increase two to threefold as 
the consequence of an acute phase reaction, C~reactive protein can increase more 
than thousandfold". Albumin and transferrin are two negative acute phase proteins, 
whose synthesis is decreased by the acute phase reaction. These acute phase induced 
changes in the synthesis rate are mainly the result of increased concentrations of 
circulating interleukin-6, interleukin In and tUlllour necrosis factor a~6,~7, 
Atherosclerosis has been suggested to be an inflammatory process of the vascular 
wall". Because fibrinogen is an acute phase protein the high plasma fibrinogen 
levels are suggested to be a reflection of vascular damage. This theory of 
inflammation as a mechanism in coronary heart disease is also indicated by the 
resuits of the ECAT Angina Pectoris study where both fibrinogen and C-reactive 
protein were risk indicators for a cardiac event within two years in patients with 
angina pectoris, Fibrinogen and C-reactive protein were strongly correlated to each 
other in this study, which strengthens the role of the acute phase reaction. In the 
Framingham Study an association has been described between cardiovascular risk 
and white blood cell count which also suggests a role of the inflammatory process89 , 
genetic predisposition 
The genetic contribution to the plasma level of fibrinogen is calculated to be between 
20%90,91 and 50%92. It is now becoming clear that an individual's response to 
environmental changes is also partly determined by genetic variation9H.9.',9.$; it has 
already been indicated that the increases in fibrinogen levels by smoking is 
associated with the genetic genotype95.96. 
chl'onie disease related increase 
It has already been mentioned above that plasma fibrinogen levels are increased in 
patients with vascular disease. Also in hyperlipidaemic patients increased plasma 
fibrinogen levels are observed97•98 • After surgery or as a result of other traumatic 
events the fibrinogen levels increase, probably as a result of an acute phase reaction. 
FIBRINOGEN DECREASE BY DRUGS 
Several drugs have been reported to reduce plasma fibrinogen levels, in adpition to 
their main activityr,,'kw: 100. Fibric acid derivatives and ticlopidine are two examples 
of sllch drugs which have been studied. 
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Fibrates 
In patients with high blood lipid levels an increased plasma librinogen level has been 
repeatedly observed",", When these patients were treated with the lipid lowering 
fibrates9I ,99.I08, the fibrinogen levels decreased to normal levels. Fibrates are a class 
of hypolipidemic compounds that effectively reduce plasma triglyceride and 
cholesterol levels and in many instances increase plasma high density lipoprotein 
levelsQwrview: 109, There are several mechanisms responsible for the lowering of 
cholesterol and triglycerides, among which an inhibition of liver acetyl eoA 
carboxylase, the rate limiting enzyme in the synthesis of fatty acids, and an increase 
of the activity of lipoprotein lipase, which promotes the catabolism of plasma 
triglyceridesIlO , Other lipid lowering drugs, the vastatins, have not been shown to be 
eff""tive in lowering the fibrinogen leveJl'", This suggests that the librinogen 
lowering is not directly coupled to the lipid lowering effect. By what mechanism 
fibrinogen is lowered by the fibrates needs to be further studied and the role of the 
acute phase mechanism or genetic factors need to be investigated, 
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Table 2. Variations in fibrinogen synthesis 
physiological effect on the plasma fibrinogen level 
factor 
age + 3 to + 10% I 10 years18,24,M,65,67-70,135,1J6 
+ 3 to + 5% / 10 years in non-smokers70,I3S 
+ 8 to + 15% / 10 years in smokers7o,1l5 
smoking no effect to + 33% in smokersM,68-70,1J5,1J7,139 
no effect in age < 35 years70,135 
8% to + 14% in smoking menM.69,m 
3% to + 7% in smoking womenM,69,1J7 
dose dependent relation with sigarettes/day"""'?u 
alcohol - 0,8% with 109/day alcohol'" 
- 6% in men with < 20 g/day alcohol137 
- 3% in women with <20g/dayalcoholl37 
body mass + 14 % in highest tertile" 
+ 0,17% / (kg/m2)135 
+ 12 % in highest tertile in men IJ9 
+ 20% in highest tertile in women IJ9 
gender + 3% to +20% in women6S,135,137' 
no effect in _non-smoking women61.\35 
+ 20% in smoking women135 
race - 16% in Japanese men compared to Caucasian72 
+ 5% in black men, compared to white44 .91 
+ 7% and +9% in black women, compared to white42 ,91 
stress + 1.3%135 and + 15%74 with higher working stress 
+ 8% after stress test" 
season + 5% to + 38% in the cold months compared to the warm77 ,78 
contraceptives no effect68,1J8, _2%70 and + 7%69 in pill users 
physical exercise no effect to -13 % 79,139 
menopause 
no effect in pers~ns < 30 years 
no effect of menopause69 
+ 5%96 and + 10%70 in postmenopausal women without 
hormone replacement therapy70 
19 
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Ticlopidille 
Another dnlg that has been shown to decrease the fibrinogen levels is the platelet 
aggregation inhibitor ticlopidine. This drug strongly inhibits the ADP-induced 
aggregation of blood platelets I 11·114 , The plasma fibrinogen levels were increased in 
patients with vascular diseases, and they could be normalized with ticlopidine ll .'i.11o, 
O'o'cr,'iew 111, This effect might be associated with recovery of the disease since in 
patients with intermittent claudication the walking distance improved. 
No mechanism has yet been identified, but it might be possible that recovery of 
the disease is accompanied by a reduction of the acute phase reaction. Another 
possible mechanism is a reduction of the level of fibrin(ogen) degradation products 
as the result of the inhibition of platelet aggregation. Since fibrin(ogen) degradation 
products are known as stimulants of the fibrinogen synthesis in the liverl11 , a 
reduction of their levels may resuli in a decrease of the fibrinogen synthesis. Until 
now, it has only been recognized that there is an effect of ticlopidine on fibrinogen 
levels in patients with vascular diseases, but there have not been studies investigating 
the mechanism. 
GENETIC CONTRIBUTION TO FIBRINOGEN LEVELS 
The three chains of fibrinogen are encoded by different genes, which are located 
adjacent to each other on the long arm of chromosome 4122,12.1, The genes for the ex 
and 'Y chain are directed in the same direction and are transcribed toward the 13 gene. 
The n gene is transcribed in the opposite direction (figure 6). The complete genomic 
DNA sequence for all three genes has been elucidated"'-"'. 
Several restriction fragment length polymorphisms (RFLP) in the genes for the 
three chains of fibrinogen have been described (figure 6)9U,127.13l1, Fowkes et al 
reported a higher frequency of the rare allele of the Bel! RFLP of the BB chain in 
patients with peripheral arterial disease"'. The RFLP of the B-fibrinogen gene are 
associated with the plasma fibrinogen levels in a number of studies'ill,9,U.l(!,m. but not 
in aIl96,131,133. No significant associations were found between plasma fibrinogen 
levels and RFLP of the c< and 'Y chains. In the Caucasian populations that have been 
studied until now, a strong linkage disequilibrium between the polymorphism' of the 
6 and ex chain has been observedl17 ,129.JJ2, 
Interaction between environmental factors and the effect of genetic variation is 
observed in determining differences in biochemical and physical characteristics in 
heallhy individuals"'''. DNA polymorphisms might also predispose to clinical 
disorders, like cardiovascular disease since the genetic-environmental interactions 
may calise some individuals to show large fluctuations while others in the same 
environment show small fluctuations. The identification of these genetic-
environmental interactions might be important in identifying individuals that are 
prone to develop high plasma levels, and therefore a higher thrombotic risk, afler a 
relatively small slimulus. 
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Figure 6. Structure of the genes for the Aa, DO and 'Y-chains of fibrinogen with tJle locations of the 
restriction fragment length polymorphisDlS. 
AIM OF THIS THESIS 
Several epidemiological studies have identified elevated plasma fibrinogen levels as a 
risk indicator for cardiac events and this thesis concerns studies on the background 
of this relation. 
Measurement of fibrinogen (Chapters 1-3) 
Of primary importance when studying risk indicators in epidemiological or clinical 
studies are the characterization and standardization of the assays that are used. For 
fibrinogen, there now is a plasma standard available, but standardization of the assay 
method has not yet had much attention. One factor that will influence the fibrinogen 
assays is the large number of different molecular forms of fibrinogen normally found 
in the circulation. Our aim in the first part of this thesis was to evaluate the effect of 
variation in fibrinogen forms on the different assays. 
The acute phase reaction and fibrinogen (Chapters 5-10) 
The acute phase reaction is known to be a main mechanism for elevation of 
fibrinogen levels in blood. Major injury can result in 2-3 fold increases of fibrinogen 
levels. A low to moderate grade of an acute phase reaction is a candidate mechanism 
of elevating fibrinogen also for prolonged periods, and may for instance be a 
reflection of the inflammatory state of the vascular wall. The acute phase reaction 
may also be (part 01) the mechanism by which fibrinogen is influenced by smoking 
or by medication (e.g. vitamin E, fibrates and ticlopidine). 
The aim of this part of the study was to estimate the role of the low grade acute 
phase reaction in the regulation of fibrinogen levels by evaluation in cross-sectional 
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and intervention studies the association of fibrinogen with the well-known acute 
phase protein, C-reactive protein. 
Modification of plasma fibt'inogen levels by medication (Chaptet's 7-10) 
Plasma fibrinogen levels are known to be modified by medication, for instance by 
fish oil plus vitamin E, fibrates and ticlopidine. However, the mechanism of it has 
not yet had much attention. Therefore, the aim of this part of the study was to 
elucidate the mechanism of fibrinogen lowering by medication: 
I) to elucidate the contribution of the low grade acute phase reaction to fibrinogen 
lowering by medication 
2) to study the association between the effects of medication on fibrinogen and 
fibrin(ogen) degradation products known to be involved in regulation of tibrinogen 
synthesis. 
3) to study the contribution of genetic heterogeneity of fibrinogen to tibrinogen 
lowering by medication in order to determine whether it is possible to identify a 
group of patients that will benefit more from tibrinogen lowering therapy. 
Genetic polymorphisms and fibl'inogen (Chapters 6,8,11,12) 
There is a difference in risk for cardiac events among individuals. This difference is 
partly genetic and might involve polymorphisms in the fibrinogen genes. These 
polymorphisms are associated with differences in the regulation of the tibrinogen 
levels. In this part of the thesis we studied whether the relation between 
polymorphisms and plasma levels of tibrinogen is different in groups of individuals 
with a different risk for an acute myocardial infarction, e.g. men and women, Inuit 
and Caucasians, patients with symptomatic coronary heart disease and healthy 
volunteers. 
There is also a difference in the allelic frequencies of these polymorphisms in 
patients with peripheral arterial disease with an increase in the frequency of the rare 
allele that codes for higher tibrinogen levels in healthy individuals. We hypothesized 
that this might more generally be the case in vascular disease. This hypothesis was 
studied in groups with different risk of cardiac events, namely in Caucasians and 
Inuit, and in patients with symptomatic coronary hearl disease and healthy 
volunteers. 
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INTRODUCTION 
Fibrinogen is a soluble plasma glycoprotein that is present in normal human plasma 
at a concentration of 2-4 giL. In pathological states it can fluctuate from 
approximately 0 to above 10 giL. It is composed of two pairs of three polypeptide 
chains (AOI, Bi3 and ')') that are interconnected by disulphide bridges. The 
aminoterminal segments of the six chains form a central domain from which the 
fibrinopeptides A and B protrude'. During clotting thrombin cleaves off the 
fibrinopeptides A from the AOI chains which leads to a conformational change of the 
molecule and, via intermediate stages, eventually leads to polymerisation into the 
insoluble fibrin fibres. Somewhat delayed also the fibrinopeptides B from the Bi3-
chain are cleaved off, which initiates the lateral polymerization of the fibrin fibres. 
The fibrin network is normally constructed of fibres that are about one I'm in 
diameter, corresponding to a width of several hundred molecules. Only 0.3% of the 
mass of a blood clot is made up of fibrin, about 80% of the volume is liquid and the 
remainder includes blood elements like platelets and red and white blood cells. 
Fibrinogen concentrations are subject to considerable biological variation. 
Fibrinogen is one of the major acute phase reactant proteins, and increased hepatic 
synthesis occurs as a physiological response to inflammation and tissue necrosis2• 
Altered protein catabolism due to intravascular consumption may also influence 
circulating plasma concentrations. The plasma fibrinogen. concentration rises 5-7% 
per ten years of ageH , and a gender difference is described in both young and old 
groups3,j. Fibrinogen levels are also correlated with smokingOwr,kw: 7, body weight4.6 
and degree of coronary stenosis6,g.12. In women, the fibrinogen levels rise after the 
menopause. The effects of hormone replacement therapy are inconsistentlJ • The 
plasma fibrinogen level is increased in users of combined oral contraceptives l4 and 
during pregnancy". 
At least three molecular forms of fibrinogen have been identitied in plasmaI6-23 • 
Fibrinogen is synthesized in the high molecular weight form (HMW), with two 
intact carboxyl ends of the OI-chain. In plasma two groups of degraded forms of 
fibrinogen can be distinguished. One group has one degraded A,,-chain carboxyl 
end and is called the low molecular weight (LMW) form, in the other form both 
A,,-chains are degraded and this is called the LMW' form. In a normal, average 
plasma 70% of fibrinogen is HMW, 26% is LMW and only 4% is LMW'. The 
LMW and LMW' forms are heterogenous due to the different length of their 
constituent Aa-chain. The enzymes responsible for the degradation have not yet been 
identified". 
There are indications of a pathological significance of the occurrence of relatively 
high levels of HMW fibrinogen. Treatment of patients with acute myocardial 
infarction (AMI) with streptokinase results in a radical consumption of their 
fibrinogen. Fibrinogen is then newly synthesized in the HMW form" which has an 
increased clotting capacity. This procoagulant tendency might explain the 
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observation that in patients with the highest H/VlW-fibrinogen levels more 
reinfarctions are observed. For the management of AMI patients it is therefore 
advisable to measure fibrinogen levels with a method that is more sensitive to HMW 
fibrinogen than to the other fibrinogen forms, because such an assay may give the 
best estimation of the thrombotic risk. Promising methods for this purpose are in 
development and will be discussed. A prethrombotic state due to increased HMW-
fibrinogen also rapidly develops after hip surgery; after MI not treated with 
streptokinase; or after any major trauma, where much HMW-fihrinogen is 
synthesized while the LMW only increases much later". 
Usually plasma fibrinogen levels are measured in the management of consumptive 
coagulopathies. During the last decade fibrinogen levels have been studied in other 
diseases. An association between fibrinogen levels and the severity of atherosclerosis 
has been repeatedly observed'·"·27. Also, the results of the Northwick Park Heart 
Study18 and several other studies in healthy populations6.19 .. ,.~ have shown that 
elevated plasma fibrinogen levels are associated with an increased risk for ischaemic 
heart disease (IHD). Although methods for fibrinogen quantification differ from 
study to study, a significant association between plasma fibrinogen levels and risk 
for cardiac events was found in all of them. 
There are several different principles on which the measurement of tibrinogen can 
be based36.37 • First, there are the clotting rate assays, that give a functional 
fibrinogen level. The second group of assays measure the amount of protein that can 
be clotted with thrombin. Furthermore, there are the methods based on heat- and salt 
precipitation of fibrinogen. Finally there are the immunological methods for which 
there is growing interest since the introduction of specitie monoclonal antibodies. 
Each of these methods will be susceptible in its own way to sources of variation. 
The expression of the three forms of fibrinogen mentioned above is likely to be 
different in clotting assays, because the thrombin clotting times of the three 
fibrinogen forms differ I8 ,2[,22.H. The different fibrinogen forms also produce clots 
with a different fibre structure38 , which might influence methods where the end point 
depends on the clot structure (Ellis and Stransky, Prothrombin Time-derived 
(discussed later». In this paper, we will foclls on the currently used methods to 
determine fibrinogen, and on the methodological aspects including specificity, 
sensitivity, interfering substances and calibration, 
CLOTTING RATE BASED ASSAYS 
The assays that are most often used in a routine laboratory are based 011 measuring 
the time it takes to clot plasma after the addition of excess thrombinJ9 , The 
concentration of fibrinogen is expressed as a function of the clotting time. By 
applying different dilutions of the plasma, it is possible to measure librinogen levels 
between 0.5 and 10 giL. It is also possible to use snake venom (Arvin) or reptilase 
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in clotting rate assays instead of thrombin. The latter enzymes function more 
specifically than thrombin because they will only split off the fibrinopeptide A". 
It has to be remembered that this method yields a functional fibrinogen level, and 
not an absolute concentration of fibrinogen. As will be discussed below, the 
fibrinogen levels found with this method are influenced by forms of fibrinogen that 
have an altered fibrinogen clotting rate. 
An additional point of importance is that the effect of certain factors (such as the 
degradation products of fibrin and fibrinogen (FDP); heparin) on the clotting rate 
assays may be different from the effect they have on the clotting rate in vivo. 
Factors Influencing the Clotting Time 
Fibrin degradation products (FDP) have a strong anticoagulant effect and affect the 
polymerisation times of fibrinogen solutions. This effect is l~loSt pronounced for 
fragments X and y'l, but fragment D also has anticlotting properties". Increased 
FDP levels are therefore expected to delay clotting in clotting rate, based assays ,and 
as a consequence yield spuriously low tlbrinogen levels. However, no effect of FDP 
« 190 J4g/mL) on the Clauss assay was found in samples containing normal 
fibrinogen levels. Only in samples with fibrinogen levels below I giL did the high 
FDP levels interfere"''''. This might be explained by a difference in the type of FDP 
in that situationH .46. Increased fibrin monomer levels in the patient are expected to 
cause spuriously high levels th~ough reduction of the cl?tting time. 
Also, an alteration in the distribution of the three tlbrinogen forms (HMW, LMW 
and LMW') in plasma may affect the Clauss assay. The LMW and LMW' forms 
have a prolonged thrombin clotting time I6 .1\1.22 and therefore changes in the ratio of 
the three fibrinogen forms will affect the thrombin clotting time and result in 
different values without differences in molar concentrations. The time required for 
the transformation from HMW- and LMW-fibrinogen to tlbrin by thrombin is 
similar, but the rate of polymerization is reduced for LMW compared to HMW and 
is even lower for LMW'. Also, the different heights of the polymerization curves 
indicate different fibril length and thickness. Clots from HMW tlbrin have thicker 
and shorter fibrils than those from LMW fibrin". A more compact clot has a higher 
turbidity and firmness than a looser clot and this influences the turbidimetric and 
mechanical end point measurements. 
Newly synthesized fibrinogen is more phosphorylated, particularly in 
fibrinopeptide A at serine 3, than normal fibrinogen25,41A8. The fibrinogen found 
after streptokinase treatment has 66% of the possible sites phosphorylated whereas 
normal fibrinogen has only 30%"'. Reports on the effect of phosphorylation on 
clotting are conflicting. Witt et al47 find no effect, but both Hanna et a14~ and 
Reganon et al 23 describe that phosphorylation increases the release of FPA, which 
they ascribe to an enhanced binding of thrombin to the phosphorylated fibrinogen. If 
indeed phosphorylated fibrinogen clots faster, this further emphasizes that not all 
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forms of fibrinogen show the same clotting behaviour. 
Another component that influences the clotting rate 'assay is heparin, which in 
patients' plasma (concentrations 0.03 . 3 IU/mL) gives apparent increases up to 20% 
of the estimated plasma fibrinogen level in the Clauss assay". This artefact might 
hinder the use of the fibrinogen level to predict the thrombotic risk. Polybrene (1,5-
dimethyl-I,5-diazaundeca-methylene polymethobromide) can be used to neutralize 
heparin in the sample". 
Little is known about the disturbance by lipids in the clotting rate assay. No effect 
was found when plasma from healthy volunteers was supplemented with plasma with 
increasing levels of i3-lipoprotein50• In assays based on a turbidimetric end point, 
lipemic and haemolytic plasmas may disturb the measurements. 
In patients with cirrhosis of the liver, the fibrinogen molecules have an increased 
sialic acid content. This causes prolonged clotting times with thrombin·~l.n. After 
removing the sialic acid from the fibrinogen molecules with neuraminidase, the 
clotting times normalize. It has been reported that during intlammation the 
gJycosylation of the acute phase proteins is aiteredH .H , As fibrinogen is an acute 
phase protein, this may result in defective functional fibrinogen levels~.'I in patients 
with an increased inflammatory status. 
One freezing-thawing step does not give levels different from those found in fresh 
plasma56. 
AccUl'acy 
In a quality control study performed in 18 different laboratories, the Clauss method 
was the most accurate haemostatic assay57, reporting a coefficient of variation (CY) 
of 3.3% between duplicate measurements in the same series, a between day CY of 
4.7% and a between centres CV of 5.3%. 
Use as Routine Assay 
The clotting rate based methods are the most frequently used in routine laboratories, 
because they measure the functional fibrinogen levels and also because they are fast, 
cheap and have little variation 58. A major problem, especially in the assessment of 
thrombotic risk, is the discrepancy between the different laboratories. This will be 
discussed below. 
Comments 
In clotting rate assays the velocity of the fibrinogen to fibrin conversion can be 
enhanced by the presence of dextran and calcium chloride. Dextran increases the 
turbidity of the fibrin polymer at subnormal plasma concentrations of fibrinogerl'w. 
Calcium ions are not essential for fibrinopeptide release nor for polymerisation of 
fibrin monomers, but they greatly accelerate the aggregation of soluble tibrin 
monomer59,60. Calcium also makes fibrinogen more resistant to. thermal and acid 
denaturation, and to digestion by plasmin61 • 
CLOTTABLE PROTEIN BASED ASSAYS 
A. ASS A YS BASED ON CLOT MASS MEASUREMENT 
Methods that determine the amount of c10ttable protein use the unique property of 
fibrinogen that it becomes a clot after the addition of thrombin. After complete 
clotting of the fibrinogen, the non-c1ottable proteins trapped in the fibrin network 
must be washed out before the weight or protein content of the clot is determined. 
The methods are time-consuming, because both complete clotting and thorough 
washing out of the non-c1ottable proteins take time. 
Compared to the clotting rate method, measurement of clottable protein is more 
representative of the molar concentration of fibrinogen, because fibrinogen forms 
with prolonged clotting times are also measured. 
Interfering FactOl's 
Arnesen et al62 found only a minor increase of up to I giL early FDP in the 
measured amount of total c10ttable protein. This is confusing, because the fragment 
X is an early FDP that still has clotting capacity. Hoffmann et al" describe a 
marked increase of the apparent fibrinogen levels when ± 2.5 giL fragment X is 
added to pooled plasma, a small increase when fragment Y is added and no effect 
from fragments D and E. These concentrations are only obtained after thrombolytic 
therapy, Interference by heparin, haemolytic plasma Of increased sialic acid content 
of fibrinogen has never been described and is unlikely. 
Fat is trapped in the fibrin clot formed from blood collected during alimentary 
lipemia. The error in the determination of fibrinogen, due to trapped fat, is small 
provided correction is made for "extraneous absorption"""'. Lipid containing 
plasmas that have been lyophilized cannot be used in a gravimetric assay, because 
clotting is disturbed by the lipids. We observed this repeatedly with this method, but 
not with other fibrinogen assays. One freezing-thawing step of the plasma yields the 
same levels as in fresh plasmaH . 
Accul'acy 
The total c10ttable protein methods have a 4.6% variation in duplicate 
measurements6S • The method is less accurate with low Hbrinogen levels, because 
weak clots are formed that are difficult to handle. 
Use in Routine Assays 
This assay is hardly ever used in a routine laboratory, because it is very labour-
intensive. However, two epidemiological studies, the Northwick Park Heart Study28 
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and the Framingham Study" employed this method. 
Comments 
Originally, the final step was drying the clot and weighing it (gravimetric assay)", 
as in the Northwick Park Heart Study". Alternatively, the fibrin clot can be 
dissolved in urea and the protein content is then calcutated from the absorbance at 
279 nm63 • To correct for non-protein contamination, such as lipids, the absorbance at 
315 nm was subtracted from the absorbance at 279 nmM • Astrup et al67 dissolved the 
clot in 2.5 N NaOH in a boiling water bath and then measured the protein content 
with sodium carbonate and phenol reagent, obtained thereby a variance of less than 
1 %. Ratnoff and Menzie" dissolved the clot in 1 N NaOH and measured the protein 
with the Biuret test. 
B. ASSAYS BASED ON CHANGE IN TURBIDITY 
The Ellis and Stransky method" is also based on complete clotting of fibrinogen by 
thrombin, but the quantitation is based on the increase in opacity (turbidity) at 470 
nm, due to the formation of fibrin. This method gives additional information on 
kinetics of fibrin formation and fibrinolysis which can be obtained from the 
continuous monitoring of the absorbance. 
Nowadays, many laboratories use automatic coagulometers. These machines often 
derive the fibrinogen levels from the prothrombin time (PT)7().7I, This method is 
based on the Ellis and Stransky method because it measures increased optical density 
after clotting. It yields good results when the prothrombin time is relatively 
normaI49,7o,71. 
Accul'acy 
The Ellis and Stransky method has a 5.6% variation between duplicate 
measurements". The PT derived fibrinogen assay gives a same day CY of 5.6% and 
a different day CY of 6.5%49. 
Use as Routine Assay 
Measurement of PT-derived fibrinogen levels is lIsed frequently nowadays, because 
this assay can be performed on automatic coagulatometers. Because this test can be 
performed in combination with the PT, it is relatively cheap. 
Conmlents 
Changes in the fibrin clot structure will affect the turbidity of the clot. Because the 
different molecular weight forms of fibrinogen and the degree of phosphorylation of 
fibrinogen affect clot structure, these factors intluence the measurement of 
fibrinogen with this method. The presence of calcium during clot formation also 
modifies the clot structure". 
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The effects of lipids on turbidity and thereby on the PT-derived measurement can 
be corrected for with the newest apparatus. In patieuts on oral anticoagulants, results 
do not significantly differ from those in the Clauss assay'l. Bilirubin « 15 mg/dL) 
and haemoglobin « 150 mg/dL) have no disturbing effectslo.". An effect of the 
clottable, early FDP has not yet been described, but is theoretically expected. 
Unless clot formation is complete, spuriously low levels are obtained. This might 
be a problem in patients receiving heparin; therefore it is usually neutralized with 
polybrene". One freezing-thawing step does not alter the measured fibrinogen 
levels". 
PRECIPITABLE PROTEIN BASED ASSAYS 
Fibrinogen can be precipitated by heating"'" or with salt"'''. These methods 
determine both the clollable and the non-c1ollable fibrinogen. 
The heat precipitation method measures the amount of protein that precipitates at 
56°C. It is very sensitive to assay conditions. An increase in the temperature of 
one °C leads to a 12% error due to co~precipitation of other proteins. The assay is 
also sensitive to the pH in the system. 
Sulphite74 ,76 and ammonium sulphate7) have been used in quantitative assays 
because they specifically precipitate fibrinogen. Other salts have the disadvantage 
that they co-precipitate many other proteins. The best results are obtained with 
sodium sulphite because it cleaves the disulphide bonds of tibrinogen specifically and 
accurately76. 
Accumcy 
If the assay conditions are well controlled the heat precIpitation methods gives 
sodium sulphite 7.1 % and coefficients of variation of 3.9%, precipitation 
precipitation with ammonium sulphate 5.4%65, 
with 
Because of the many possible 
technical errors and interferences, these methods are generally considered 
unreliable" . 
Use in Routine Assays 
As the precipitation methods are prone to errors they are not routinely used. 
Comments 
Low levels of fibrin monomers «0.1 giL) do not inlluence the precipitation of 
fibrinogen by heat or by salt. Lipids in the sample do not influence the turbidimetric 
measurement when sufficient care is taken of the cooling procedure in the heat 
precipitation method73 . 
If the assay conditions are well controlled the heat precipitation method is not 
influenced by moderate haemolysis, heparin, fibrin monomers, hyperlipemia and 
bilirubin". There is however an effect of early fibrin(ogen) degradation products (X 
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and V), but not of D and E", if they are present in large amounts (> 15% of the 
fibrinogen level). 
IMMUNOLOGICAL ASSAYS 
Immunological methods measure the fibrinogen related antigens, rather than the 
amount of fibrin that can be formed. They include immuno-precipitation methods 
like radial immunodiffusion (RID)" or rocket immuno electrophoresis" where 
polyclonal antibodies are applied. These precipitation assays need polyclonal 
antibodies, which unfortunately crossreact with fibrin degradation products, 
fibrinogen degradation products and soluble fibrin. The enzyme immune assays 
(EIA) can use either polyclonal or specific monoclonal antibodies (e.g. specific to 
HMW + LMW fibrinogen"). The use of fibrinogen-specific monoclonal antibodies 
specifically determines fibrinogen and gives an assay system that has a lower 
detection limit than clotting rate or total clollable protein methods. The disadvantage 
of EIAs is that they are more time~consllming than clotting rate assays, although for 
instance the recently developed HMW + LMW fibrinogen EIA" takes less than I 
hour (apart from sample preparation time). 
The specificity of the monoclonal antibodies used in the HMW + LMW fibrinogen 
assay has the advantage of measuring specifically those molecular weight forms of 
fibrinogen that have the highest clollability and therefore are possibly associated with 
the highest thrombotic risk. 
Interfering Factors 
It depends on the specificity of the antibody''' whether FDP are measured in 
immunological assays. Usually, polycionaJ antibodies crossreact' with FDP, but the 
FDP levels have to be very high to noticeably influence the fibrinogen levels. In 
patients treated with streptokinase, apparently normal fibrinogen levels are found in 
radial immuno diffusion assays due to the high level of FDP. The clolling rate and 
total clollable protein assays would suggest a marked reduction of tibrinogen in these 
patiznts46 • 
The influence of the different forms of fibrinogen also depends on the specificity 
of the antibody. The recently developed HMW + LMW fibrinogen EIA" uses 
antibodies that do not detect the LMW' form of fibrinogen. Most polyclonal 
antibodies are not expected to react differently to the three fibrinogen forms. 
However, as stated above they will cross-react with FDP. 
Effects of lipids, heparin, haemolysis, phosphorylation and sialic acid on the 
measurement have not been reported,. but are unlikely. One step of freezing-thawing 
does not influence the RID assay56. In the rocket immuno-electrophoresis the 
addition of EDTA is required. 
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AccUI'acy 
When RID is performed on blood plasma that has been collected in heparin, the 
fibrinogen levels will be 10.7% higher than in sodium citrate plasma, whereas the 
concentrations in EDTA plasma are 10.3% higher than the heparin plasma". This 
difference may partly be due to the dilution effect of plasma in citrate. Heparin is 
known to inhibit the formation of antigen-antibody complexes in immunoassays, 
The same day CV of the HMW + LMW EIA was between 3 % and 7 %, depending 
on the plasma dilution used, the different day CV was between 2.8% and 7.7%". 
Use as Routine Assay 
The traditional immunological methods were very time consuming, a radial 
immunodiffusion assay takes three days. In 1110st routine laboratories the 
immunological methods are mainly used when the presence of dysfibrinogenaemia is 
suspected. 
The earlier EIAs took one day because they used relatively long incubation 
periods. The new HMW+LMW fibrinogen EIA only takes one hour, from the first 
incubation to the end of the staining reaction79 , which makes it suitable for routine 
use. 
COMPARISON BETWEEN METHODS AND BETWEEN LABORATORIES 
Standards 
To identify an incre~sed fibrinogen level as a potential cardiovascular risk factor, it 
is essential that a correct standard is used. Furlan" reported that there were giant 
differences between the indicated levels of commercial fibrinogen standards and the 
actual levels. To overcome the problem of differences between standards, it is 
desirable to establish the potency of a standard after a collaborative study, by 
agreement with the participants. For a long term reference standard the stability has 
to be checked, An international standard for fibrinogen is now avaiiableM • 
Compal'ison Between the Diffel'ent Methods 
In various studies the available fibrinogen assay methods have been compared. In 
general, there is good correlation between different methods when rank order is 
considered (i.e. high levels with one method yield high levels in another and, 
similarly, for intermediate or low levels7J.~.'. There is also a high degree of 
consistency in different studies of the association between fibrinogen levels on the 
one hand and physiological factors (e.g. smoking, age, body mass index (BMI)) and 
risk of arterial disease on the other. 
One study compared the clotting rate", clottable protein (PT-derived) and 
immunological (RID) methods in plasma samples from healthy individuals and 
patients with acute pneumonia and postoperative patients with increased fibrinogen 
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. levels". Palareti et al" found large discrepancies between the results obtained with 
the same samples applying different methods when they used the standard included 
in the different test kits. When they calibrated all methods to the same reference, 
there was satisfactory agreement, i.e. in the relation between different methods and 
the average of the methods. The most accurate is the Clauss method, but all methods 
had an inaccuracy below 8%. Although agreement in the group as a whole was 
acceptable, differences in agreement between the healthy individuals and the patients 
was not studied. Less agreement might be observed in patients with increased levels 
of HMW- and phosphorylated fibrinogen. 
In another study Exner et al" compared the Clauss method, total clotlable 
fibrinogen (protein and clot opacity), salt «NH,),SO, and Na,SO,) and heat 
precipitation methods to measure the plasma fibrinogen levels in patients with 
various diseases, e.g. consumptive coagulopathy and hepatic cirrhosis. The 
correlation of the total clottable protein level with the other methods was satisfactory 
(>0.91), but the results of salt precipitation methods were inaccurate at low levels 
(below I giL) and gave spuriously high values in jaundiced samples. The Clauss 
method had the best reproducibility. 
Comparison Between Laboratories 
The differences between laboratories are much larger than those between different 
methods in one laboratory. In 1993, the results of the College of American 
Pathologists (CAP) Proficiency Testing Program in 2250 laboratories from 1988 to 
1991 were published". Poor interlaboratory reproducibility was described. The 
authors ascribe Ihis to both instrument and reagent variables. The absence of an 
international standard for plasma fibrinogen was believed to be the major reason for 
the reagent variation. 
In the European Concerted Action on Thrombosis (ECAT) project the patients' 
plasma samples were not analyzed centrally and therefore the study included a 
quality control programme. The CY between the 16 participating European 
laboratories was assessed as 5.3% for the Clauss assay, which is only slightly higher 
than the mean different day CY of 4.7%". These variation levels remained constant 
after five quality assessment exercises~5. 
PHYSIOLOGICAL V ARIA TION 
We have recently reported a longitudinal study of healthy volunteers" which found 
that the longitudinal variation for fibrinogen within an individual (physiological + 
methodological variation) was 18%. Because the methodological variation was very 
small, its effect on this within-individual variation was negligible. Similar within-
individual variations have been described in healthy volunteers by Thompsonl\7 and 
Marckmann". Because the variations within individuals are comparable to the 
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variation between individuals, it will be necessary in order to classify groups with 
different thrombotic risks to study large groups or to calculate habitual levels from 
multiple samples. 
Pathology 
An overview of fibrinogen levels in different diseases and of acquired dysfibrinogen 
is given by Dang et al". Hereditary dysfibrinogenemia may yield decreased levels 
with functional fibrinogen assays and normal or slightly decreased levels of 
fibrinogen with immunological assays. Most of these dystibrinogens are either 
asymptomatic or calise a bleeding tendency. However, several families have now 
been identified in which the dysfibrinogen yields apparently low levels in functional 
assays in association with thrombophiliaowr,kw: \\9. 
In epidemiological studies for haemostatic indicators of cardiovascular risk, the 
gravimetric assay28,31,33,90, clotting assays32.35.91,91 and immunologic assaysJO,B,34 work 
equally well. 
CONCLUSION 
In this paper we have described the major categories of assays. The clotting rate 
assays give a functional fibrinogen level, are reproducible, fast, cheap and, in 
normal circumstances, not very easily affected by disturbing factors. The tests can 
be lIsed in automatic coagulorneters with turbidimetric end point assessment. The 
clottable protein assays also give tibrinogen levels based on the clotting capacity, but 
prolonged clotting is not detected by these tests. The advantage of the Ellis and 
Stransky derived methods is that they can easily be used in automatic coagulometers 
in combination with the prothrombin time. 
A promising development in immunological methods is the introduction of the ElA 
that uses monoclonal antibodies specific for the HMW and LMW forms of 
fibrinogen. As these are the most clottable forms, this assay may eventually be 
valuable to assess thrombotic risk. 
When using plasma Hbrinogen levels to determine thrombotic risk, it is very 
important to have I) a reliable method and 2) a good standard. When such a 
standard is used, the different methods give comparable results in healthy volunteers. 
Good comparability is also described for patients, but the evidence is less 
convincing. An international reference for fibrinogen is now available. 
The value of the different assays to estimate thrombotic risk has not yet been 
described. Therefore, epidemiological studies are needed in which the value of 
fibrinogen as risk indicator is compared with different assays, to establish a 
standardized fibrinogen method. 
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ABSTRACT 
Plasma fibrinogen levels are an important indicator for the risk of cardiac events. 
There is much diversity in the fibrinogen molecules that can be found ill vivo. The 
methods that are available for the assessment of plasma fibrinogen levels have 
different specificities for these forms of fibrinogen, which suggests that they may not 
detect the cardiac risk equally well. 
The heterogeneity of fibrinogen is partly explained by the degradation of the AD! 
chains, resulting different molecular weight (MW) forms, namely the high (HMW), 
the low (LMW) and the very low (LMW') forms that normally constitute 70%, 26% 
and 4%, respectively of the total fibrinogen in plasma. In this study we evaluated if 
and how these molecular" weight forms influenced the results of fibrinogen assays, 
inclnding clotting rate assays using either thrombin, peptidase or reptilase and an 
enzyme immuno assay (EIA) based on monoclonal antibodies an which detects 
fibrinogen that has both intact amino- and carboxy terminal ends of the Aa-chains. 
The clotting rate assays showed complex clotting curves for the three forms at 
increasing concentrations. The sensitivity of the ETA for the HMW fibrinogen forms 
was found to be three times higher than for the LMW form, while as expected the 
LMW' form was hardly detected. It is therefore concluded that the fibrinogen assays 
need to be compared in prospective, epidemiological studies to select the assay(s) 
which give(s) optimal assessment of the risk of cardiac events. 
INTRODUCTION 
The plasma level of tibrinogen has been identitied as a strong risk indicator for 
cardiovascular disease l .s. The mechanisms underlying this relation have not yet been 
identified. A possible mechanism might be that increased plasma fibrinogen levels 
will stimulate clot formation. Fibrinogen might also be directly associated with 
cardiac risk because of its important contribution to the plasma viscosity9.HI; because 
fibrinogen stimulates the growth and migration of smooth Illuscle cells l 1.l2; because it 
is involved in the aggregation of blood platelets13 and because it is associated with 
plaque growth!'. Another hypothesis is that atherosclerosis is due to a chronic 
inflammation of the vascular wall 15 and that this causes increased plasma levels of 
fibrinogen as a consequence of an acute phase responsel6 , 
In the above mentioned epidemiological studies a variety of tibrinogen assays was 
applied, namely assays based on the clotting rate5.g or the amount of clottable 
protein1.2,4 and immunological assays3, The association between the risk for cardiac 
events and the plasma tibrinogen level was observed with any of the methods. 
However, since each assay has its own characteristics and tibrinogen occurs in 
several different molecular weight forms 17 it is conceivable that the various assays 
will give different information and indicates that their value in risk assessment may 
vary. This suggests that it will be worthwhile to evaluate the fibrinogen assays for 
50 mel.l~uring molecular weight i'clnns of' fihrillngen 
optimal assessment of cardiac risk. 
One of the reasons for molecular heterogeneity in the fibrinogen molecules is 
limited degradation of the COOH-terminal ends of the AOI chains, resulting in three 
molecular weight forms of fibrinogen in plasmals.n , Fibrinogen is assumed to be 
synthesized in the high molecular weight form (HMW), with both AOI-chains intact 
at the carboxyl-terminal ends. In plasma two degraded forms exist, one form in 
which one of the AOI-chains is degraded at the carboxyl end. This form is called the 
low molecular weight (LMW) form. In the other form both AOI-chains are degraded 
and this form is called the LMW' form. In a normal plasma 70% of fibrinogen is 
HMW, 26% is LMW and only 4% is LMW"'. The enzyme or enzymes, responsible 
for the degradation have not yet been identified, but analysis of the COOH-terminal 
end of the AO:'~chain has excluded plasmin, gelatinase and trypsin2U.~. 
The clotting behaviour of these three fibrinogen fOfms is different IiUII.12 , The 
thrombin clotting rate of the HMW forms is higher than that of the LMW forms. 
With the LMW' form the longest clotting times are observed. The difference in 
clotting times is more pronounced when reptilase is lIsedl~. It is expected that these 
different clotting characteristics may influence the functional fibrinogen assays that 
use thrombin" or reptilase IVhen the ratios of HMW, LMW and LMW' differ from 
normal. The methods that measure the fibrinogen protein concentration, such as 
enzyme immuno assays with polyclonal antibodies will probably not be affecled by a 
difference in clotting behaviour. 
Moreover, these variations in ~haracteristics of the three molecular weight forms 
snggest that their contribution to the cardiac risk might be different, and require a 
further definition of the speciticity and sensitivity of assays for the three molecular 
weight forms of fibrinogen. The aim of this study lVas to define in more detail the 
sensitivity of various clotting (Clauss, peptidase and reptilase tests) and enzyme 
immuno methods (total fibrinogen, HMW + LMW librinogen) for measuring the 
different forms of fibrinogen and as a consequence for the measurement of total 
fibrinogen levels. 
MATERIALS AND METHODS 
Materials 
Aprotinin (Trasylol®) was obtained from Bayer (Leverkusen, Germany), soybean 
trypsin inhibitor from Sigma (St Louis, MO, USA), diisoprophylOuorophosphale 
(DFP) and B-alanine were obtained from Aldrich (Beerse, Belgium). Sepharose-
lysine, Sepharose-heparin and Sepharose-6B-CL were obtained from Pharmacia 
(Woerden, the Netherlands). Acrylamide and bisacrylamide were obtained from 
BDH (Poole, England). 
Buffers 
0.15 M phosphate buffer contained 27 illillollL ethylenedinitrilo letraacetic acid 
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disodium sail (EDTA) and 20 KIUlL trasylol pH=7.45. Owren buffer contained of 
0.029 mollL sodium diethylbarbiturate, 0.126 mol/L NaCI, pH=7.35. Fibrinogen 
solvent consisted of 8 vol 0.3 mol/L NaCI, I vol Owren buffer and I vol 10 
KIU/mL trasylol as described by Holm et al. 1 •• 
Fibrinogen isolation 
Nine volumes venous blood (250 mL) were collected of heallhy volunteers in I 
volume sodium citrate (0.11 mol/L) with the protease inhibitors trasylol (400 
KIU/mL), soybean trypsin inhibitor (I mg/mL) and DFP (I mmol/L) and 
immediately placed in melling ice. After centrifugation (30 min, 3000 g, 4°C) the 
plasma was collected and fibrinogen was isolated as previously described (27). 
Briefly, the plasma was diluted three times in phosphate buffer. The plasma was 
passed over a Sepharose-Iysine column to remove the plasminogen. Then (NH,),S04 
was added to a final concentration of 25%. The precipitate was collected by 
centrifugation (20 min 3000 x g, 4°C), dissolved in the phosphate buffer and passed 
over a Sepharose-6B-CL column run in the same buffer. The fracti'ons of the second 
eluded peak were pooled and precipitated with 50% (NH,),SO,. The precipitate was 
collected after centrifugation (20 min 3000 x g, 4°C), resuspended in tibrinogen 
solvent and subsequently dialysed against Owren buffer containing 0.011 M citrate. 
Finally, the fibronectin was removed by passing the tibrinogen solution over a 
Sepharose-gelatine column. 
Alternatively, the fibrinogen was jsolated using fi-alanine, essentially as described 
by Straughn". Briefly, B-alanine was added to a final concentration of I mol/L and 
incubated on ice for 30 min. The precipitate was removed by centrifugation for 30 
min at 2000 x g, 4°C. To the supernatant l3-alanine was added to raise the final 
concentration to 3 mol/L, and incubated for 30 min on ice. The precipitated 
fibrinogen was collected by centrifugation for 20 min at 9000 x g, 4°C and 
dissolved in 154 mmol/L NaCI with 0.011 mol/L citrate. The fibrinogen was 
reprecipitated by adding B-alanine to a final concentration of 3 mol/L and incubation 
for 30 min on ice. The fibrinogen was collected by centrifugation for 25 min at 2000 
x g, 4°C and dissolved to a concentration of approximately 5 in Owren buffer with 
0.011 mollL citrate giL, and then dialysed for 16 hour against the same buffer. 
table 1. Pnx:ipilalion fractions of I1brinogen, 
fraction m', 
fraction 1 
fraction 2 
fraction 3 
The expected main fihrinngen funn Mnleculal' weight 
in the fractiuns 
HMW-fihrinogen 340,0000a 
LMW-fihrinogen 305,0000a 
LMW'-fihrinogen 270,000 Oct 
52 measuring lIIolf;'cular wci.uht fnnm: 01' lihrinogen 
Fractionation of moleculul' weight fOl'llls of filH'inogen by sNluential (NH">2S0" 
precipitation 
The molecular weight forms of fibrinogen were separated as described previouslyl7. 
Briefly, saturated (NH,),s04-solution was added to a fibrinogen solution to a final 
concentration of 19% (v/v) and incubated for 10 minutes. The precipitate was 
collected by centrifugation (1200 x g, 10 min)(fraction I) and resuspended 154 
mmol/L Nael in 1/3 of the original volume. The precipitate obtained between 22 
and 24% {NH,),S04 saturation was collected (1200 x g, 10 min.)(fraction 2) and 
resuspended in 154 mmol/L Nael in 1120 of the original volume; and finally the 
precipitate between 26 and 30% (NH,),SO, saturation was collected by centrifugation 
(1200 x g, 10 min.)(fraction 3) and resuspended in 154 mmol/L Nael in 1/40 of the 
original volume. The precipitates were reslIspended in and dialysed against 154 
mmol/L Nael (table I). The whole procedure was performed at room temperature. 
Electrophoresis 
SDS/polyacrylamide gel electrophoresis was performed according to the method of 
Laemmli, with resolving gels containing a gradient of 2.5 - 16 % (w/v) acrylamide 
and stacking gels of 2.5% acrylamide29 , The individual chains of tibrinogen were 
examined on SDS/polyacrylamide gels under reducing circulllstances, with resolving 
gels containing 10% (w/v) acrylamide and stacking gels of 5% acrylamide. After 
staining of the bands with Coomassie blue, the bands were scanned. 
Fibrinogen assays 
The fibrinogen concentrations in the puritied fractions were estimated by the optical 
density at 280 nm, using the OD (I %,280 nm) = 15.0, but we are aware that this 
factor might vary for the three forms of fibrinogen. 
Total fibrinogen antigen was determined with an enzyme immuno assay (ETA) that 
uses a pool of rabbit anti human tibrinogen IgG's as catching antibodies-lU and 
peroxidase conjugated monoclonal antibodies against fragment DO (DO 13)·11 as 
tagging antibodies. 
(HMW+LMW)~fibrinogen levels were determined using an enzyme imll1uno assay 
(EIA)"(Organon Teknika, Boxtel, the Netherlands). In Ihis assay a monoclonal 
antibody against the intact carboxyi-terminal end of the fibrinogen A,,-chain is used 
as the capture antibody (G8), and a monoclonal antibody against the amino-terminal 
end of the A,,-chain, including fibrinopeplide A (YI8) as the tagging antibody. 
Clotting times of the three fibrinogen forms were determined lIsing thrombin, 
according to Von Clauss16 , reptilase and peptidase according to the instructions of 
the manufacturer «DIAMED, Morat-Murten, Switserland) in a dilution series of 0.1 
- 0.5 mg/mL (concentrations determined by the 10lal fibrinogen EIA). The clolling 
times were determined in the. presence of 10% citrated plasma of a patient that is 
deficient in fibrinogen (functional and immunological levels <0.2 mg/mL)(kind gift 
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of Prof. Egbring, Marburg, Germany). 
RESULTS 
On SDS-PAAGE gels the bands of the fibrinogen forms were clearly different for 
HMW, LMW and LMW' - fibrinogen forms and showed the expected pattern (figure 
I). Scanning of the density of the SDS-PAAGE gels, using the 'Y-band as an internal 
control (100%), gave a density of the Aex band in fraction I of 155% (SD 26%, 
n=4) while in fractions 2 the Aex band had decreased to 113% (SD 7%, n=4). In 
fraction 3 the Aex band had further decreased to 34 % (SD 10%, n =4). Furthermore 
it is observed that several lower molecular weight bands appeared and that the peak 
of the Aex chain had broadened (table 2, figure I) in the LMW' fraction. No 
difference was observed in the patterns between the fibrinogens that had been 
isolated using B-alanine or using (NH,),SO, precipitation followed by gel filtration. 
Tnble 2. Me.'ln (SD) of the density of the re."pective hands after .<.;canning results of the SDS~PAAGE 
gel of fibrinogen foons under redUCing conditions. The density of the I3rl-chain has heen used as 
internal standard. 
fraction HMW 
fraction LMW 
fraction LMW' 
340 kD 
305 kD 
270 kD 
67 kD 
56 kD 
47 kD 
Aa-chain 
127% 
·87% 
41% 
(14%) 
(6%) 
(9%) 
I3B-chain 
100% 
100% 
100% 
y-chain 
101 % 
84% 
92% 
HMW 
LMW 
LMW' 
Aa-chain 
Bll-chain 
'Y-chain 
(27%) 
(9%) 
(12%) 
Figure 1. SDS/polyacrylamide gels of fihrinogen fractions 1 (mainly HMW), 2 (mainly LMW) and 3 
(mainly LMW') under non-reducing and reducing conditions 
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Fibrinogen assays 
The levels measured in the fractions with the EIA for tptal fibrinogen were virtually 
equal to the levels that were calculated from the optical density of the fibrinogen 
solution at 280 nm. Figure 2 shows that the dilution curves of the three fractions 
were parallel to each other and to pooled plasma. In the EIA for HMW + LMW 
fibrinogen the HMW fraction was 127% (SD 14%, n=3) of that of pooled plasma 
and LMW was detected approximately a factor three less sensitive with 41 % (SD 
22%) of pooled plasma (figure 3). Since the monoclonal antibodies in this assay 
were insensitive to LMW' fibrinogen, it was not expected that this fraction would be 
detected. In fraction 3 we measured 13 % (SD 7%) of pooled plasma which 
indicates contamination with fibrinogen forms that have intact A,,-chains (figure 3). 
The results of the three clotting rate assays were very similar (figure 4). In the 
Clauss, the peptidase and the reptilase based assays the clotting rate of the HMW 
fraction was slightly higher than that of pooled plasma, the curve of the LMW 
fraction crossed that of the pooled plasma, while the LMW' fraction has longer 
clotting times than pooled plasma. It was remarkable that the dilution curves of the 
fibrinogen fractions were not parallel to each other or to pooled plasma (figure 4). 
00450 
2.0 ~-
1.5 
1.0 
0.5 
, .. , 
0.0 
0.01 0.1 1 
fibrinogen (lJg/mL) 
Figure 2. Typical example of dilution curves of pooled plasma ( ) , HMW (----), 
LMW (----), and LMW' ( ..... ) fibrinogen in the enzyme inmlUllo assay for total fib~nogen. 
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00"0 
2.0 
55 
fibrinogen (~g/mL) 
Figure 3. Typical example of dilution curves of pooled plasma ( ), HMW (----), LMW 
(----), and LMW' (" ....... ) fibrinogen in the enzyme immuno assay for HMW + LMW tihrinogen. 
clotting time clotting time clotting time 
30 
10 
0.1 0.5 0.1 0.5 0.1 0.5 
added fibrinogen (~g/mL) added fibrinogen (J.l9/mL) added fibrinogen (J.lgJmL) 
a b c 
Figure 4. The clotting characteristics of pooled plasma ( l, HMW (----l, LMW (----), 
an,d LMW' (' ....... ) fibrinogen when thrombin (a), peptidase (b) and reptilase (e) are used as enzymes 
to start the clotting. 
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DISCUSSION 
In the circulation fibrinogen can be found in many different forms. There are for 
example differences in the extent of degradation of the carboxyHerminal ends of the 
Aa-chain, resulting in HMW, LMW and LMW' fibrinogen. This heterogeneity of 
fibrinogen makes it necessary to assess the specificity of different fibrinogen assays 
for the various forms. 
The results of this study suggest only a slightly higher sensitivity for the HMW 
fibrinogen forms in clotting rate assays, independent of whether the clotting was 
initiated with thrombin, peptidase or reptilase. In the EIA for HMW+LMW 
fibrinogen the responses with the HMW fibrinogen forms are much higher than 
those for the other forms. 
The HMW, LMW and LMW' fractions of fibrinogen isolated using fi-alanine 
precipitation had much longer clotting times with thrombin, peptidase or reptilase 
than the corresponding fractions prepared from fibrinogen isolated by the method 
described by Ruyven et al27. On the SDS-PAAOE gels the band pattern of the 
fractions obtained by the two isolation methods of tibrinogen were similar, and 
HMW, LMW and LMW' yielded the expected patterns. This suggests some 
denaturation of the fibrinogen using the fi-alanine precipitation lllethod2~. When we 
compared the clotting curves of the three fibrinogen forms that were derived from 
fibrinogen, isolated as described by Ruyven et al 27 we observed that the clotting time 
for LMW' was somewhat longer than that for HMW, which was somewhat longer 
than HMW. This might be ascribed to a decrease in the number of "b" binding site 
involved in the lateral polymerisation of fibrin". 
To our surprise the clotting curves of the HMW, LMW and LMW' fractions 
were not parallel to each other or to those of pooled plasma in none of the three 
clotting assays. This indicates that the fibrinogen levels, measured with clotting rate 
assays rate assays, depends on a complex composite of relative contributions of the 
three fibrinogen forms, which will make the interpretation of these clotting rate 
assays complicated. 
The fibrinogen levels, measured with the ETA for HMW+LMW fibrinogen, are 
mainly determined by the HMW level, since this form is detected three times more 
sensitive than the LMW form and since the LMW' form is hardly detected at all. 
Every LMW fibrinogen molecule has one epitope for the 08 monoclonal antibody 
and might therefore, theoretically, be detected as well as a molecule with two 
epitopes. Since there was a clear difference in sensitivity for the HMW and LMW 
forms, it might be suggested that the two intact carboxyl-terminal ends of the Aa-
chain in the HMW form are cooperative. Because the LMW fraction is contaminated 
with HMW and the LMW' fraction contains some LMW fibrinogen, the actual 
differences in sensitivity of this HMW + LMW ETA for the three fibrinogen forms 
might be greater. 
In normal plasma a distribution of 70% HMW, 26% LMW and 4 % LMW' has 
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been reported. Using the relative sensitivities of the ErA towards the different chains 
(127%, 41 % and 13% for BMW, LMW and LMW', respectively), the calculated 
fibrinogen concentration was 99.5%. This indicates that measurement in a mixture 
of the MW fibrinogen forms, i.e. plasma, gives a simple addition of the different 
forms in this assay. 
If the clotting characteristics of fibrinogen determine the thrombotic risk, it will be 
expected that BMW fibrinogen form contributes most to the risk. A higher 
thrombotic risk by BMW fibrinogen has also been suggested by the study of 
Thorsen et ai, who describe that the ADP-induced aggregation of blood platelets of 
the LMW fibrinogen was only 75% of the effect of the BMW form", while with a 
mixture of LMW and LMW' fibrinogen the aggregation was even further decreased 
to 50%. However, there are also indications that there is no increased tendency of 
HMW to thrombus formation because no difference was found in the amounts of 1251 
labelled BMW and 'JlI labelled LMW that had been incorporated. in venous thrombi 
in patients that had undergone total hip arthroplasty'·'. 
It might also be possible that the LMW fraction is the most dangerous fibrinogen 
form, because clots made of LMW fibrin have thicker fibres J6 ....fll which makes the 
LMW clots more difficult to lyse than clots of BMW fibrin"'''. Increases in the 
LMW form would be best detected by the ratio of the fibrinogen levels measured 
with the HMW + LMW EIA oyer the total fibrinogen l,vel: this ratio will be lower if 
there is relatively more LMW fibrinogen. 
Our conclusion is that the clotting rate assays and the EIA for HMW + LMW 
fibrinogen are sensitive to the quality of fibrinogen. It would be interesting to study 
if the highest sensitivity for BMW fibrinogen forms makes the BMW + LMW EIA 
or a ratio of the EIA over the Clauss a better indicator of the thrombotic risk. The 
characteristics of method that identifies the most dangerous form of fibrinogen might 
also give the best indication of thrombotic risk. 
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ABSTRACT 
In patients with liver cirrhosis the fibrinogen molecule is under constant attack of 
various proteolytic enzymes, which might affect results of the different assay 
systems for fibrinogen. We therefore studied the measurement of fibrinogen in the 
plasma of patients with mild, moderate and severe cirrhosis of the liver. Fibrinogen 
levels were measured with the Clauss method (functional fibrinogen); an enzyme 
immuno assay (EIA) for HMW + LMW fibrinogen; and an assay that measures the 
total clottable fibrinogen. With all three methods we found normal or slightly 
increased fibrinogen levels in patients with mild or moderate cirrhosis, whereas 
patients with severe cirrhosis had decreased levels. No evidence was found for 
increased partial fibrinogen proteolysis, resulting in increases of LMW'-fibrinogen in 
cirrhotic patients. 
We also documented the fibrin(ogen) degradation, and we observed that fibril/ogen 
degradation products levels increased slightly with the severity of the disease, but 
were still in the normal range in patients with severe cirrhosis. This indicates a very 
low level of primary fibrinolysis. Fibrin degradation products levels increased much 
stronger, which points to intravascular coagulation. The levels of the fibrin 
degradation products remained below the level where they are expected to intluence 
the Clauss assay. 
In patients with liver cirrhosis the measurement of plasma tibrinogen levels with 
the three studied methods gi~e comparable results. Fowever, the assay for total 
c10ttable protein can not accurately measure very low fibrinogen levels, which can 
be frequently observed in severe cirrhotics. We suggest to apply the Clauss assay in 
cirrhotic patients because of this and because it has a good reproducibility and 
because the test is cheap, quick and easy to perform. 
INTRODUCTION 
Fibrinogen is a symmetrical glycoprotein consisting of two Acx, two B6 and two "1-
chains. Under normal conditions fibrinogen occurs in three molecular forms l -6: 1) 
the high molecular weight form (HMW-fibrinogen) with both Acx-chains intact; 2) 
the low molecular weight form group (LMW-tibrinogen) with one Acx-chain intact 
and the other Ac¥-chain shortened in the carboxyl-terminal region to varying extent; 
and 3) the group of LMW'-forms of tibrinogen with both Acx-chains shortened to 
different degrees. The percentages of HMW-, LMW- and LMW' -fibrinogen in 
healthy individuals are about 70%, 26% and 4%, respectively. The LMW and 
LMW'-forms can be considered as partly proteolysed derivatives of the HMW-form 
of fibrinogenl-4. The enzyme or enzymes, responsible for this degradation, have not 
yet been identified'. Although fibrinogen degradation by plasmin iI/ vivo can give 
degradation products of similar size, analysis of the amino acids of the C-terminal 
region of the Acx chains of LMW- and LMW'-fibrinogen has shown that these 
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fibrinogen fOfms do not result from plasmin degradation ill vifro o.7, 
Fibrinogen is also subject to several other proteolytic processes. Firstly the 
conversion to fibrin by thrombin, the product of an activated coagulation system and 
secondly the degradation by plasmin, the product of an activated fibrinolytic system. 
Several assays exist for the assessment of fibrinogen levels. Examples are the 
Clauss assay, based on the clotting rate8; an assay for c10ttable fibrinogen9; and a 
recently described EIA which quantitates the amount of the HMW + LMW forms of 
fibrinogen lO• These assays are affected to different extents by the presence of 
fibrinogen derivatives and the amounts of the three molecular forms. 
The Clauss method is influenced by the presence of anticoagulant .fibril/ogel/ 
degradation products (FgDP) and fibrin degradation products (FbDP)", which will 
lead to spuriously low fibrinogen levels. Soluble tibrin will lead to apparently 
increased fibrinogen levels. The amount of c/o((ab/e .fibril/ogel/ will be increased by 
clollable degradation products. The EtA for HMW+LMW.fibril/ogel/ will not detect 
LMW' fibrinogen lO, 
The aforementioned proteolytic processes may be strongly affected during cirrhosis 
of the IiverI2+ 18 , and the resulting t1brinogen derivatives may have effects on the 
recording of fibrinogen levels, depending on the method used. As a consequence 
conclusions as to the effects of the severity of the disease on fibrinogen levels may 
not be easy to draw. 
We studied the measurement of fibrinogen levels with the functional Clauss 
method, the total clollable fibrinogen assay and the EIA for HMW+LMW 
fibrinogen in healthy individuals and in patients with mild, moderate and severe 
cirrhosis of the liver. We also documented the status of t1brin(ogen) degradation 
using assays for soluble fibrin", FgDP''', FbDp2I and TDP (total degradation 
products = FgDP+ FbDP)22 (table I). 
Our data show that in patients with liver cirrhosis there is an ongoing disseminated 
intravascular coagulation with concomitant reactive fibrinolysis which is more active 
than the primary fibrinolysis. The more severe the cirrhosis, the higher the FbDP 
and TDP levels in the patients. We evaluated to what extent these tibrinogen 
derivatives affected results in three different assays for fibrinogen and from this 
evaluation we suggest to apply the Clauss assay in patients with liver cirrhosis. 
PATIENTS, MATERIALS AND METHODS 
Patients 
The study group comprised 44 patients with biopsy-proven cirrhosis of the liver. The 
patients were classified according to Pugh's modification of the Child classificationlJ 
as mild (Child A, n = 20), moderate (Child B, n = 10) and severe (Child C, n = 
14), Twelve apparently healthy volunteers were included as normal controls. 
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Informed consent was obtained from the patients and the volunteers. The study was 
carried out according to the principles of the Helsinki Declaration. 
Blood samples 
Nine volumes of venous blood were collected between 10.00 and 12.00 a.m. in 
plastic tubes containing one volume of cold trisodium citrate O. I I moilL, and placed 
immediately in melting ice. Plasma was prepared by centrifugation (2000 x g, 30 
min, 4°C) and stored in small aliquots at -70°C. 
Assays (an overview is given in table I) 
Total c10ttable fibrinogen (modification of Jacobsson') was determined by allowing 
1 mL plasma to clot with 25 IU of thrombin for two hours at room temperature. The 
clot was washed with 0.15 M NaCI, dried and subsequently suspended in 6.7 M 
alkaline urea. The fibrinogen concentration is calculated from the optical density at 
280 nm (A(lcm,I%) = 15.75). 
FUllctional flbl'illogell levels were determined according to Clallss ll • The standard 
curve was made using purified fibrinogen (Merz & Dade, DOdingen, Switzerland). 
Table I. Assays for fibrinogen and its degradation products 
Method 
Clauss method 
Jacobsson modification 
BfA (HMW +LMW)-fibrinogen 
EIA FgDP 
EIA FbDP 
EIA TDP 
BIA soluhle fibrin 
What is measllred 
Functional I1hrinogen llssay 
Total clottahle protein 
HMW + LMW degradation products of 
lihrinogen, with two intact (HMW) or one 
intact and one degradetl Aa-chain (LMW) 
Fihrinogen degradation products 
Fihrin degradation products 
Fihrin + fihrinogen degradation products (sum of 
FgDP + FhDP) 
Soluhle fihrin 
(HM\V + LMW)-fibrinogen levels were determined using an enzyme immuno assay 
(EIA)iO. In this assay a monoclonal antibody against the carboxyl terminal end of the 
fibrinogen AQ'-chain is used as the capture antibody (OS), and a monoclonal 
antibody against the amino-terminal end of the AQ'-chain (YIS) as the tagging 
antibody. Thus the EIA will only measure HMW- and LMW-tibrinogen. LMW'-
fibrinogen will not be detected, but can be calculated as the difference between the 
fibrinogen values determined with the assay for total clottable fibrinogen and 
fibrinogen as determined with this EIA. The standard curve was made from pooled 
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citrated plasma in which the fibrinogen concentratipn was determined by a 
gravimetric method24 . 
Fibrinogen degradation pl'oducts (FgDP) were measured using a test kit 
(Fibrinostika FgDP, Organon Teknika, Tumhout, Belgium)". In this sandwich EIA, 
a monoclonal antibody (FDP-14), directed against an epitope on the stretch 52-114 
of the fibrinogen B6-chain", specific for FgDP and FbDP and not reactive with 
fibrinogen or fibrin is used as a capture antibody. A horse-radish peroxidase (HRP)-
conjugated monoclonal antibody, specific for fibrinopeptide A (YI8/HRP) is used as 
a tagging antibody. As a consequence of the combined specificities of FDP-14 and 
Y18, the EIA is specific for FgDP and does nol detect librinogen (HMW, LMW nor 
LMW'), fibrin of FbDP. 
Fibrin degradation products (FbDP) were measured using a lest kil (Fibrinoslika 
FbDP, Organon Teknika, Tumhout, Belgium)". In this sandwich EIA, FDP-14 (see 
above) is used as capture antibody. The tagging antibody (DD-J3/HRP), elicited 
against D-dimer, makes this EIA specilic for FbDP. Although Ihe DD- 13 anlibody 
was directed against D-dimer, it does not discriminate between crosslinked and 1100-
crosslinked forms of FbDP. It does nol detect HMW-, LMW- or LMW'-tibrinogen, 
fibrin or FgDP. 
Total degradation products (TDP) were measured using a lest kil (Fibrinostika 
TDP, Organon Teknika, Tumhout, Belgium)". In this sandwich EIA, FDP-14 (see 
above) is used as the capture antibody. The tagging step is done wilh a mixlure of 
Y18IHRP and DD-13/HRP (see above). The assay assesses Ihe tala I of FgDP + 
FbDP (= TDP) and does not detect HMW, LMW and LMW'-librinogen or fibrin. 
Soluble fibrin was measured lIsing a sandwich EIA (Fibrinoslika Soluble Fibrin, 
Organon Teknika, Turnhout, Belgium)J<J in which monoclonal antibody anti-Fb-112 
specific for soluble fibrin, is used as capture anlibody. The lagging slep is wilh G8 
conjugated with HRP (see above). The assay assesses soluble fibrin and does not 
delect fibrinogen, FgDP or FbDP. 
Inmml1oblotting: Aa-chain degradation was visualized by immullobiotting after 
polyacrylamide electrophoresis essentially as described by Gron et a1.6 , using 
Y18/HRP for immunostaining. 
Statistical analysis was performed using non-parametric tests. Correlations were 
calculated with the Spearman rank correlation and the I1brinogen levels in the groups 
chapter 3 67 
were compared with the Kruskall Wallis test. Any probability less than 0.05 was 
considered to represent a significant difference. The assay variation was expressed 
by the standard deviation of the duplicate measurements and was calculated using the 
formula: 
(differenoos of the duplicate measuremenO· 
2 .. numberof assays 
RESULTS 
Levels of fibrinogen and soluble fibrin 
The median levels of functional fibrinogen (Clauss assay) were 1.8 giL in the 
normal group (defined as 100%),2.1 giL (i.e. 117% of normal) in Child A, 2.4 giL 
(137% of normal) in Child Band 1.3 giL (74% of normal) in Child C (Fig. I). The 
fibrinogen levels in patients with Child C cirrhosis were signilicantly lower than the 
levels in the other patients. 
The median levels of total c10ttable fibrinogen were 2.1 giL in the normal group 
(defined as 100%), 2.2 giL (i.e. 103% of normal) in Child A, 2.2 giL (103% of 
normal) in Child Band 0.86 giL (41 % of normal) in Child C. In this assay 
fibrinogen levels under I giL gave too low fibrinogen levels, because there was 
incomplete recovery of the clotted fibrinogen. 
With the EIA for (HMW+LMW)-fibrinogen we found 2.65 giL in the normal 
group (defined as 100%), 2.65 giL (i.e. 100% of normal) in Child A, 3.50 giL 
(132% of normal) in Child Band 1.90 giL (i.e. 72% of normal) in Child C. 
The differences in absolute levels of fibrinogen are probably due to differences in 
calibration material (see Materials and Methods), There was a good correlation 
between the fibrinogen levels, measured with the three assays (between EIA and 
Clauss method R = 0,88, P < 0,001, between EIA and total clottabIe fibrinogen 
method R = 0,89, p < 0,001, between Clauss method and total c10ttable fibrinogen 
method R = 0.88, P < 0.001). There was no indication for systematic errors in 
these assays. The assay variation was 3% in the Clauss assay, 5% in the tota.! 
c10ttable protein assay and 6% in the EIA, 
The calculated LMW' levels (tibrinogen measured with the total c10ttable 
fibrinogen minus levels measured with the EIA) were comparable in the individuals 
in the four groups. This is supported by our tinding that with itllillunobiotting no 
increases in the degraded Aa-chains could be demonstrated (results not shown). We 
conclude therefore that there are no increased LMW' fibrinogen levels in cirrhotic 
plasma. 
Plasma levels of soluble fibrin in patients with a severe cirrhosis were comparable 
to levels in the normal group, i,e, below 10 I'g/ml. 
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Plasma flbrin(ogen) degradation producls 
The levels of fibrin degradation products were different between groups of patients 
with differenl severity of the cirrhosis using the Kruskall Wallis test (p<O.OOI). The 
median in Ihe normal group was 0.23 I'g/ml, in Child A 0.33 I'g/ml, in Child B 
0.66 I'g/ml and in Child C 2.45 I'g/ml (Fig. 2). 
The levels of fibrinogen degradalion producls (FgDP) also differed significantly (P 
< 0.03) in the four groups using the Kruskall Wallis test. In the normal group the 
median was 0.23 "g/ml, in Child A 0.261'g/ml, in Child B 0.34 I'g/ml and in Child 
C 0.40 I'g/ml (Fig. 2). 
As could be anticipaled from Ihe FgDP and FbDP levels, a similar difference 
belween Ihe patient groups could be found for the levels of the total degradalion 
products (fDP)(P < 0.001) using the Kruskall Wallis test. The median in the 
normal group was 0.41 I'g/ml, in Child A 0.64 I'g/ml, in Child B 1.19 I'g/ml and in 
Child C 2.75 I'g/ml (Fig. 2). The levels of the total degradation producls 
corresponded well with Ihe calculated sum of the separately determined levels of 
FbDP and FgDP (R = 0.98), with no indication for a systematic error. 
DISCUSSION 
In this study we assessed fibrinogen and some of its derivatives in plasma of patients 
with varying degrees of liver cirrhosis. We found normal or slightly increased levels 
of fibrinogen using Ihe functional Clauss test, the EIA and with the assay for total 
clotlable fibrinogen in patients with liver cirrhosis classified as Child A and B. With 
Ihe three tesls for fibrinogen we only found decreased levels of fibrinogen in Child 
C cirrhotics, which may be the result of an increased consumption or a decreased 
synthesis. 
Partial fibrinogen proteolysis appears to be a normal physiological event, since 
slightly-proteolysed forms of fibrinogen occur under normal conditions. These 
slightly-damaged fibrinogen forms (LMW and LMW') are clottable and will 
contribute to the result of functional assays, such as the Clauss method. It was 
expected that in patients with liver cirrhosis there is a higher degree of proteolysis, 
because Lipinski 17 and Weinstein lS described an increased proteolysis of fibrinogen 
in patients with liver cirrhosis. However, the results of our study indicate that the 
LMW' is not affected, because a good correlation was found between the fibrinogen 
levels measured wilh a recently-developed enzyme immuno assay (EIA) for 
(HMW + LMW)-fibrinogen and fibrinogen as assessed by the Clauss method or the 
total clottable fibrinogen method in plasma from patients with di fferent stages of 
liver cirrhosis. The calculated LMW' levels did not change with increasing degree of 
cirrhosis. Also, iml11unoblotting experiments performed to visualize a possible 
increase of degraded Aa-chains showed no differences of degraded Aa-chains 
between the studied groups, which further supports the conclusion that there is no 
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significant increase in LMW' formation in liver cirrhosis. 
The soluble fibrin levels found in severe cirrhotics were comparable with those 
found in the normal group « 10 I'giml), indicating that the haemostatic balance is 
not severely disturbed. 
Activation of the coagulation system in patients with liver cirrhosis has been 
suggested by various authors'''''. The increased levels of FbDP found here indicates 
that some activation of the coagulation system takes place, but that the fibrinolytic 
system is able to cope with the generation of fibrin. We also found a correlation of 
the degree of cirrhosis with fibrinogen degradation products, which is expected when 
plasm:in is formed without prior activation of the coagulation system. However, the 
levels of the fibrinogen degradation products show only a minor increase, which 
indicates that there is either a very low grade of primary tlbrinogenplysis or that the 
small amount of FgDP is the result of spillover cleavage of fibrinogen by plasmin. 
FbDP and TDP are known to have a significant influence in the Clauss test. 
However, in this group of patients the levels of FbDP and FgDP did not reach the 
levels that are known to affect the Clauss test indicating that even in severe 
cirrhotics, the Clauss method gives accurate results. 
In conclusion: The level of activation of the coagulation system correlates with the 
level of liver cirrhosis in this group. The increases in .fibril/ONell degradation levels 
in the patients with more severe cirrhosis indicate a low level of ongoing primary 
fibrinolysis. We could not show an increased degradation of the A,,-chains of 
fibrinogen. In the Clauss, nor ,in the total clottable tibrinogen assay nor in the EIA 
could a disturbance be found of degradation products or fibrinogen or fibrin as they 
can be found in patients with mild, moderate or severe liver cirrhosis, Therefore, we 
believe that for measuring the fibrinogen levels, all three methods can be used. 
However, we suggest to use the Clauss assay, because it can accurately measure low 
fibrinogen levels, has a good reproducibility and because the test is cheap, quick and 
easy to perform. 
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CHAPTER 4 
REGULATION OF HISTIDINE-RICH GLYCOPROTEIN (HRG), 
FIBRINOGEN AND C-REACTIVE PROTEIN SYNTHESIS THROUGH 
CYTOKINES IN PRIMARY CULTURES OF HEPATOCYTES FROM 
CYNOMOLGUS MONKEY. 
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ABSTRACT 
Histidine-rich glycoprotein (HRG) is a human plasma protein that is synthesized by 
the liver. During the acute phase reaction the plasma levels of HRG are decreased. 
We could confirm this negative acute phase behaviour in cell culture experiments 
with cynomolgus monkey (Macaca fascicularis) hepatocytes that were cultured in the 
presence of conditioned medium from stimulated monocytes/macrophages. Both the 
protein and mRNA levels of HRG were decreased whereas the protein and mRNA 
levels of the positive acute phase proteins C-reactive protein (CRP) and fibrinogen 
were increased, To investigate the mechanism of the negative acute phase reaction of 
HRG in more detail, the effects of interleukin 6 (IL6), interleukin IS (ILlS) and 
tumour necrosis factor-OI (TNFOI) were documented. Both the protein and the mRNA 
levels of HRG were markedly reduced by ILlS and TNFOI, whereas interleukin-6 
([L6) had no effect. Different effects were observed for the positive acute phase 
proteins fibrinogen and CRP, where secreted protein and production of mRNA were 
increased by IL6 and decreased by TNFOI, and fibrinogen was additionally decreased 
by ILlS. 
Our observations indicate that hepatocytes from humans or cynomolgus monkeys 
can be considered a suitable model for studying the regulation of HRG. We showed 
that HRG is a negative acute phase protein and that the negative acute phase reaction 
in hepatocytes from the cynomolgus monkey is regulated by TNFQ' and ILlS, and 
not by [L6. 
INTRODUCTION 
Histidine-rich glycoprotein (HRG) is a plasma glycoprotein that ill vitro modulates 
both coagulation and fibrinolysis I , A range of possible functions arises from the 
capacity of HRG to interact with multiple ligands, including heparin2, plasminogenJ, 
thrombospondin4 and fibrinogen and fibrin5, An association between HRG levels and 
the risk of thrombosis is suggested by the high prevalence of elevated plasma HRG 
levels in patients with venous thrombosis6 , In addition several thrombophilic families 
with familial elevation of HRG have been described'·'. Patients who develop deep 
venous thrombosis during the acute stage of a myocardial infarction have higher 
HRG levels than patients who do not develop this complicationII'. 
Only limited knowledge is available about the regulation of the plasma HRG 
levels. [n several studies a significant decrease of HRG levels (17% to 36%) has 
been found upon administration of oral contraceptives l l. 12 , A decrease is also 
reported in diseases like severe liver malfullctionlJ and sepsisl4, or in response to 
immunosuppressive steroid therapylS, Furthermore HRG levels are negatively 
correlated with C-reactive protein (CRP) levels, indicating that HRG levels exhibit a 
negative response in the acute phasel6 , In addition, treatment of rabbits with 
turpentine resuits in a four to five fold decrease of the mRNA levels of HRGI7. 
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The acute phase synthesis of proteins in the liver .is mainly regulated by the 
cytoldnes inter Ie, kin-6 (IL6) , interleukin-I n (ILl n) and tumour necrosis factor-a 
(TNFa)"·20. These cytoldnes can be secreted by stimulated monocytes", Since HRG 
is synthesized only in the liver" we decided to study the. regulation of the HRG-
synthesis by these three cytokines in cultured hepatocytes. 
In the study of the regulation of HRG the cell culture model that most approaches 
the in vivo situation would be primary cultures of human hepatocytes. However, 
human hepatocytes are difficult to obtain and a large variation in the quality of the 
hepatocytes due to a high diversity in the donor lifestyle complicates this model. 
Several alternative cell culture systems can be suggested to study HRG synthesis. 
The first IDe the human hepatoma cell lines HepG2 and Hep3B, which are cell lines 
secreting many human liver proteins2J· ov~rvi<w: 24 and in which the regulation of the 
protein synthesis bears great resemblance to the regulation in primary hepatocytes. A 
disadvantage of the use of hepatoma cell lines is that the cells are dedifferentiated 
and thereby lost several functions. An alternative model may be primary monolayer 
cultures of hepatocytes from the cynomolgus monkey (Macaca t~lscicularis), a 
nonhuman primate. The HRG of old world monkeys has several antigenic domains 
which are similar to domains in human HRG25 ,26, Additionally, it has been shown 
that the cynomolgus monkey can be used as a model to study the development of 
atheroscJerosis27 , which is often considered as a process of chronic inllammation18 , 
and to study the lipid and lipoprotein metabolism"''', 
We studied the HRG secretion of the hepatoma cell lines HepG2 and Hep3B and 
of primary human and cynomolgus monkey hepatocytes, We then documented the 
acute phase regulation of HRG in primary hepatocyte cultures of Macaca 
fasclcularis, We investigated the HRG secretion and mRNA levels in the presence of 
conditioned medium from monocytes/macrophages. The regulation mechanism was 
further studied in experiments where the hepatocytes were cultured in the presence 
of the cytokines IL6, ILin and TNP", Key experiments with TNP" were performed 
with primary human hepatocyte cuitures, 
MATERIALS AND METHODS 
Hepatoma cell lines. The established cell lines HepG2 and Hep3B, derived from 
human liver tumours, were obtained from Dr. B.B. Knowles (Wistar Institute of 
Anatomy and Biology, Philadelphia, PA, USA), The cells were cuitured in 
Dulbecco's modified Eagle's Medium (DMEM) medium (Plow Laboratories, Irvine, 
Scotland, UK), supplemented with 10% heat-inactivated fetal bovine serum (30 min 
56'C), 2 mmoliL L-glutamine, 100 l'g/mL streptomycin and 100 IUimL penicillin 
(Boehringer Mannheim, Mannheim, Germany) at 37°C in a 5% COl 195% air 
atmosphere. The medium was renewed twice a week. The experiments were started 
when the cells had grown to can fluency, 
Primary hepatocyte cultures. Isolation of parenchymal cells from human and 
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monkey liver was performed by a modification of the two step collagenase method" 
as described previously34-36. Human donor livers became available through the 
Rotterdam Auxiliary Liver Transplantation Program. Livers from Macaca 
fascicularis (1.5-3 years old) were obtained from the National Institute of Public 
Health and Environmental Protection (RIVM), Bilthoven, the Netherlands. The 
animals were bred at the RIVM and served as donors for kidneys used in the 
production of poliomyelitic vaccine at this institute. Viability, based on the ability of 
hepatocytes to exclude trypan blue dye (0.11 %) was 66-96%. The parenchymal cells 
were seeded on fibronectin coated culture dishes at a density of 2 x 10' viable cells 
per cm> and were maintained in Williams E (WE) medium, supplemented with 10% 
heat-inactivated fetal bovine serum (30 min 56°C), 2 mmoliL L-glutamine, 135 
nmoliL insulin, 50 nmol/L dexamethason, 100 pg/mL kanamycin, 100 pg/mL 
streptomycin and 100 IU/mL penicillin at 3rc in a 5% CO,/95% air atmosphere. 
After 14-16 hours the non-adherent cells were washed from the plates and the cells 
were maintained in the same culture medium. 
Conditioned medium (Cl\1) from monocytes{macl'ophages.' Monocytes were 
isolated as described previously37, Briefly, mononuclear cells were isolated from the 
blood of healthy blood donors using density centrifugation over Ficoll (Pharmacia, 
Woerden, the Netherlands), resllspended in M 199 medium and incubated in culture 
wells for 45 minutes. The monocytes, that had specifically attached to the plastic, 
were then cultured for 48 hours in MI99 medium, supplemented with 10 pg/ml 
lipopolysaccharide from Escherichia coli (LPS)(serotype 0128:BI2, Sigma), 10% 
fetal bovine serum (not heat-inactivated), 2 mmol/L L-glutamine, 100 pg/mL 
streptomycin and 100 IU/mL penicillin at 3rc in a 5% CO,/95% air atmosphere as 
described previously". Conditioned medium was collected and stored at -200C until 
use. The concentrations of ILiB in CM has recently been described to range from 
2.5-500 U/mL and of IL6 from 500-10000 UimL as determined by immunoassay". 
Incubation of hepatocytes with cytokines. The effect of conditioned 
monocyte/macrophage medium was studied by culturing the cells during two 
consecutive 24 hours incubation periods in the presence of 10% conditioned 
monocyte/macrophage medium. The effects of the cytokines on protein secretion and 
mRNA levels were also studied by culturing the cells during two consecutive 24 
hours periods in the presence of cytokines with final concentrations of 50 and 250 
Uiml IL6; 50 and 500 U/ml ILiB and 10,25,50,100 and 250 Uiml TNF". The 
protein measurements and mRNA a.ssays were performed after the second incubation 
period. 
Assays 
The antibodies that were used for the measurement of HRG, eRP and fibrinogen 
were raised against purified human proteins, but were also suitable for the 
measurement of HRG, eRP and tibrinogen in the media of hepatocytes frolll the 
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cynomolgus monkey. Human pooled plasma was .used for the reference curve in the 
assays for HRG, fibrinogen and CRP, therefore the lavels of these proteins are 
expressed as equivalents of the corresponding human proteins. 
HRG secretion was measured in conditioned hepatocyte medium with a sandwich 
ELISA specific for HRG, Polyclonal rabbit anti-HRG antibodies raised against 
purified human HRG (Behringwerke, Marburg, Germany) were used for coating. 
Rabbit anti-HRG IgG was used as tagging antibody. The detection limit was O.S 
ng/ml. 
Fibrinogen secretion was measured in culture medium with an enzyme immune 
assay39, using monoclonal antibodies against the COOH terminus of the Aex chain as 
catching antibody and horseradish peroxidase labelled monoclonal antibodies against 
the NH, terminus of the ACi chain as tagging antibody. 
C-reactive protein secretion was measured in conditioned medium with an enzyme 
immune assay, using horseradish peroxidase labelled rabbit polyclonal antibodies 
against human CRP (DAKO, Denmark) as catching and tagging antibodies. 
Total cell pl'otein. Cell protein was assessed with the Lowry method for total 
protein40 lIsing bovine serum albumin (BSA, Sigma) as reference. 
mR1~A analysis. RNA was isolated from the hepatocytes after the second 24 hours 
period using the method described by Chomzynski and Sacchi'l Equal amounts of 
RNA from different incubation experiments were separated on a denaturing 1.2% 
agarose gel containing 0.22 mollL formaldehyde. The RNA was then transferred to 
a nylon membrane (Amersham, UK) by Northern blotting. The membranes were 
hybridized at 65'C in 7% sodium dodecyl sulphate with 0.5 mollL NaHPO, and 10 
mmol/L EDTA, pH=7.2 using Jlp labelled probes which were labelled with a 
random primer method (Amersham, Bucks, UK). The complete 2.1 kb eDNA 
fragment of human HRG", eDNA for the BB chain of librinogen (gift of Dr. S. 
Lord, Chapel Hill, USA), eDNA of CRr", and a 1.2 kb fragment of rat 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) eDNA (Kindly provided by 
Dr. R. Offringa)" were used as probes. The blots were routinely washed at 65'C 
two times with 2 x SSC (I x SSC = 0.15 mollL NaC1I0.015 mollL sodium citrate, 
pH=7.0), 1% SDS and two times with 0.3 x SSC, I %SDS. Autoradiograms were 
prepared using Kodak XAR-S film and intensifying screens at -70'C. The mRNA 
bands were scanned using a Hewlet Packard ScanjetPlus, after which quanti tat ion of 
the relative amounts of mRNA was conducted using the density of the 28S RNA 
band, stained by ethidiul11 bromide, as an internal standard. 
Statistical analysis. The effects of conditioned monocyte/macrophage medium and 
of the individual cytokines on the protein synthesis of HRG, CRr and tibrinogen 
were studied with the Student's t-test. The statistical package SOLO for personal 
computers was used to do the calculations. P levels under 0,05 were considered 
significant. 
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figure 1. Effect of 2 times 24 hours treatment with interleukin-6 (lL6), interleukin-ifl (lLlIl), tumour 
necrosis factor a (TNFa) or conditinned medium from LPS-slilllu]ated n1onocytes/lllacrophages on the 
secretion of histidine-rich glycoprotein (HRG)(A), C-reactive protein (CRP)(B) amI fihrinogen (C) by 
cynomolgus monkey hepatocytes_ An average of 4 experiments was performed for eHch concentration 
of a cytokine. The levels are expressed as a percentage of the control. The me,lIl ahsolute synthesis of 
HRG under basal culture conditions was JOO ng/mg cell protein/24 hOllrs (SO 98, r:mge 17-359, 
n=12), of eRP this was 63 ng/lllg cdl protein/24 hours (SO 57, range 8-194, n=l3) and of 
fibrinogen 2.24/lg/mg cell protein/24 hours (SD 0.93, nmge 0.86-4.06, n= 12). 
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RESULTS 
HRG productioll by hepatoma cell lilies and prill/my hepatocytes 
HRG was analyzed in the media of HepG2 and Hep3B cells cultured either with 
serum free medium or with medium supplemented with 10% FCS or 1% (w/v) 
HSA. However, no HRG could be detected in the conditioned media after 24 and 48 
hours with our assay that has a detection limit of 0.5 nglml HRG. Also, no HRG 
mRNA could be demonstrated in the hepatoma cells. 
In primary cultures of simian hepatocytes a mean basal HRG secretion of 100 (SD 
98, range 17-359, n=12) ng/mg cell protein124 hours was found, whereas in human 
hepatocytes a basal level of HRG secretion of 173 (SD 188, range 12-430, n=4) 
nglmg cell protein/24 hours was observed. The mean basal CRP synthesis in the 
simian hepatocytes was 63 ng/mg cell protein124 hours (SD 57, range 8-194, n= 13) 
and for fibrinogen it was 2.24 I'g/mg cell protein124 hours (SD 0.93, range 0.86-
4.06, n = 12). In both simian and human hepatocytes substantial amounts of mRNA 
could be detected with the human eDNA probe for HRG. The length of the human 
and simian mRNA was 2.4 and 2.9 kb, respectively. The human HRG mRNA length 
was in agreement with published data". 
Elfecls of conditiolled fIlonoCYleimocroplwge medill/II 
After culturing simian hepatocytes for two consecutive 24 hours periods in the 
presence of 10% conditioned medium from lipopolysaccharide (LPS) stimulated 
monocytes/macrophages the HRG secretion had decreased to 71 % of the control (SD 
11, range 61-86%, p=O.OI, n=4). A marked increase of the CRP secretion to 
390% (SD 156%, range 173-589%, p=0.07, n=4) and of the fibrinogen secretion 
to 310% (SD 156%, range 183-581 %, p=0.05, n=4) of the control levels were 
observed (figure I). The density of the HRG mRNA band was compared with the 
density of the 28S RNA band, which was therefore used as a measure of the amollnt 
of RNA that was analyzed. With the conditioned medium a decrease of the HRG 
mRNA level to 15% of the control was observed while the mRNA levels of CRP 
and fibrinogen had increased (figure 2). 
Elfeci of illdividual cylOkilles all secre/ed proldll ({lid mRNA levels 
When the hepatocytes had been cultured for two times 24 hours in the presence of 
ILl13 or TNFa, the HRG secretion had decreased in a dose dependent way. showing 
a decrease to 79% of the control at 500 U/ml ILlS (SD 14%, p=0.004, n=9) and a 
decrease to 66% of the control at 500 Ulml TNFa (SD 9%, p<O.OOI, n=6) (tigure 
I). The HRG secretion was not significantly influenced by IL6 at concentrations up 
to 250 U/ml. In 3 key experiments with human hepatocytes the HRG secretion was 
decreased 30% by 500 lU/mL TNFa, comparable to the effects in simian 
hepatocytes. 
The secretion of the acute phase protein CRP was dose dependently elevated by 
IL6 (380% of control levels with 250 UlmL IL6), but not intluenced by 500 lU/mL 
ILlS. A dose-dependent decrease was observed with TNF", (22% of the control 
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figure 2. Effect of 2 limes 24 hours treatment with interleukin-6 (IL6), interieukin-ill (lLlB), tumour 
necrosis factor ex (TNFa) or conditioned medium from LPS-slimulated monocyles/macrophages on the 
mRNA levels of histidine-rich glycoprotein (HRG), fibrinogen and C-re,active protein (CRP) in 
cynomolgus monkey hepatocytes (n= I), The intensity of the 28S RNA bands was used as an internal 
standard to correct for differences in the amount of total RNA applied to the gel. 
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levels with 500 U/mL TNF,,)(figure I). 
The synthesis of fibrinogen was dose-dependently decreased by ILl ft (50% of 
control levels with 500 UlmL) and TNF" (14% of control levels with 500 UlmL 
TNF,,). Culturing of the simian hepatocytes in the presence of IL6 showed a dose-
dependent increase of the fibrinogen secretion (225 % of the control levels with 250 
U/mL IL6)(figure I). 
To investigate the regulatory mechanism of HRG, eRP and fibrinogen secretion, 
the effects of the cytokines on the HRG, CRP and Bft-fibrinogen chain mRNA levels 
were assessed by Northern blot hybridization (figure 2). Since the GAPDH mRNA 
levels were increased by TNF" (results not shown), the density of the 28S RNA 
band was used as an internal control. The decrease of the mRNA levels of the three 
proteins after culturing the simian hepatocytes in the presence of TNF" was dose-
dependently and much stronger than the decrease of the secreted protein. HRG 
mRNA levels were 10%, fibrinogen Bft mRNA levels 2% and CRP mRNA levels 
33% of the control levels with 500 U/mL TNFa. Culturing the hepatocytes with 
ILln also showed a dose-dependent decrease of the mRNA of the three proteins that 
was much stronger than the effect of the secreted proteins, but the effect is less 
pronounced for HRG and BG fibrinogen. HRG mRNA levels were 49%, fibrinogen 
Bn mRNA levels 38% and CRP mRNA levels 75 % of the control levels with 500 
UlmL ILlG. No effect of IL6 on the HRG mRNA level was observed. 
DISCUSSION 
Most acute phase proteins are synthesized in the liver. Therefore, cultured 
hepatocytes might be used as a model system for studying the acute phase behaviour 
of several proteins such as HRG. Primary cultures of human hepatocytes can be 
considered as the 1110st physiologically relevant cell culture system, but since their 
availability is limited, we evaluated alternative models. 
Firstly, the hepatoma cell lines HepG2 and Hep3B were considered, because they 
are known to produce many proteins that are also synthesized in the human liverB .24 . 
It has repeatedly been shown that there is also consistency in the regulation of the 
synthesis of these proteins4s,46, However, we could not detect the presence of HRG 
in conditioned medium of these cell lines, making HepG2 and Hep3B cells 
unsuitable for studying the regulation of HRG. The absence of HRG in conditioned 
media of HepG2 cells has previously been described by Fair et al". The acute phase 
protein CRP is also not produced by HepG2 cells"'''. However, hepatoma cell lines 
have been described as being useful for the study of a number of other acute phase 
proteins, like fibrinogen, haptoglobin and albulllin2J·24 . 
Secondly, primary monolayer cultures of hepatocytes from the cynomolgus 
monkey were evaluated. In these cells mRNA encoding for HRG was detected and 
they secreted HRG in the culture medium in comparable quantities to primary human 
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hepatocyte cultures. Therefore, primary cultures of simian hepatocytes were lIsed to 
study the acute phase regulation of HRG. We started by culturing simian hepatocytes 
in the presence of conditioned medium (CM) from LPS stimulated 
monocytes/macrophages which contains high levels of the cytokines IL6, lLlB and 
TNFa. CM induced a marked decrease of the HRG synthesis and exerted even 
larger effects on the level of HRG mRNA. This confirms that HRG is a negative 
acute phase reactant, as has previously been suggested by studies in patients with 
inflammatory diseases l6 and shown in studies performed in cultured rabbit 
hepatocytes l7 . CM significantly increased the secretion of the positive acute phase 
proteins fibrinogen and CRP, that were used as controls for the stimulation of the 
acute phase of the cultured hepatocytes. 
The decreasing effects of CM, TNFa and ILIB on the mRNA levels of HRG, BB 
fibrinogen and CRP was much more pronounced than their effects on the protein 
secretion. The secretion of the proteins is the accumulated secretion of a 24 hour 
period, while the mRNA levels represent the situation in the hepatocytes at the end 
of this 24 hour period. This might be the explanation for the differences in the 
magnitude of the effects that we observed. Another explanation might be that the 
cytokines affect RNA transcription or other steps in the protein synthesis. 
To characterize the regulation of the HRG synthesis by the acute phase the effects 
of individual cytokines on the HRG secretion were studied. Our results with the 
primary cultured simian hepatocytes identified TNFa and ILIB as the cytokines that 
regulate the HRG synthesis. The cytokine that is the 'strongest determinant of the 
synthesis of most positive acute phase proteins, IL6, produced only a small, but not 
significant decrease of the HRG secretion. ILIB and TN Fa have also been described 
to decrease the synthesis in hepatoma and primary human hepatocytes of albumin 
and transferrin, two other negative acute phase proteinslil.4.~.4'Uli. However, although 
IL6 has been described as decreasing the secretion of these two proteins in hepatoma 
and primary human hepatocytes, it did not affect the HRG secretion in simian 
hepatocytes in our study. This suggests that there are either species differences in 
the regulation of acute phase proteins or that the regulations of the negative acute 
phase proteins do not always parallel each other. Differences in the regulation of 
acute phase proteins are further indicated by our observations on the secretion of 
fibrinogen which was increased by IL6 and decreased by ILl Band TNFa, while 
CRP secretion was increased by IL6, decreased by TN Fa and not affected by ILI~. 
The models to study the regulation of protein synthesis in hepatocytes have their 
own advantages and limitations. For example, the effects of cytokines on the 
synthesis of acute phase proteins in human hepatoma cell lines are not consistent in 
the different ceIl lines. Also, the effects are not always identical to the effects in 
primary human hepatocyte cultures because hepatoma cells may have 
dedifferentiated49 , resulting either in different regulation of some proteins or in a 
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loss of the capacity to synthesize specific proteins like HRG and eRP. On the other 
hand, the advantage of human hepatoma cell lines is that they yield a reproducible 
model. The preferred primary hepatocyte model would be human hepatocytes. Since 
their availability is limited, hepatocytes from other species are regularly used. The 
disadvantage here is the possibility of species differences. Especially for acute phase 
proteins, these differences have been described. For example, eRP is an acute phase 
protein in human, but not in goat and cow that have a constitutional high level of 
eRP which do not rise following inj ury51,52 indicates that the acute phase reaction 
needs to be studied in a species that is as closely related as possible. Since the 
cynomolgus monkey is an old world monkey, it is relatively close to human. 
In our study we only had the opportunity to compare the effect of TNFa in human 
and simian hepatocytes. In both models, the HRG secretion was decreased by 
TNFo:. Furthermore, the positive acute phase effects of cytokines on eRP and 
fibrinogen in hepatocytes from the cynomolgus monkey were comparable to the 
effects that have been described for these cytokines in human hepatocytes"·". The 
similarity in the observations in human and simian hepatocytes suggests that primary 
cultures of hepatocyles from cynomolgus monkeys may be considered a suitable 
model system for studying acute phase proteins. However, care must be taken in 
extrapolating the results of simian hepatocytes to the human situation, because 
differences between the two systems are also observed, for example, in human 
hepatocytes where both ILl fi and IL6 stimulate the eRP synthesis''!, while we 
observed no effect of ILW on eRP secretion in simian hepatocytes. This requires 
further comparative studies in human and simian hepatocytes. 
The results of this study showed that TN Fa and ILl fi down regulated Ihe HRG 
secretion and mRNA levels in primary cultures of simian hepatocytes. IL6 does not 
appear to be an important cytokine for the regulation of the HRG synthesis, as 
opposed to its strong effect on the synthesis of most positive acute phase proteins, 
such as fibrinogen and eRP. 
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ABSTRACT 
The plasma levels of fibrinogen and C-reactive protein (CRP) are associated with the 
risk for ischaemic heart disease (IHD). Both these proteins are significantly 
increased by the acute phase reaction. The cytokines that have a major role in the 
regulation of synthesis of acute phase proteins by the liver are interleukin 6 (IL6) , 
interleukin IB (ILl B), and tumour necrosis factor Ci (TNFCi). The production of 
these cytokines will be increased by an inflamed vascular wall. It has therefore been 
suggested that plasma fibrinogen and CRP levels reflect the inflammatory condition 
of the vascular wall as well. 
Smoking is another well-known risk factor for cardiovascular disease. Both 
fibrinogen and CRP have been reported to correlate with smoking habits. If the 
inflammatory state of the vascuiar wall is increased by smoking, it will result in 
increased plasma cytokine levels and consequently in increased levels of acute phase 
proteins. 
In this study we evaluated the inflammatory state of 34 patients with severe 
coronary artery disease (CAD)(with complaints of angina and scheduled for PTCA) 
and 30 healthy controls comparable for age and smoking habits. We measured 
fibrinogen, CRP, ILlB, IL6 and TNFCi-levels and also combined the individual 
proteins in an index which we denominate as the inflammatory index. 
Our data indicate an elevated inflammatory status in the patient group compared to 
the healthy controls. When we discriminate between smokers and non-smokers, we 
find a significant higher inflammatory status: in non-smoking patients than in non-
smoking controls; in smoking patients than in smoking controls; in smoking than in 
non-smoking patients; and in smoking than in non-smoking controls. 
Our results indicate an increased inflammatory condition of the vascular wall in 
patients with severe CAD compared to healthy controls. Furthermore, we 
demonstrate that in patients with CAD and in healthy controls, smoking increases 
the inflammatory state as reflected by an index consisting of fibrinogen, CRP and 
IL6. Remarkably, the increase of fibrinogen in CAD patients could not be fully 
explained by increased inflammation. 
INTRODUCTION 
Elevated plasma fibrinogen levels have been identified as an independent risk 
indicator for coronary artery diseases in healthy populations l -6• Recently, in the 
ECAT-Angina Pectoris study on patients with angina pectoris both plasma fibrinogen 
and C-reactive protein (CRP) levels were higher in the event group'. In this study 
both the fibrinogen and the CRP level wete well within the clinical normal range in 
both the high and the low risk groups. Other inllammatory markers, slich as 
leucocyte count6,!(.9, monocyte countHl , cytokines in the atheroma ll , expression of 
granulocyte and monocyte receptors 12 , and inflammatory infiltrates in cardiac 
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arteries ll have also shown a correlation with the pathogenesis of coronary artery 
disease. 
In general, during inflammation the levels of the acute phase proteins fibrinogen 
and CRP are increased. A contribution of inflammation to atherosclerosis has been 
suggested"'''. Ross et aI." postulates that advanced lesions of atherosclerosis result 
from excessive inflammatory - fibroproliferative response to numerous different 
forms of insults. The resulting low grade inflammation of the vascular wall is even 
suggested to be the main II mechanism" of atherosclerosisl9, The plasma t1brinogen 
and CRP levels might then very well represent the inflammatory condition of the 
vascular wall, because an association has been found between the number of 
diseased vessels and the plasma fibrinogen levels2~21. 
Smoking increases the risk for cardiovascular disease2J·2~. In general, the idea is 
that smoking enhances the platelet aggregation" or reduces the oxygenation status of 
the blood, by an increase in the tonus of the coronary arteries and by the binding of 
carbomonoxide to haemoglobin3Cl-33, However, both fibrinogen and eRP show a 
correlation with smoking habits as welF,26.27.J~~3~ which may suggest that smoking 
induces an inflammatory reaction of the coronary arteries, tinally leading to 
aggravation of the coronary artery disease. The correlation with smoking might also 
be mediated through the acute phase reaction. Therefore, we established in this study 
the relation between smoking habits of patients with severe coronary artery disease 
(CAD) and healthy controls on the one hand and the inflammatory status, as 
reflected by the levels of fibrinogen, CRP, interleukin-lfi (ILlfi), interleukin-6 (IL6) 
and tumour necrosis factor-a (TNFa), on the other. 
PATIENTS AND METHODS 
Patients and eontrols 
Thirty-four patients (26 male, 8 female) with complaints of angina and scheduled for 
percutaneous transluminal coronary angioplasty (PTCA) were enroled in this study. 
On the diagnostic coronary angiogram only one target vessel was considered 
responsible for the complaints. The mean (I SD) age was 54.2 (8.3) years. Fifteen 
patients had a history of myocardial infarction, 6 patients had undergone PTCA 
earlier and in 2 patients a coronary artery bypass graft (CABG) operation had been 
performed before their participation in the study. The severity of anginal complaints 
was scored according to the New York Heart Association classification: eight 
patients were in Class II, 17 patients were in Class III and 9 patients were in Class 
IV. The patients did not take any medication known to intluence tibrinogen levels. 
On coronary angiography one vessel disease (VO) was documented in 29 patients, 
two VD in 4 patients and three YD in I patient. The target vessel was the left 
descending artery (LAD) in 17 patients, the left circumtlex artery in 7 patients and 
the right coronary artery in 10 patients. Thirty healthy male blood donors, 
comparable for age (54.0 (6.4) years),,·40 and smoking habits, formed the control 
group. 
The study was conducted in accordance with the Declaration of Helsinki: approval 
was given by the Medical Ethical Committee of the Erasmus University, Rotterdam 
and written consent was obtained from the patients. 
Smoking 
The participants were interviewed for their smoking status. If smoking was stopped 
within one month before blood sampling the participant was considered a smoker. 
The ex-smokers who had stopped smoking at least 6 months before blood sampling 
were considered non-smokers. No patients stopped smoking between I and 6 months 
before the start of the study. Sixteen patients and 15 controls were smokers. 
Blood Sampling 
Blood was collected and anticoagulated with 5.4 mM EDTA in melting ice. After 
centrifugation at 2000 x g for 15 min the plasma was collected and stored at -80·C 
until use. The buffy-coat fraction was lIsed for monocyte isolation. 
Cytokine secretion of monocytes 
Monocytes were isolated from the buffy-coat fraction which was reconstituted with 
phosphate buffered saline (PBS) to 20 ml, layered on top of a Lymphoprep 
(Nycomed, Haarlem, The Netherlands) gradient, and centrifuged at 800 x g for 10 
min at room temperature. The fraction containing the mononuclear leucocytes was 
washed with PBS. Next, the erythrocytes were lysed in 155 mmol/L NH,CI, 10 
mmol/L NaHCO" 0.1 mmollL EDTA. The remaining mononuclear leucocytes were 
washed once with ammonium chloride solution, once with PBS and were then 
resuspended in RPMI-medium (Flow Laboratories, Irvine, UK) with 2 % fetal calf 
serum. The percentage of monocytes in this fraction was determined from cytospin 
preparations and in general amounted to 25%. 6.3 x IG~ cells were transferred into 
96-wells culture plates (Costar, Badhoevedorp, The Netherlands) and incubated at 
3TC in a humidified environment of 5 % CO,/95 % air in the presence or absence of 
5 ng/ml Iipopolysaccharides". After 24 h supernatanls were collected and stored at -
70·C. 
Fibrinogen 
Fibrinogen is measured with an enzyme imllluno assay that lIses the monoclonal 
antibody 08 (directed against the COOH-terminal part of the tibrinogen a-chain) as 
a catching antibody and peroxidase conjugated - Y 18 (directed against the NH,-
terminal part of the fibrinogen a-chain) as lagging antibody", 
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C-reactive protein 
C-reactive protein is measured with a sensitive enzyme immuno assay that uses 
rabbit anti-human C-reactive protein (Dako) as a catching and a tagging antibody. 
Cytoklnes 
IL6, ILlS and TNFa were measured with enzyme immuno assays according to the 
instmctions of the manufacturer (Medgenix, Amersfoort, the Netherlands). 
Innanunatory index 
Because the study groups are small and with a large variation, we combined the 
inflammatory markers in an inflammatory index to study the total acute phase 
condition of the patients. The inflammatory index was composed by replacing the 
data for each variable with their ranks and adding those ranks. Eventually, the 
inflammatory index consisted of fibrinogen, CRP and IL6. We did not include ILIB 
and TNF" because they did not contribute. 
Statistical analysis 
The distribution of the variables was positively skewed. Logarithmic transformation 
gave a normal distribution for fibrinogen, CRP and TNF" , but not for IL-IB and 
IL6 and therefore we used non-parametric tests (Mann-Whitney, median and range) 
to study the single variables. The inflammatory index was studied using analysis of 
covariance with adjustment for age and gender as described by Conover''', who 
shows that parametric tests can be assessed for analyzing rank transformed data. 
Because the fibrinogen levels were normally distributed after a logarithmic 
transformation, we studied the effect of smoking and CAD on fibrinogen in healthy 
controls and patients after adjusting the fibrinogen levels for CRP and IL6 in a 
multiple regression analysis. 
RESULTS 
When we compared the plasma levels of acute phase proteins in the patient group 
with those in the control group we found that the fibrinogen levels in the patients 
were significantly higher than those in the healthy controls (table I). We found no 
difference for CRP. When comparing the plasma levels of the individual cytokines, 
we observed only a difference in IL6 and not for ILl G and TNFac. We constructed a 
parameter that represents the inflammatory markers by replacing the data for 
fibrinogen, CRP and IL6 with their ranks and adding these ranks of the grouped 
variables, ILlB and TNF" were not included in this index because they did not 
contribute. We then noticed that this inflammatory index is signiticantly higher in 
patients (mean 114) than in controls (mean 79)(p=O.0002} using the Mann-Whitney 
test (table I). 
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Table 1. Median and (range) of acute phase markers in healthy controls and patients. 
Controls Patients p 
Fibrinogen (gIL) 2.09 (1.34-3.05) 2.87 (1.7-4.7) 0.0002 
C-reactive protein (mg/L) 1.99 (0.27-20) 1.3 (0.1-20) n.s. 
Interleukin-lfi (pg/ml) 0(0-46.0) 0.22 (0-50.3) n.s. 
Interleukin-6 (pg/ml) 0(040.8) 1.81 (0-38.9) 0.0001 
Tumour necrosis factor-a (pg/ml) 8.8 (3.1-82.8) 8.7 (0.7-43.2) n.s. 
Combined marker index 79 (26-135) 114 (45-183) 0.0002 
p gives the significance between the control and patient group as found with the Mann~WWtney test. 
When the patient and control groups were subdivided into smokers and non-smokers 
the acute phase protein fibrinogen levels were higher in smoking than in non-
smoking controls (2.3 giL and 1.9 giL, respectively), but simi";r in non-smoking 
and smoking patients (both 2.9 g/L)(table 2). The plasma fibrinogen levels were 
higher in non-smoking patients than in non-smoking controls, and also higher in 
smoking patients than in smoking controls. We further observed that smoking gives 
a comparable increase of the CRP levels in CAD patients and healthy controls (0.9 
vs 3.0 giL and 1.0 vs 4.0 giL, respectively). The levels of the lL6 and lUll were 
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Table 2. Acute phase markers (median and range) in healthy controls and patients. considering their smoking status. 
controls patients 
Don-smokers smokers non-smokers smokers 
Fibrinogen (gIL) 1.93 2.29 2.87 2.86 
(1.34-2.74) (1.35-3.05) (1.65-4.73) (2.00-4.55) 
C-reactive prokin (mglL) 1.00 3.97 0.85 3.01 
(0.27-20) (0.27-20) (0.11-5.68) (0.31-20) 
Interleukin-1B (pg/ml) 0 0 0 0.87 
(0-46.0) (0-46.0) (0-7.3) (0-50.3) 
Interleukin-6 (pg/ml) 0 0 0.1 3.8 
(0-40.8) (0-0) (0-9.5) (0-38.9) 
Ti~"Ue no;;:crosis factor-a (pg/ml) 6.3 10.3 8.5 9.3 
(3.1-82.8) (3.1-24.5) (0.7-42.5) (2.4-43.2) 
Combined marker index 69 89 93 132 
(27-135) (26-130) (45-152) (66-183) 
SignificanCl:: kvds in columns A: betwIXn non-smoking and smoking controls 
B: between non-smoking and smoking patients 
C: between non-smoking controls and non-smoking patients 
D: betwoXn smoking controls and smoking patients 
n.s. Significance le\'d >0.1 in the Mann Whitney kst 
n.d. not determined (too many VeT)' low k\'ds) 
A B C D 
0.Q7 n.s. 0.02 0.008 
n.s. 0.02 n.S. n.s. 
D.S. 0.08 n.s. n.s. 
n.d. 0.02 0.06 <0.001 
O.lD D.S. D.S. n.s. 
0.03 0.002 0.04 0.007 
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very often below the detection limit, which hampered the study of the control group. 
The levels of these cytokines were highest in the smoking patient group. No 
significant effects on the TNF" levels were found. 
Combining fibrinogen, CRP and IL6 in an inflammatory index resulted in highly 
significant differences between non-smokers and smokers in both the patients and the 
controls. The inflammatory index was also significantly elevated in smoking patients 
in relation to smoking controls and in non-smoking patients in relation to non-
smoking controls (table 2). 
When we adjusted the fibrinogen levels for CRP and IL6 we still observed 
significantly higher values in non-smoking patients than in non-smoking controls 
(p <0.001) and in smoking patients when compared to smoking controls (p=0.03). 
The effect of smoking on the adjusted fibrinogen levels in patients and in healthy 
controls was not significant (data not shown). 
We also studied the secretion of cytokines by normal and LPS-stimulated 
monocytes of non-smoking and smoking patients. The results showed that smoking 
did not affect the basal cytokine secretion or the LPS-induced cy.tokine production 
(table 3). There was no relation between the cytokine secretion of normal and LPS-
stimulated monocytes and the cytokine levels we measured in plasma. 
Table 3. Median and range of cytokin~,s secreted hy liropoly.~acchari{k (LPS) stimulated ami 
unstimulated monocytes of patients. 
unstimulated 
monocytes 
LPS-stimulalcd 
monocyles 
HtB 
116 
TNFa 
HIli 
IL6 
TNFa 
non-smokers 
3t (0-272) 
340 (H381) 
47 (2-218) 
113 (19-461) 
891 (19-1952) 
84 (24-266) 
smokers p 
63 (0-210) n.s. 
794 (0-2230) n.s. 
61 (0-293) n.s. 
125 (O-5(5) n.s. 
1106 (3-2284) n.s. 
64 (0-457) n.s. 
p gives the significance bdw~en the control Hnd patient group as found with the Mann-Whitney test. 
DISCUSSION 
We studied the inflammatory markers t1brinogen, CRP and the cytokines IL6, III n 
and TNFa in patients with severe PAD and in healthy volunteers. The patients had 
significantly higher levels of tibrinogen and IL6 than controls. As anticipated, the 
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inflammatory index was higher in patients than in controls. Even though the majority 
of the levels would cli'nically not be considered incre~sed, our results indicate that 
patients with CAD have an increased habitual inflammatory status. 
When we then studied the effect of smoking on the plasma fibrinogen levels in the 
two groups, we found an effect of smoking in healthy controls, but not in patients. 
Previously, it has already been reported in individuals withollt cardiovascular disease 
that smoking increased fibrinogen levels in a dose dependent way26,J7, The absence 
of an increase of fibrinogen levels in patients suggests that the fibrinogen-increasing 
effect of smoking is eliminated in patients where the tibrinogen is already increased 
by CAD. The PLAT study on patients with vascular disease also described the 
absence of an effect of smoking on the plasma fibrinogen levels21 • 
The CRP levels were equally elevated by smoking in the controls and the patients. 
The effects of smoking on CRP have repeatedly been reported in healthy controls,,·J8 
but the effect of smoking on CRP in CAD patients has not been studied before. 
The association between smoking and the acute phase proteins fibrinogen and CRP 
suggests that smoking induces a low-grade, continuous inflammatory status. This 
does not necessarily mean that the vessel wall is more inflamed, but the 
identification of smoking as a risk factor for ischaemic heart disease strongly 
suggests that smoking has an effect on the condition of the vascular wall. 
The regulation of the tibrinogen and CRP synthesis in the liver is mainly by IL6, 
ILiB and TNF,,"4'. In this study the levels of IL6 and ILiG are higher in smoking 
than in non-smoking patients, but no conclusions can he drawn for the controls 
because in too many individuals the levels are below the detection limit. TNFlX is 
not influenced by smoking. 
Because of the modest sample size of this study, we combined fibrinogen, eRP 
and IL6 in an inflammatory index. ILiG and TNF" were not included in this index, 
because they did not contribute. We found a comparable increasing effect of 
smoking on the intlammatory index in controls and atherosclerotic patients, This 
further supports the hypothesis of an increased inflammatory status in 
smokers7 ,26,27,3-t-38. 
In this study we only had one blood sample from each patient. It is known that 
acute phase proteins, especially eRP, react very strongly to inllammatory reactions. 
Even a light common flu gives a marked elevation. This process should be separated 
from the levels that were increased as a result of the intlammatory status of the 
blood vessels47 • Therefore it is advisable to use multiple samples in order to 
determine a basal, constant level for acute phase proteins and exclude the outliers. In 
this study, a few CRP levels were above the clinical normal value of 10 mg/L and 
this increase might be caused by some other disease. Because we lIsed nonparametric 
statistics or parametric statistics on rank transformed data our results are not biased 
by these patients, but more precise resuits will be obtained if habitual levels can be 
determined. 
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Monocytes are a major source of various cytokines. Because smoking patients had 
a higher inflammatory index than non~smokers we studied whether the basal or the 
LPS~stimulated production of cytokines in monocytes of smokers was increased. 
This was not the case. This might indicate that smoking does not bring circulating 
monocytes in an activated condition. Although there is also no association between 
plasma levels of cytokines and the basal or LPS-induced cytokine production of 
monocytes it is still possible that smoking has an effect on local cytokine release by 
monocytes or has an effect on other cytokine-releasing cells, like the endothelial 
cells that line the (coronary) blood vessels. 
To evaluate whether the acute phase reaction was the only regulatory mechanism 
that contributed to the observed increase in the levels of fibrinogen, we also studied 
the fibrinogen levels when we adjusted those for CRP and IL6. The effect of 
smoking in controls was reduced, indicating that smoking indeed induces an 
inflammatory response. However, we still found ,both smokers and non-smokers, a 
significant contribution of atherosclerosis to the fibrinogen levels. This implies that 
another mechanism may also be involved here, which may be at least partly genetic, 
as it has been reported that up to 51 % of the fibrinogen level is genetically 
determ i ned48 .49 • 
In summary, we have shown that l) patients with CAD have a higher 
inflammatory status than healthy controls; 2) that the intlammatory status is 
increased by smoking both in CAD patients and in healthy controls; and 3) that the 
increase of the plasma fibrinogen levels in patients with coronary artery disease 
cannot be fully explained by an increased inflammatory status. 
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CHAPTER 6 
INTER- AND INTRAINDIVIDUAL VARIABILITY IN PLASMA 
FIBRINOGEN, PLASMINOGEN ACTIVATOR INHIBITOR (PAD ACTIVITY, 
C-REACTIVE PROTEIN AND HISTIDINE-RICH GLYCOPROTEIN IN 
YOUNG HEALTHY VOLUNTEERS 
Anton CW de Bart', Moniek PM de Maatl.', Bart C Hennis', Adrie C Havelaar', 
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'Gaubius Laboratory TNO-PG, Leiden, and 'Dept. Internai Medicine II and 
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ABSTRACT 
We investigated the intraindividual variability in plasma levels of fibrinogen, 
plasminogen aclivator inhibitor (PAl) activity, C-reactive protein (CRP) and 
histidine-rich glycoprotein (HRG) in 20 healthy, young individuals and compared 
this with the interindividual variability in a comparable group, For each of these 
parameters the intraindividual variation (13% for fibrinogen, 4% for 10g(PAI-
activity), 14% for 10g(CRP), I % for HRG of the total variance) is smaller than the 
interindividual variation (87%, 96%, 86%, 99% of the total variance, respectively). 
The results in this group indicate that for assessment of an individual level multiple 
sampling will not be needed for HRG and PAl-activity, For fibrinogen duplicate 
sampling will be recommended and for CRP triplicate sampling is recommended 
because that will make the identification of incidental peak values possible. In an 
epidemiological study the sample sizes, based on the variance of this transversally 
studied group of healthy young individuals, needed to detect a 15% difference 
between two groups will be 142 for fibrinogen, 162 for PAl-activity, 412 for CRP 
and 86 for HRG, 
Additionally, we studied the contribution of genetic polymorphisms of the 83-
fibrinogen (Bell and G/A~") and PAl-activity (Hilldm and CA-repeat) genes to the 
intra- and the interindividual variation. The fibrinogen genotypes were associated 
with plasma fibrinogen levels. However, no effects of fibrinogen or PAl 
polymorph isms on intraindividual variation were observed in this group of young, 
healthy individuals. One has to be conscious that different variations might be 
possible in groups of older or diseased individuals. 
INTRODUCTION 
Fibrinogen l -7 as well as plasminogen activity inhibitor-l (PAI-ll and C-reactive 
protein (CRP)' are variables that have been identified as risk indicators for 
cardiovascular disease in variolls epidemiological studies. Elevated plasma levels of 
histidine-rich glycoprotein (HRG) are associated with venous thrombosis'! and 
patients who develop venous thrombosis during the aClite phase of a myocardial 
infarction have higher HRG levels lO• Therefore interest is developing in the 
measurement procedures of these factors, because accurate and specific knowledge 
of plasma fibrinogen, PAl-activity, CRP and HRG levels will increase their value as 
risk indicators. 
The plasma levels of fibrinogen, PAl-activity, eRP and HRG are intluenced by 
various life style aspects. Fibrinogen is raised by smoking, obesity, increasing age 
and by oral contraceptive use ll ,l2. A negative association has been found between 
mild alcohol intake and the plasma fibrinogen concentrationl.l. PAl-activity is raised 
by sl1loking l4, increasing ageL'i,16, pregnancyl1, regular alcohol intake 1it ,l9 and fish oil 
conslllllption2(1. Training21 and lise of oral contraceptives or anabolic steroids2l can 
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reduce plasma levels. Furthermore, PAl-activity levels in plasma are subject to 
diurnal variation23 , CRP levels are increased in smokers5,24.2\ with physiological 
stress26 and are associated with obesity5, HRG is decreased by estrogens21.18 and 
anabolic steroids29 • 
The acute phase reaction can increase the plasma fibrinogen levels two to fourfold 
and CRP levels can increase even a hundredfold. PAI-l and HRG are also an acute 
phase proteins, but the effect on their plasma levels is much smaller. PAl-activity 
will also increase in acute phase situations, but HRG is a negative acute phase 
protein3Q..32, When using these factors as risk indicators we are interested in habitual 
levels and not in short-t,ime fluctuation by transient acute phase reactions. In most 
epidemiological studies one blood sample is taken, which is then accepted as 
representing the habitual level. 
Several investigators have reported genetic polymorphisms of the fibrinogen and 
PAI-l genes. The genotypes were associated with plasma fibrinogen and PAI-
levels33-36 , Humphries et ap-t also reported that individuals carrying the rare allele of 
the Bell polymorphism of the Bn-fibrinogen gene have a larger longitudinal 
variation of their fibrinogen levels. 
In this study we have investigated the value of single and multiple sampling in 
assessing the habitual levels of fibrinogen, PAl-activity, CRP and HRG in young, 
healthy individuals. We also documented the contribution of genetic polymorph isms 
of fibrinogen and PAl to their habitual plasma levels and to their longitudinal 
variation in plasma levels of these factors. 
VOLUNTEERS, MATERIALS AND METHODS 
Healthy individuals 
In the longitudinal study 20 apparently healthy volunteers were included with a 
median age of 31 years range (24-58). Of the 10 males and 10 females, two were 
smokers. The median body mass index (BMI) was 22.3 kg/m' range (16.9-28.7). 
Blood was collected every three weeks during 6 months (from december 1990 to 
june 1991), At each visit the volunteers completed a questionnaire on factors 
influencing fibrinogen, PAl-activity, CRP and HRG levels (smoking, diet, alcohol 
use, medication, disease). 
For the transversal study the first blood sampling from the volunteers of the 
longitudinal study was used, extended with blood samples from 39 healthy male 
volunteers from whom only one blood sample was drawn. In the transversal group 
(n=59) the median age was 38 years (range 24-58), the median BMI 25.1 kg/m' 
range (16.9-31.5) and 22 were smokers. 
Blood collection 
Venous blood was collected into CTAD (Becton Dickinson, Meylan Cedex, France) 
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or sodium citrate (final concentration 0.011 maUL) under strictly standardized 
conditionsH . Plasmas were stored at -70°C. 
Assays 
Fibrinogen levels were determined according to Clauss3s and expressed as gIL using 
as a standard pooled citrated plasma in which the fibrinogen level was determined 
with a gravimetric method". PAl-activity levels were obtained from the CTAD 
plasma using the Verheijen method'" and expressed as lU/ml, using pooled plasma 
(7.6 lU/mL) as a standard. CRP levels were measured with an enzyme immuno 
assay that used rabbit antibodies to CRP (DAKO, Denmark) as both catching and 
tagging antibody and expressed as mg/L. CRP standard serum (Behringwerke, 
Marburg, Germany) was used for calibration. HRG levels were determined by single 
radial immuno diffusion41 with rabbit antibodies raised against puritled HRG 
(Behringwerke, Marburg, Germany) and the levels are expressed as percentage of a 
plasma paoloI' 20 healthy volunteers (%PP). 
The within-day and between day coefficients of variation were 1. 7% and 6.3% for 
the fibrinogen assay, 6% and 12% for the PAl-activity assay, 2.9% and 7.2% for 
the CRP-EIA and 9% and II % for the HRG-assay, respectively. 
Detection of polymorph isms 
The Bc/I restriction fragment. length polymorphism (RFLP) of the BiJ-fibrinogen 
gene was assessed by Southern blot analysis of Bell digested genomic DNA using a 
iJ-fibrinogen cDNA probe (courtesy Dr. S. Lord) as previously described". 
The G/A4l5 RFLP of the Bfi-fibrinogen gene was determined by amplification of 
thc polymorphic region by polymerase chain reaction (PCR), followed by digestion 
with the restriction enzyme Hae3 as described by Thomas et al-1.' • 
The Hil/(nn RFLP of the PAI-I gene" was assessed by Southern blot analysis of 
Hill(nn digested DNA using a PAl-I eDNA probe (courtesy of Dr. P. Bosma). 
Determination of the genotype of the polymorphic (CA)n region in the PAl-I gene 
was performed as described beforeJ~. The most frequent allele was designated UZH 
and the other alleles were designated by their base pair differences from z. Thus, the 
following allele types z, z+2, z+4, z+8 and z+ 10 can be identitied. 
Statistical evaluation 
The (geometrical) mean level of the nine samplings was used as the habitual level. 
Dne to skewed distribution of PAl-activity and CRP levels, we used logarithmical 
transformed data. The distribution of fibrinogen and HRG levels was not 
significantly deviant from norlllal and therefore not transformed. The arithmetical 
mean is given for fibrinogen and HRG, where the geometrical mean is given for 
PAl-activity and CRP. 
Table 1. Estimates of components of variation in plasma fibrinogen, PAl-activity, CRP and HRG levels of 20 healthy volunteers 
followed over 6 months. 
Dind n,,,, mean total interindividual intraindividual 
fibrinogen (gIL) 20 164 2.64 va.-iance 0.807 0.706 0.101 
% of total variance 87% 13% 
log (PAl-activity) (lUlL) 20 164 0.805 variance 5.11 4.91 0.20 
% of total variance 96% 4% 
log (CRP) (mg/L) 20 164 -0.125 variance 4.04 3.46 0.58 
% of total variance 86% 14% 
HRG (%PP) 20 164 113 variance 7173 7074 99 
% of total variance 99% 1% 
nind number of volunteers 
nOb' number of observations up to 9 per volunteer) 
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In Ihe longitudinal study one-way analysis of variance (ANOY A) was performed 10 
separate the sources of variation. We applied an additive variance component model 
in which: Y;j (the value of person i at time j) = p. + "; + eu 
In this model p. is the true mean of the population, 3;, is the deviation from the true 
mean of the ith person (i = 1. ... 20). The residual, eu, thus comprises the intra-
personal variation and intra-serial analytical variation. The random terms ~ and £jj 
were assumed to be independent and normally distributed with zero expectations. 
The measurement number was not added as a factor, because the deviations from the 
true mean are ass limed to be independent from the sample time. 
The within subject component can be reduced by using the average of m repeated 
measurements, using the formula: a2[c>I=(a2" +a2Jm). 
In the transversal study analysis of covariance (ANCOY A) using multiple linear 
regression analysis was performed to evaluate Ihe effect of genetic Bn-fibrinogen and 
PAl genotypes on plasma levels of tlbrinogen and PAl-activity, respectively. Age, 
body mass index (BMI) and gender were added as covariables and mean (standard 
error of the mean) are given. From those individuals that also participated in the 
longitudinal study, results from the first sampling were llsed in the transversal 
analysis. 
The statistical package SOLO was used for the analysis and p-values below 0.05 
were considered significant. 
RESULTS 
Figures I to 4 show the data of plasma tlbrinogen, PAl-activity, CRP and HRG in 
20 individuals (sampled repeatedly up to 9 times) over a period of 6 months. Both 
intra- and interindividual variation is obviolls for all variables. The estimated 
contributions of the intra- and interindividual variation to the total variance is given 
in table 1. The contributions of the intraindividual variation of a parameter to its 
total variation were I % for HRG, 4% for 10g(PAI-activity), 13% for fibrinogen and 
14% for 10g(CRP), which was much smaller for each parameter than the 
interindividual variation, which ranged between 86% mid 99%. Information from the 
questionnaire that the participants of the longitudinal study tilled in at every visit 
could explain only a limited number of the peak values. 
The descriptive statistics of the transversal analysis are presented in table 2. The 
plasma levels observed in this enlarged group (n =59) are comparable to the levels in 
the longitudinal group (n =20). 
In table 3 the influence of the Bell and GI A4 .'.' polymorphisms on the plasma 
levels of fibrinogen are shown. Individuals with the rare allele have higher 
fibrinogen levels. The Bell and GI A 4" tlbrinogen polymorphism were closely linked 
in this group. Taking the habitual levels (mean of all longitudinal samplings) from 
110 ,'uriuhilit)' lit' lihrinuJ,:cn, PAl, eRP Hnd HRG 
Table 2. Mean range (central 95%) of plasma fibrinogen. PAl-activity, eRP anu HRG levels in the 
transversal study with 59 healthy volunteers. The arithmdical mean'is given tllf fihrinogen and HRG. 
the geometrical mean for PAI-aclivity and eRP, 
n"", mean (range of central 95 %) 
fibrinogen (g/L) 59 2.64 (1.85-3.43) 
PAl-activity (IU/ml) 59 8.81 (2.57-30.21) 
C-reactive protein (mg/L) 59 0.83 (0.12-6.00) 
HRG (%PP) 59 99.2 (49.4-149) 
Table 3. Influence in the transversal study and on the hahitulIl level of the longitudinal study of 
genetic polymorphisills on plasma fibrinogen levels, aujusted for age, gender, anu BMI. 
fihrinogen (gIL) hahitnal librinogen (gIL) 
RFLP n"" mean SEM n,m l11t'an SEM 
Bell OIBI 42 2.58 0.06 15 2.54 0.05 
01B2/0202 14 2.91* 0.08 5 2.98*** 0.09 
G/A,455 GIO,m 36 2.57 0.06 15 2.54 0.05 
G/A--4SSIAIA-tSS 18 2.81** 0.10 5 2,98*** 0.09 
• significantly different from inuiviuuals with gt;)notypt;) BIB 1 (p=O.006) 
•• significantly different from imliviuuals with gt;)l1otypt;) G/G-t'i5 (p=O.03) 
••• significantly difterent from individuals with gt;)notypt;) 82B2 or genotype G/O-HS 
(p=O.OO2). Since tht;) gt;)notypt;)s wt;)re in complete linkllge disequilihriulll, tht;) data <Ire the 
same for hoth RFLP. 
""" number of indiviuuals 
SEM standard error of the mean 
the individuals in the longitudinal study a slightly larger effect of the polymorphism 
on the plasma fibrinogen levels was observed. In the longitudiual study we found no 
association between the intraindividual variation and the fibrinogen genotypes using 
ANOV A analysis. 
The Hilllnn PAl polymorphism was not associated with the levels or the 
intraindividual variation of PAl-activity. The CA repeat polymorphism of the PAl 
gene showed many different genotypes, as expected for a multiple allele 
polymorphism. No effects of any of the alleles were detectable for either the 
(habitual) level or the intraindividual variation of PAl-activity. 
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Figure 1. Plasma fihrinogen levels in 20 individuals on up to 9 samplings over a 6 months period. 
Each dot represent the level of one liampling. 
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Figure 2. Plasma plasminog~n activator inhihitor (PAI)-aclivit)' levels in 20 individuals on up to 9 
samplings over a 6 months period. Each dot represent the level of one sampling. 
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Figure 3. Plasma C-reactive protein levels in 20 individuals on up to 9 samplings over a 6 months 
period. Each dot represent the level of one sampling. 
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Figure 4. Plasma histidine-rich glycoprotein (HRG) levels in 20 individuals on up to 9 samplings owr 
a 6 months period. Each dot represent the level of one sampling. 
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DISCUSSION 
Because elevated fibrinogen, PAl-activity and CRP levels have gained interest as 
risk indicators for cardiovascular disease1-s and elevated HRG is associated with 
thrombosis9•10 it has become important to accurately know the habitual levels of these 
parameters. Until now, single fibrinogen, PAl-activity, CRP and HRG 
measurements are accepted to represent habitual levels. This might be inaccurate as 
the plasma levels of these proteins are for instance influenced by a transient acute 
phase reaction, which Illay lead to temporary variations in the plasma levels. In the 
present study we documented the inaccuracy of estimating habitual levels when only 
1 plasma sample is studied and how many samples should be taken to obtain 
estimates of habitual plasma levels of fibrinogen, PAT-activity, CRP and HRG. 
In a longitudinal study of 9 blood samplings in 20 individuals we showed that for 
plasma fibrinogen levels the intraindividual variation has an contribution of 13% to 
the total variance. It is required to perform multiple sampling in order to decrease 
the contribution of this intraindividual variation and to obtain an estimate of the 
habitual level that is accurate when compared to the interindividual variation. With 2 
random samplings of plasma fibrinogen levels the contribution of the individual 
variation will be reduced to less than 10%, indicating a correlation between the 
interindividuai variance and the total variance above 0.90, which we lIsed as an 
arbitrary unit. In this study the period between the samplings was 3 weeks. Peak 
values were not consistent in consecutive samplings, indicating that a period between 
samplings of 3 weeks is sufficient for disposing of peak effects. 
To compare the interindividual variation in our group with the variation reported 
in other studies, we calculated the coeft1cient of variation (CV) in a transversal part 
of the study on 59 healthy individuals (single sampling). We found a CV of 0.15, 
which is in good agreement with the results of Marckmann et alH and Thompson et 
al44 • It was catculated that a sample size of 142 (2 groups of 7t) individuals will be 
needed to differentiate two groups with a difference of 1 standard (leviation of the 
mean, We choose this example of I standard deviation because in the Northwick 
Park Heart Studyl it was shown that this difference will give a 84 % increase for the 
risk of cardiac events in the next five years. 
When we studied the variation in the logarithmically transformed PAl-activity data, 
we observe that almost all variance can be ascribed to the interindividual variation. 
The intraindividual variation is well below 10% and therefore single sampling is 
sufficient. The sample size required to measure a difference of 15% of the 10g(PAI-
activity) between two groups is 162 individuals. For PAl-activity, eRP and HRG the 
association between increase and cardiac risk is not so well established as for 
fibrinogen. Since I standard deviation of fibrinogen is 15% of the mean level, we 
calculated the sample size for 15% differences between the groups. 
For the logarithmically transformed CRP levels we lind a 14% contribution of the 
intraindividual variation to the total variance, The mean of two samplings will give a 
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good estimation of the habitual level. However, if we study ligure 3, we frequently 
observe outliers. Therefore, in assessing the habitual level, we advise to perform 
three of more measurements to be able to identify and exclude these outliers. For the 
same reasons as for librinogen, a 3 week period between sampling can be used. The 
sample size required to measure a difference of 15% of the 10g(CRP) between two 
groups is 412 individuals. In this study the contribution of the analytical variance 
was not analyzed separately, but it is included in the intraindividual variation. For 
librinogen measurements with the Clauss method it has been described" that the 
analytical variance is only a small part of the intraindividual variation. For the other 
methods the variation is already below 10% sO that reduction of the analytical 
variation will not be required. 
The intraindividual variation of plasma HRG level is very small (onty I % of the 
total variance) and can therefore be neglected. Multiple sampling is thus not 
warranted to determine the habitual HRG level. The sample size required to measure 
a difference of 15% of the HRG level between two groups is 86 individuals. 
If duplicate sampling will be performed, the required sample size for fibrinogen 
will go from 142 to 133, while for CRP it will go from 412 to 381. This implies 
that when the intraindividual variation is relatively low, multiple sampling will 
hardly influence the number of individuals that need to be studied in an 
epidemiological sludy. However, for the reliable determination (10% criterium) of 
the habitual level of an individual, multiple sampling will be necessary. 
The genetic polymorph isms of the B6-librinogen gene showed an association with 
the plasma librinogen levels obtained by simple sampling in the transversal group. 
These findings are in agreement with other studies in heallhy volunteersH .. q . The 
association between the habitual levels (mean of lip to nine samplings) of the 
individuals of the longitudinal study and genotypes of the B6-RFLP were more 
signilicant and the difference between the levels was somewhat larger as expected. 
Since the association was already significant with single sampling, multiple sampling 
will not give an essential improvement. 
No association was found between the genotypes and the intraindividual variation 
in the longitudinal group. The genotypes of Hil/dlll and CA-repeat polymorphisms 
of the PAl gene did not associate with either habitual plasma levels or intraindividual 
variation. The association was also not significant when the habitual 10g(PAJ-
activity) levels of individuals in the longitudinal study were evaluated. It might be 
interesting to study the contribution of genetic elements to the variation of fibrinogen 
and PAl-activity in a larger study, because there are reports about different reaction 
to acute phase stimulation (e.g. smoking) in individuals with different G/A-455 
genotypes of the B6-librinogen RFLP. 
In conclusion, we observed that the intraindividual contribution of the total 
variance in a longitudinal study of librinogen, PAl-activity, CRP and HRG is lower 
than the interindividual variation. However, multiple sampling is advised for 
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fibrinogen to decrease the contribution of the intraindividual variation under 10% 
and for CRP to exclude the outliers. A contribution of genetic polymorphisms of the 
Bfl-fibrinogen gene to the interindividual, but not the intraindividual, variation was 
observed. 
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ABSTRACT 
High plasma levels of tibrinogen, C-reactive protein (CRP) and plasminogen 
activator inhibitor (PAl) activity are associated with an increased risk of ischaemic 
heart disease and stroke. There are indications that N-3 fatty acids are involved in 
the production of these proteins, but only in the presence of an adequate amount of 
the antioxidant vitamin E. 
In this study we have evaluated the effect on plasma levels of tihrinogen and eRP 
of fish oil containing N-3 fatty acids and the natural antioxidant vitamin E. II 
healthy young volunteers with fibrinogen and CRP levels in the normal range were 
supplemented for one week with 30 glday tish oil, containing 60 lU vitamin E. No 
effects on fibrinogen and on CRP were found, indicating that tish oil has no effect 
on basal levels of fibrinogen and CRP. The effect of vitamin E on fibrinogen, CRP 
and PAl activity levels was evaluated in 20 healthy volunteers (age 21-31) who 
received vitamin E (dose doubling every 2 weeks from 25 to 800 lUlday) for 12 
weeks. No significant changes in fibrinogen, CRP and PAl a<;tivity levels were 
found. 
From these studies we conclude that it is unlikely that short term supplementation 
with fish oil or vitamin E influences the levels of the acute phase reactants 
fibrinogen, CRP or PAl activity in healthy young volunteers with normal levels of 
these risk indicators. 
INTRODUCTION 
High plasma levels of fibrinogenl.2, C-reactive protein (CRr)1 and plasminogen 
activator inhibitor (PAl)} are associated with an increased risk of myocardial 
infarction and stroke. Plasma levels of the three proteins are increased during the 
acute phase reaction. It has been suggested that the actual factor which may increase 
the risk of heart disease and stroke is a chronic local inflammatory state and that the 
plasma levels of fibrinogen, CRP and PAl are indicators thereof and as sllch 
positively associated with riskl.4 . 
The major initiators of increased synthesis of acute phase proteins in the liver are 
the cytokines interlcukin-6 (IL6), interleukin-I n (ILl n) and tissue necrosis factor-a 
(TNFa)'. Activated monocytes and other activated cells of the reticulo-endothelial 
system are major sources of these cytokines. N-3 fatty acids reduce the response of 
Illonocytes to stimuli which may result in a reduced production of cytokines6 . On the 
other hand, polyunsaturated fatty acids in LDL, if not well protected by 
antioxidants, are more susceptible to oxidation. There is acclllllulating evidence that 
oxidation of LDL will lead to activation of cells in the vascular wall to produce 
cytokines, resulting in a local intlalllmatory reaction4 . Vitamin E protects LDL 
against oxidative modification1 which may explain the observation in epidemiological 
studies that there is an inverse relation between intake and plasma levels of dietary 
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antioxidants and the risk of myocardial infarctionsg ·9. 
Recently, Haglund et allO reported effects of fish oil supplemented with vitamin E 
on fibrinogen levels also in healthy volunteers rendering it possible that basal 
synthesis of fibrinogen is influenced. The aim of this study was to evaluate in 
healthy volunteers the effect of fish oil and the antioxidant vitamin E on fibrinogen 
and in addition PAl activity and to document the acute phase condition by measuring 
eRP. 
VOLUNTEERS AND METHODS 
Volulltee .. s 
To evaluate the effect of fish oil containing a moderate dose of vitamin E, 11 
healthy volunteers (age 18-22) were supplemented with tish oil (Maxepa: 30 gram 
daily containing 5.4 g EPA, 3.6 g DHA, 60 mg Vitamin E) for one week. 
To evaluate the effect of vitamin E, 20 healthy volunteers (age 21-31) were given 
vitamin E (consecutively 25-50-100-200-400-800 mg/day, each for 2 weeks) for 12 
weeks. 
Methods 
(HMW+LM\V) Fibrinogen levels were determined in EDTA plasma lIsing an 
enzyme immuno assay (EIA)II, In this assay a monoclonal antibody against the 
carboxyl terminal end of the fibrinogen Aa-chain is used as the capture antibody 
(G8), and a monoclonal antibody against the amino-terminal end of the Aa-chain 
(YI8) as the tagging antibody. Thus the EIA wilt only measure HMW and LMW 
fibrinogen. 
C-reactive protein was measured with an EIA based on rabbit polyclonal antibodies 
against human eRP. One volunteer with eRP levels > 10 mg/l was excluded, 
because this high level is an indication of substantial inflammation. 
PAl activity was measured according to Verheijenl2. 
Statistical methods 
Because CRP and PAl activity were positively skewed, the data were transformed 
logarithmically before analysis. Mean (for eRP and PAl the geometrical mean) and 
its 95 % confidence interval are presented. The effects of tlsh oil and vitamin E 
treatment were studied with the paired Student I-test. Correlations were calculated 
with the Pearson correlation test. All statistical methods were performed with the 
SOLO computer program. 
RESULTS 
In the eleven young volunteers the one week treatment with 30 g tish oil plus 60 mg 
vitamin E per day had marked effects on plasma fatty acids (mean decrease of 39%) 
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and on triglyceride levels (mean decrease 36%), as reported previouslyi3. In 
contrast, neither fibrinogen nor CRP levels did show a signiticant change (table I). 
In accordance with the differences in behaviour of fibrinogen and CRP versus 
triglyceride and fatty acids, no relations were observed between these two categories 
of variables. 
In the twenty healthy young volunteers receiving up to 800 mg/day vitamin E, 
plasma vitamin E levels showed an increase from 23.6 ± 3.6 I'M to 61.2 ± 11.8 
I'M. Triglyceride and total cholesterol levels did not change (data not shown). No 
significant changes in fibrinogen or CRP activity were found (table 2); in 
accordance, using the Pearson correlation test, signiticant correlations of 0.74 and 
0.78 between the levels before and after treatment were found for fibrinogen and 
eRP, respectively. For PAl activity we also found no significant changes, but a 
correlation between pre- and post-values was absent. 
Table 1. Mean (95 % confidence interval) of plasma tihrinogen and CRP levels hefore and after 
week fish oil administration in 11 healthy young volunteus. 
Fibrinogen (gIL) 
CRP (mglL) 
before fish nil 
1.9 (1.7 -2.t) 
0.83 (0.47-1.5) 
aft('r thh oil 
1.7 (1.6-1.9) 
0.9 t (0.54- 1.5) 
Table 2. Mean (95% confidence interval) of plasma tlhrinogen, eRP and PAl activity levels hetore 
and after 12 weeks vitamin E supplementation in 20 he,llthy young volunteers. 
Fibrinogen (gIL) 
eRP (mgIL) 
PAt (IUlmL 
DISCUSSION 
before "Hamin E 
1.8. (1.6 -2.0) 
0.37 (0. t9-2.0) 
5.0 (4.6-6. t) 
after vitamin E 
1.8 (1.5-2. t) 
0.29 (0. t6-0.56) 
6.2 (5.3-7) 
One requirement for reducing plasma tihrinogen levels by tish oil treatment on 
fibrinogen levels might be an adequate amount of vitamin E, Haglund et al lO showed 
in 12 healthy volunteers that fibrinogen levels decreased after supplementation with 
30 ml fish oil containing 45 mg vitamin E per day, whereas no effects were found 
when the volunteers were given 30 1111 fish oil with 9 mg vitamin E per day for a 
three week period. 
We found no effects on fibrinogen levels after administration of fish oil with 
relatively high vitamin E levels or after administration of moderate to high doses (up 
to 800 mg/day) of vitamin E for 12 weeks. Although our studies had a different 
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design, our results can not confirm the results of Haglund, 
A possible explanation for the absence of fibrinogen decrease in our lish oil study 
might be the duration of ollr fish oil administration, which was only one week in our 
study, while Haglund gave his volunteers fish oil for three weeks. The treatment 
period with vitamin E, however, should have been suftlcient (12 weeks), 
An analysis of· the literature reveals that the studies showing a decrease of 
fibrinogen levels concerned patients with increased fibrinogen levels. A prolonged 
low grade acute phase reaction is the main mechanism known to increase habitual 
fibrinogen levels. Therefore we documented in our volunteers the level of the acute 
phase reactant eRP. Our volunteers had 110 increased fibrinogen or eRP levels at 
the start of the study, Qur fiudings of absence of a change in both fibrinogen and 
CRP would therefore support the above analysis that !ish oil or vitamin E might be 
mainly active in case of elevated levels of these components. 
We conclude that in young, healthy volunteers witho~lt signs of a stimulated acute 
phase reaction, supplementation with vitamin E has no effect on the mentioned 
variables. It remains to be tested whether effects can be found in individuals with 
elevated levels of fibrinogen and/or eRP, e.g. smokers. 
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ABSTRACT 
The mechanisms of the antithrombotic effect of the platelet aggregation inhibiting 
agent Ticlopidine might include a decrease of the plas",a llbrinogen level. The effect 
of ticlopidine on increased fibrinogen synthesis following trauma, such as surgery, is 
however not known. 46 patients who underwent suprapubic prostatectomy were 
randomized to receive either (group A) Ticlopidine (2 x 250 mg daily) from the 
second preoperative day until the seventh postoperative day or (group B) placebo up 
tilJ the day of surgery and further acenocollmarol against post-operative thrombosis. 
We measured the plasma fibrinogen levels pre- and post-operatively and observed 
that the level and in particular the rise of the plasma tibrinogen concentration was 
not different in the two groups, It is concluded that compared with the standard 
treatment in group B ticlopidine does not influence trauma-induced tibrinogen 
increase. 
INTRODUCTION 
Ticlopidine has been reported to reduce the number of thromboembolic events and of 
restenosis in patients undergoing haemodialysisl and cardiac surgery'l,], It also 
improves the walking ability in patients with intermittent cJauciication45 , 
The main effect of Ticlopidine appears to be on the tirst and second phase of the 
blood platelet aggregation induced by ADP, collagen and platelet aggregation 
factor,,7, Varying effects are reported concerning the effect on the aggregation 
through the arachidonic pathway and in contrast to aspirin, ticlopidine does not 
inhibit cyelo-oxygenase', The activity is suggested to be mediated through blocking 
platelet fibrinogen receptors9 or altering platelet ADP-binding lO.tI , However, no 
exact biochemical mechanism of ticlopidine has been established, and in view of 
discrepancies between in vitro and in vivo effects, the formation of at least one 
active transient metabolite is sllnnised 12 , 
Recently. an additional effect of Ticlopidine in patients with peripheral 
atherosclerotic disease or ischaemic cerebrovascular disease has been reported; 
namely a decrease in the plasma fibrinogen leveI D . 17 , This finding is particularly 
interesting because an elevated plasma tlbrinogen level is a risk factor for 
arteriosclerosis, stroke and myocardial infarction l8 , The fibrinogen decreasing effect 
has sofar only been observed in patients, with the exception of diabetic subjects l9 
and no information of effects in healthy volunteers is available as yet. 
It remains possible therefore that the effect of ticlopidine is confined to situations 
with induced increases in tibrinogen. In this context we studied the effects of 
ticlopidine in a group of patients who underwent an urologic operation, viz 
suprapubic prostatectomy2(', Post-operatively there always is an increase in the 
plasma fibrinogen levels, induced by surgical trauma, 
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PATIENTS AND METHODS 
Patients 
effect of' ticlopidine Oil the postopcrath'c fihrinogen illcl'ea.~e 
Fifty consecutive patients admitted to the urological ward for open prostatectomy 
were - with informed consent - randomly allocated to one of two groups (A or B). 
Group A received Tic1opidine, 250 mg twice daily from the second pre-operative 
until the seventh post-operative day; group B received a placebo from the second 
pre-operative day until the day of surgery. Post-operatively, patients in group B 
were treated with acenocoumarol like the other patients on the ward not participating 
in the study. The patients and technicians performing the leg scanning were not 
informed about the medication. 
Excluded from the study were patients with seriolls liver or renal disease, 
haemorrhagic diathesis, or patients who received drugs that could interfere with 
platelet function. Post-operatively, all patients were treated with Baralgin" to prevent 
painful bladder spasms. Patients taking part in this trial did not receive f-
aminocaproic acid. Of the fifty patients who entered the study, four could not be 
evaluated. Two patients appeared on return from the operation room to have 
undergone a trans-urethral prostatectomy, one patient turned Ollt to suffer from a 
bladder carcinoma. One patient was excluded from the trial because of technical 
errors in the leg scanning (belonged to group B). 
Eventually group A consisted of 26 patients, group B of 20. There were no 
differences between the two groups regarding risk factors for heart and vessel 
disease. More information on this patient group, platelet aggregation inhibition, 
bleeding complications, and isotopic DVT can be tound in ref. 21. 
Methods 
Plasma fibrinogen levels were measured on day -3 (start of the study), day 0 (day of 
the operation) and day +3 by the Clauss method" in platelet-poor plasma (PPP). 
Patient compliance was assessed by platelet ADP-aggregation. Aggregation was 
measured in a Peyton aggregometer: 9 ml of blood was collected in I ml 0.109 M 
Na citrate, centrifuged for IS min at 100 x g for the preparation of platelet-rich 
plasma (PRP). Two ml of this PRP was centrifuged tor 10 min at 1500 x g in order 
to obtain PPP. The aggregation tests were performed between I and 2 hours after 
collection of the blood. To induce aggregation, ADP (Sigma Chemie) was added to 
PRP with a final concentration of 0.5 I'giml. Aggregation was expressed as percent 
of maximal aggregation. 
Thrombosis was detected by 125I-tibrinogen uptake test2J , 
Data analysis was performed by non-parametric tests for both independent and 
paired samples. Any probability equal or less than 0.05 is considered to represent a 
significant difference between the data studied. 
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RESULTS 
The biological effect of Ticlopidine was monitored by following the ADP-induced 
aggregation of the patients' blood platelets. Ticlopidine inhibited the ADP-induced 
aggregation as shown in Fig. 1. In the placebo group, some impairment of 
aggregation was also seen, but on day 0, the ADP-induced aggregation was already 
significantly more reduced in the Ticlopidine group compared with the control 
group. 
Both the Ticlopidine group and acenocoumarol group showed significantly 
increased fibrinogen levels on day 3 compared with preoperative levels (P < 0.001) 
(Fig. 2). The levels were not significantly different in the two groups (P > 0.20). 
The individual rise in postoperative fibrinogen levels was also not different in the 
two groups. 
125 % of maximal aggregation 
100 1 75 I I 
50 1 1 ~ -<y* 25 1 
0 
-3 0 3 
treatment day 
Figure 1. ADP induced aggregation in group A (CD) and group D (0). (*p<O.Ol) 
During the whole study only one case of clinically detectable Jhrombosis was 
encountered; this was a patient in the placebo group who showed transient signs of 
deep vein thrombosis (DVT) in his left calf. By means of the "'I-fibrinogen uptake 
test DVT was detected in four patients of group A (12.7%) and in seven patients in 
group B (28.5%), including the patient with clinical thrombosis, all within the first 
three postoperative days. This difference is not significant (p = 0.23). In group A 
only one case of bilateral thrombosis was found, in group B four cases2!. 
132 effect of Hclopidine on the postoperative flbrinogen increase 
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Figure 2. Mean plasma fibrinogen levels 011 days *3. 0, and +3 in group A (CD) and group n (0), 
DISCUSSION 
A significant reduction in the ADP-induced platelet aggregation from the day of 
surgery onwards witnessed the biological effect of ticlopidine in the treatment group, 
where ticlopidine was given from day -3 onwards, As it is unethical to withhold 
anticoagulants after surgery the control group was postoperatively treated with 
acenocoumarol. 
The fibrinogen levels in the ticlopidine group and the placebo-acenocoumarol 
group were similar at the start of the study (day -3) and no effect on these basal 
levels was apparent at day 0 pre-operatively. It indicates that ticlopidine had no 
effect 011 the constitutive synthesis of fibrinogen in this group of men. In men of this 
age group an enlarged prostate is considered normal, therefore they can be 
considered healthy. Until now, all reports of ticlopidine effects on plasma fibrinogen 
levels dealt with patient groups"·l7. It is therefore possible that the observed 
fibrinogen lowering only occurs in disease and is, in fact, a normalization of the 
elevated fibrinogen levels. On the other hand, these studies describe fibrinogen 
decrease after a treatment period of several months 13-17 • It is possible that our 
treatment period was too short to show an effect on the base-I ine levels as the 
biological half life of fibrinogen is 2'/2 days. 
The post-operative rise in fibrinogen concentration is a measure for the acute phase· 
stimulated production. This rise was not different in the two groups, indicating that 
ticlopidine is not capable of preventing the post-operative rise of the fibrinogen 
concentration. In other studies"'''' it has been suggested that the action of ticlopidine 
on the fibrinogen level is an anti-intlammatory effect. Randi14 hypothesized that 
ticlopidine acts by inhibiting the exposure of fibrinogen receptors on platelets which 
results in a decrease in the fibrinogen levels. After major surgery there is important 
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platelet stimulation, but we couid not observe a reduction of the fibrinogen rise. 
Therefore, it is unlikely that this mechanism plays a major role in the acute 
increase of fibrinogen levels after surgery. 
Palereti et aP' report a longitudinal study where the fibrinogen levels increased 
gradually in the placebo group. The end of the 21 month follow-up study coincided 
with the winter months. The elevated incidence of illness in the winter may 
contribute to this increase. In the ticlopidine group, this relation was not seen. 
Therefore it is possible that a reduction of disease induced tibrinogen elevation may 
be the underlying mechanism. 
Further studies that measure other acute phase proteins (e.g. C-reactive protein) 
and cytokines (e.g. interleukin-6) may elucidate the effect of ticlopidine on the acute 
phase induced increase of tIbrinogen levels. 
We can only conclude that, after operations with a high post-thrombotic risk, the 
fibrinogen increase is not significantly altered by ticiopidine in its magnitude, in 
comparison with the acenocolllllaroi treatment. That both treatments have reduced 
the fibrinogen increase to a similar extent is not probable, since no effect of 
acenocoumarol on fibrinogen levels has been described in the literature. 
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ABSTRACT 
Elevated plasma fibrinogen levels represent an increased risk for cardiac events. 
Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets 
and it also has been described that ticlopidine can decrease the plasma fibrinogen 
level in patients with vascular diseases. The mechanism of this decrease has not yet 
been elucidated and therefore mechanisms that are known to affect fibrinogen levels 
were studied, viz. the acute phase reaction, total fibrin and t1brinogen degradation 
(TDP) levels and the fibrinogen GI A ~jj Bfl-chain polymorphism. 
The fibrinogen lowering effect of ticlopidine was studied in 26 healthy volunteers 
and in 26 patients with stable angina pectoris in a double blind, placebo controlled, 
randomized cross-over study. Plasma fibrinogen levels were measured with the 
Clauss assay and enzyme il1lllluno assay for high plus low molecular weight 
(HMW+LMW) forms of fibrinogen. C-reactive protein and TDP levels were 
measured with an EIA. 
In the healthy volunteers Ihe functional fibrinogen levels had decreased 0.20 giL 
(9%, p<0.05) after 4 weeks of ticlopidine administration, whereas the 
HMW + LMW fibrinogen levels, Ihe CRP and the TDP levels were not significantly 
decreased. In the stable angina pectoris patients the baseline fibrinogen, CRP and 
TDP levels were significantly higher than in the volunteer group. After four weeks 
ticlopidine administration the functional fibrinogen levels had decreased with 0.39 
giL (II %, p<0.005), whereas Ihe HMW+LMW tibrinogen, the CRP and the TDP 
levels were not significantly changed. Neither in the volunteers or the patients was 
the effect of ticlopidine on the t1brinogen levels associated with the tibrinogen Of A 
455 genotype. 
Therefore, the fibrinogen lowering effect of ticlopidine is unlikely to be regulated 
by the acule phase reaction, TDP-Ievels or the tibrinogen G/A~j·j Bfl-chain 
polymorphism. 
INTRODUCTION 
It has been shown repeatedly that elevated plasma levels of t1brinogen indicate a risk 
for the development of cardiovascular diseasesP , peripheral arterial diseaseR and 
stroke9 • After adjusting for other risk factors stich as cholesterol levels and smoking 
the fibrinogen levels remained significantly associated with risk of athcrothrombotic 
events. Additionally, the plasma levels of fibrinogen are associated with the severity 
of atherosclerosislfl-ll. Since it has been suggested that atherosclerosis is an 
inflammatory process of the vascular walJl\ the increased plasma levels of the acute 
phase protein fibrinogen that are observed in patients with cardiovascular disease l2. 16 
might reflect an elevated intlallltllatory status of the vascular wall of these patients. 
Although a causal relation between elevated plasma t1brinogen levels and increased 
risk of atherothrombotic events has not yet been delinitively established, mllch 
138 modulation til' l'ihrilltlgen hy ticl()pidine 
interest has developed for agents that can lower the fibrinogen levels. An agent that 
has shown to have a decreasing effect on t1brinogen levels in patients with coronary 
diseases is ticlopidine17-25 • The main effect of ticlopidine is the inhibition of platelet 
aggregation and for that reason it is consequently used in the reduction of 
atherothrombotic events26-2&, Ticlopidine is not functional in itself, but is transformed 
in an active, not yet identified, metabolite". 
Although the additional fibrinogen lowering effect of ticlopidine has repeatedly 
been observed, the underlying mechanism still has to be elucidated. Studying 
patients that already have elevated plasma fibrinogen levels, makes it impossible to 
differentiate between normalization and systemic decrease of the basal fibrinogen 
levels. Such a separation of mechanisms can only be made when both patients and 
healthy volunteers are studied, but these studies have not yet been performed. 
The most important mechanism that regulates the plasma tibrinogen levels is the 
acute phase reaction, which can lead to a two to fourfold increase. In patients with 
vascular disease a modest increase of the inllammatory state has been observed, 
demonstrated by increased plasma levels of several markers of inflammation, such as 
fibrinogen, interleukin-6, leucocyte receptors on vascular endothelium, 
complement l6 ,3o.32, If ticiopidine influences the acute phase status, it may involve the 
cytokine secretion of activated cells, resulting in a normalization of the plasma 
fibrinogen levels. Additionally, the plasma levels of other acute phase markers, like 
the strong acute phase reactant C-reactive protein, are then expected to decrease. 
Upregulation of fibrinogen synthesis in response to increased t1brin(ogen) 
degradation was indicated by a correlation between plasma tibrinogen levels and 
fibrin(ogen) degradation products (FDP)". Ticlopidine is known to inhibit the 
aggregation of blood platelets by preventing the exposure of the glycoprotein lIb/IlIa 
complex, which is the receptor of fibrinogen on platelets". This decrease of the 
fibrinogen binding to platelets might be a mechanism eventually leading to lowering 
of the production of FDP and consequently to lowering of the plasma fibrinogen 
levels, since it has been reported that FDP stimulate the fibrinogen synthesis of 
cultured human hepatocytes3S-J7 , This possible mechanism would imply that 
ticlopidine administration lowers tlbrinogen through lowering of the FDP levels. 
The studies that have been performed until now have all measured the functional 
fibrinogen levels. A lowering of the tibrinogen levels that are measured with 
functional tests (viz. the Clauss test") might also be explained by a decrease of the 
clotting characteristics of the fibrinogen molecules. Methods that measure the 
fibrinogen antigen levels, like enzyme immuno assays (EIA) will not be altered if it 
is the functionality of the fibrinogen that is affected by ticlopidine. 
Another contribution to the fibrinogen regulation might be genetic. Di fferent 
genotypes of DNA polymorphisms of the fibrinogen BG-chain are known to be 
associated with plasma fibrinogen levels)9~l. Besides higher tibrinogen levels, it has 
been described that individuals with the rare allele of these tibrinogen 
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polymorphisms also have a larger longitudinal variation of their plasma fibrinogen 
concentrationJ9 , In individuals with a low grade inflammatory state, e.g. smokers, 
Ihe effect of the polymorphism is more pronounced". This suggests that the rare 
allele might be more sensitive to environmental influences which increase fibrinogen 
synthesis. Consequently, the effect of ticlopidine administration of plasma fibrinogen 
levels might also depend on the genotypes. 
In this study we analyzed the effect of ticlopidine on fibrinogen activity and 
HMW + LMW antigen levels in a group of healthy volunteers and in a group of 
patients with stable angina pectoris. We tested the hypothesis that the decrease of 
plasma fibrinogen levels by ticlopidine a) results from an effect on the acute phase 
reaction by analyzing also C-reactive protein, b) is an effect on the fibrin(ogen) 
degradation by studying the correlation between the effect of ticlopidine on 
fibrinogen and the effect on levels of circulating fibrin(ogen) degradation products 
and c) whether genetic polymorphisms of the flbrinogen genes contribute to the 
effect of ticlopidine on plasma flbrinogen levels. 
PATIENTS AND METHODS 
Subjects 
One hundred male Caucasian blood donors of the Rotterdam Red Cross Blood Bank 
were asked to participate in this study. The flrst thirteen with the BIBI genotype 
and the first thirteen consecutive donors with the B I B2 genotype formed the healthy 
volunteer group. The men were between 30 and 50 years of age and had no history 
of vascular disease. Volunteers were not included if they suffered from any disease 
and did not use any non-study medication. Twenty-six consecutive patients that 
visited the cardiology outpatient departments of the Medical Centre Alkmaar (n = 18) 
or the University Hospital Rotterdam (n=8), having angina pectoris (NYHA 2-3/4) 
with evidence of coronary artery disease by either I) coronary angiography, 2) 
documented myocardial infarction or 3) a positive exercise test formed the patient 
group. Patients were not included if they had other diseases than coronary artery 
disease. The patients only lIsed medication for their cardiac complaints. The stable 
angina pectoris patients and the healthy volunteers were excluded from the study if 
they ever had had illnesses with bleeding risk, recent surgery or previous allergic 
reactions to medication. 
Three individuals in the healthy volunteer group and one in the patient group had 
to leave the study because they developed pruritus, these individuals were replaced. 
No individual left the study for another reason. The demographic characteristics of 
the two groups are described in table I. The study was approved by the Medical 
Ethical Committees of the Medical Centre Alkmaar and the University Hospital 
Rotterdam and written consent was obtained from the volunteers and patients in 
accordance with the Declaration of Helsinki. 
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Table I. Baseline data of the healthy volunteers and the stable angina pectoris group. Mean (SD) are 
given for age and DMJ. 
age 
gender 
DMI 
Design of the study 
healthy volunteers 
41.6 (5,2) 
26 male 
25,3 (4.4) 
patients 
65,3 (9,2) 
24 male! 2 female 
25,8 (0,6) 
This study was a randomized double-blind AB/BA cross-over study, First all groups 
received placebo for two weeks to let the participants get used to taking the 
medication. Then the volunteers and the patients were ramdomized and either 
ticlopidine (250 mg 2 dd) or placebo were administered for four weeks, followed by 
a wash-out period of two weeks and the second test period in a cross-over design. A 
wash-ollt period of two weeks was used, since the platelet aggregation had then 
returned to normal" and becallse the half life of fibrinogen is 100 hours"', Blood 
was sampled at the start (visit I), after the two-week adaptation Period (visit 2), 
after 2 (visit 3) and 4 (visit 4) weeks in the first treatment period, after the two-week 
wash-out period (visit 5) and after 2 (visit 6) and 4 (visit 7) weeks in the second 
treatment period (see figure 1), 
group 1 
group 2 
visit 
day 
1 
o 
Ticlopldlne 
i 
i 
Placebo 
2 
14 
3 
28 
i 
i 
4 
42 
Placebo 
I 
i 
Tlclopldlne 
5 
56 
6 
70 
7 
84 
Figure 1. Treatment schedule for the healthy volunteers and the stable angina pectoris patients. 
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Assays 
Platelet count and total white blood cell count were performed at each visit as safety 
measurements, platelet count had to remain> 150,OOO/mm] and total white blood 
cell count> I,SOO/mm'. No volunteer or patient ever had levels that were below 
these limits. The maximal platelet aggregation in platelet rich plasma after induction 
by ADP 5 I'M was determined using a Peyton aggregometer (Salm en Kipp, 
Breukelen, the Netherlands) at visits 4 and 7 to check the compliance. 
Plasma fibl'inogen levels were functionally determined by the Clauss method38 • 
High plus low molecular weight (lIMW + LMW) fibrinogen levels were 
determined with an enzyme immuno assay (Fibrinostika intact fibrinogen, Organon 
Teknika, Boxtel, the Netherlands) according to the instructions of the manufacturer. 
In this assay a monoclonal antibody against the carboxyl-terminal end of the 
fibrinogen A-chain is used as the capture antibody (GS), and a monoclonal antibody 
against the amino-terminal end of the Aa-chain as the tagging antibody (Y IS). Thus 
the EIA will only measure HMW plus LMW t1brinogen, and not LMW' ". 
Total fib";n(ogen) degmdntion prodncts (TOP) were determined with an enzyme 
immuno assay (Fibrinostika TOP, Organon Teknika, Boxtel, the Netherlands) 
according to the instructions of the manufacturer. In this BIA, a monoclonal 
antibody specific for the degradation prot/uL'ls of fibrinogell {JIlt! fibrin, and not 
reactive with fibrinogen or fibrin, is used as the capture antibody (FDP-14) and the 
tagging step is. done with monoclonal antibodies against fibrinopeptide A (Y IS) and 
D-Dimer (FDP-13), whereby' it assesses the total of degradation products of 
fibrinogen and fibrin". 
C~l'eactive pI'otein was determined with an EfA that used rabbit antibodies against 
human CRP (DAKO, Denmark) as catching and tagging antibody. 
DNA polymOl'phisms (Ben, Taql, G/A~") were determined as described before41.47 • 
Briefly, genomic DNA was amplified with the appropriate primers, after which the 
reaction product was incubated with the respective restriction enzyme. After 
separation on 2% agarose gels with ethidiulll bromide the fragments of different 
length were visualized under ultraviolet light. 
Statistical analysis 
Because CRP and TOP were positively skewed, the data were logarithmically 
transformed before analysis. The distribution of the resulting variables, called 
10gCRP and 10gTDP, was not different from normal. The IIrst analysis addresses the 
question whether any systematic differences in the composition of the treatment and 
status groups occur. This was done by (ANOV A) of the baseline levels for both 
visits 1 and 2 of functional and HMW + LMW antigen IIbrinogen, 10gCRP and 
10gTDP. Adequacy of the length of the wash-out period was determined by ANOV A 
applied to the data of visit 2 (baseline period I) and visit 5 (baseline period 2). The 
fixed factors were visit, group and visit*group, the random factor was patient nested 
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by group. See Senn page 63" for more details. If the visit*group interaction was not 
significant, the wash-out period was regarded as adequate. The analyses were 
performed separately for patients and volunteers. 
The effect of ticlopidine on the plasma fibrinogen levels in patients and volunteers 
separately was estimated using a paired student's t-test. The effect of genetic 
polymorphisms on the plasma fibrinogen levels was assessed using ANOV A with 
polymorphism group and status as fixed factors. 
All computations were done using the statistical package SAS. 
RESULTS 
Healthy volullleers 
The mean (SD) baseline level of functional plasma fibrinogen was 2.35 giL (SD 
0.35) and for LMW+HMW fibrinogen this was 1.97 giL (SD 0.53)(table 2). The 
geometrical mean (central 95% range) of CRP was 0.21 mg/L (0.02-2.36) and for 
TDP this was 0.18 j<g/mL (0.03-1.00). The baseline functional and HMW+LMW 
antigen levels of fibrinogen were not significantly correlated with logCRP or 
logTDP levels using Pearson's correlation analysis. 
The design of this study was AB/BA cross-over and a 14 day wash-out period was 
applied. Using a general linear model procedure it was observed that the levels after 
the wash-out period were comparable to the baseline data. 
After a 2 week administration of ticiopidine these levels had decreased to 2.18 giL 
and after 4 weeks the mean functional fibrinogen levels was 2.16 giL (SD 0.57) with 
an average decrease of 0.20 giL (SD 0.33) (=mean increase of 9%) while the 
HMW + LMW levels were unchanged. There were no significant changes in the CRP 
or TDP levels. 
The ratio of the functional fibrinogen over the HMW + LMW librinogen at baseline 
and after 4 weeks ticiopidine administration were comparable (1.23 and 1.16, 
respectively) suggesting Ihat the function of the librinogen molecules has nol been 
changed by ticiopidine in the volunteers. 
No relation between the Bell, G/A4l.' or Taql polymorph isms and the plasma 
fibrinogen level was observed. Also no difference in the effcct of ticlopidine on 
fibrinogen levels was observed in individuals with the different genotypes of the 
Bcll, G/A4" and Taql polymorphisms. 
Patients with stable Gllgina pectoris 
The mean (SD) baseline levels in the patient group of functional plasma fibrinogen 
were 3.44 giL (SD 0.61) and of LMW+HMW they were 2.70 giL (SD 0.60)(table 
3), both significantly higher than in the healthy volunteers (p<O.OOI). The 
geometrical mean (central 5-95% range) of CRP was 1.45 mg/L (0.15-14.44) and 
for TDP this was 0.28j<g/mL (0.05-1.62), also significantly higher than in the 
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Table 2. (geometric) mean (central 95 % range) of functional fibrinogen and HMW + LMW fibrinogen 
antigen, C-reactive protein (CRP) ami tolal fibrin plus fibrinogen degradation products (TDP) in the 
healthy volunteers at baseline and after two and four weeks of ticlopidine administration, 
volunteers 
baseline 2 weeks 4 weeks 
functional fibrinogen (gIL) trcatment 2.35 2,18* 2,16$111 
(1.55-2.95) (1.09-3.33) (1.02-3.30) 
placebo 2.25 2.17 2.19 
(1.25-3.25) (1.05-3.29) (1.27-3.11) 
HMW + LMW fibrinogen (giL) treatment 1.97 2.07 1.94 
(0.91-3.03) (0.41-3.73) (0.68-3.20) 
placebo 2.17 2,08 2.26 
(0.77-3.57) (0.78-3.38) (0.78-3.74) 
CRP (mgIL) treatment 0.21 1.19* 0.83 
(0.02-2.36) (0.12-11.59) (0.12-5.87) 
placebo 0.69 0.81 0.74 
(0.13-3.78) (0.06-11.82) (0.08-6.82) 
TDP (l,glmL) treatment 0.18 0.15 0.17 
(0.03-1.00) (0.05-0.50) (0.03-1.00) 
placebo 0.16 0.15 0.14 
(0.03-0.87) (0.03-0.64) (0.05-0.40) 
• significantly different from the level at haseline (p<0.05) using a paired Student's t-test 
$III significantly different from the level at baseline (p<0.005) using a paired Shlden!'s t-test 
healthy volunteers (p~0.003 and p~0.05, respectively). The baseline funclional 
fibrinogen levels were strongly correlated with the 10gCRP levels (R~0.73, 
p<O.OOOI) but not with the 10gTDP levels. The baseline HMW+LMW fibrinogen 
levels were not correlated with the 10gCRP and the 10gTDP levels. 
Analogous to the healthy individuals, it was observed that in the patients the 14 
day wash-ont period was also sufticienl. 
After a 2 week administration of ticlopidine the fibrinogen Icvels were not changed 
but after 4 weeks the functional fibrinogen levels had decreased to 3.18 giL (SD 
0.62)(p~O.01) with an average decrease of 0.39 giL (SD 0.60) (~ mean decrease of 
11 %) while the HMW+LMW levels were unchanged. 
The ratio of the functional fibrinogen over the HMW + LMW tibrinogen at baseline 
was 1.23 and after 4 weeks ticlopidine administration it had slightly increased to 
1.28, which was not significant, suggesting that the function of the fibrinogen 
molecules has not changed by ticiopidine in the patient group. 
No relation between the Bell, G/A-4,~5 or Taql polymorphisllls and the plasma 
fibrinogen level was observed. Also no difference in the effect of ticlopidine on 
fibrinogen levels was observed in individuals with the different genotypes of the 
Bell, GIA4 " and Taql polymorph isms. 
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Table 3. (geometric) mean (central 95 % range) of llinciional fihrinogen ,mu HMW + LMW fihrinogen 
antigen, C-reactive protein (eRP) and total fibrin plus fihrinogen degradation products (TDP) in the 
angina poctoris patients at haseline and after two and four weeks of ticlopidine adminislrulion. 
patients 
baseline 2 weeks 4 weeks 
functional fibrinogen (gIL) treatment 3,56 3,39 3.18** 
(2,22-4,66) (2,15-4,63) (1.94-4.42) 
placebo 3.41 3,33 3,42 
(1.97-4,85) (1.85-4,81) (2,08-4,76) 
HMW + LMW fibrinogen (gIL) treatment 2,70 2,68 2,76 
( 1.50-3,90) (0,94-4.42) (0,68-4,84) 
placebo 2,75 2,73 2,77 
(0,69-4,81) (1.23-4,23) (0,81-4,73) 
eRP (mg/L) treatment 1.45 3,18 1.86 
(0,15-14.44) (I. 94-4.42) (0,24-14,30) 
placeho 1.57 1.40 1.13 
(0,13-19.49) (0,15-12,94) (0,16-8,00) 
TDP <J<g/mL) treatment 0,28 2.36 0.29 
(0,05-1.62) (0,24-23,57) (0,05- 1.57) 
placeho 0,29 0.28 0,28 
(0,04-0,61) (0,05-1.60) (0,06-1.36) 
• significantly different from the level at baseline (p<O.05) using II rain~d Student's I-k,sl 
.. significantly different from the level at haseline (p<O.005) using a paired Slutleni':-; I-test 
DISCUSSION 
In this study possible mechanisms for the fibrinogen decrease by tic10pidine were 
analyzed in a group of healthy volunteers and in a group of patients with stable 
angina pectoris. In the healthy volunteers the functional fibrinogen levels decreased 
0,20 giL (9%) afler 4 weeks tic10pidine administration and in the patients with slab Ie 
angina pectoris the decrease was 0,39 giL (II %), 
In the group of healthy volunteers there was no Ilssociation at baseline between the 
funclional fibrinogen levels and Ihe levels of CRP and TDP, This mighl suggest thai 
the fibrinogen levels in the healthy volunteers are IltrueU baseline levels, without an 
elevation due to stimulation of the fibrinogen synthesis by an acute phase reaction or 
increased TDPs, A basal slate is further suggested by the low levels of- CRP and 
TDP. After 4 weeks of ticlopidine administration a reduction of the functional 
fibrinogen levels with 0,20 giL (9%) was observed, In the Northwick Park Heart 
Studyl an increase of the plasma fibrinogen level with I standard deviation relative 
to the mean gave a 82% increase for the risk of a myocardial infarction within 5, 
years. This 1 standard deviation was ± 15 % of the mean value, which suggests that 
the 9% decrease that we observed as a result of tic10pidine administration might 
have therapeutic significance, 
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In the stable angina pectoris patients the fibrinogen levels were higher than in the 
healthy volunteers. This increase is much larger than the 5 % increase per 10 years 
that might be explained by the age difference between the groups. In the patient 
group the absolute reduction of the functional fibrinogen was much larger than in the 
volunteers, but the percentage reduction was comparable (11%). 
Only the functional fibrinogen levels, and not the CRP and TDP levels were 
influenced by ticlopidine. This is in accordance with the results of Drolle! et ai, who 
found no alterations of the CRP levels or leucocyte counts in patients with peripheral 
arterial disease who were treated with ticlopidine for three monthsl.~. 
Ticlopidine was more effective than aspirin in the prevention of stroke in patients 
who had experienced transient ischemic attacks were compared in the Canadian-
American Ticlopidine Study (CATS)". Fibrinogen lowering could not be observed 
with the platelet aggregation inhibitor aspirin in healthy controls5u or patients with 
coronary artery diseaseH ,$2. The difference in the effect of ticlopidine and aspirin on 
the plasma fibrinogen levels might contribute to this difference in efficacy. 
The fibrinogen lowering effect of ticlopidine is only observed with the functional 
Clauss test and not with the HMW+LMW EIA. However, the ratio of these two 
assays is not changed by the ticlopidine administration in the volunteers or the 
patients. This suggests that the functionality of the IIbrinogen molecule is not 
affected by ticiopidine. The variability of the EIA is larger (between day CV = 
12%) than that of the Clauss assay (between day CV 4.2%), which might explain 
why no decrease of HMW + LMW I1brinogen is fOllnd while functional fibrinogen 
levels decreased and the ratio of functional over HMW + LMW fibrinogen was not 
changed. 
Both in the healthy volunteers and the stable angina pectoris patients no correlation 
was observed between the genotypes of the BB-chain polymorphism and the 
fibrinogen levels. This is in contrast to several other observations·19A2.H, but some 
other studies also found no effects4151 . This might be explained by the low number 
of smokers in this study, since only 3 volunteers and 1 patient smoked. It has been 
reported that the relation between the (if A--I~5 fibrinogen polymorphism and 
fibrinogen levels in much stronger in smokersI6.4J .5-1. We further did not observe a 
relation between the decrease of the tlbrinogen levels and this polymorphism. 
Since the percentage reduction of functional tlbrinogen levels in the volunteers and 
in the patients was comparable after 4 weeks ticlopidine administration, and since an 
effect of ticlopidine on the acute phase reaction, the TDP levels or the ratio 
functionallHMW + LMW fibrinogen were not changed by ticiopidine, it is suggested 
that the functional metabolite of ticlopidine might directly affect the fibrinogen 
synthesis by human hepatocytes. A change of quantity rather than quality is also 
indicated by Drouet et a125, who found 10% reduction of the fibrinogen levels with 
several methods (immunoreactive, clottable protein, Clauss, kinetic methods) in 
patients with peripheral arterial disease that had been treated with ticiopidine. 
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We conclude that since ticlopidine decreases the fibrinogen levels both in healthy 
volunteers and in patients with stable angina pectoris, and a contribution of the acute 
phase reaction and fibrin(ogen) degradation products is not suggested. No effect of 
DNA-polymorphisms of the fibrinogen BB-chain was observed. However, further 
and particularly longer studies will be necessary to further elucidate the mechanism 
of the fibrinogen decrease by ticlopidine. 
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ABSTRACT 
Elevated plasma fibrinogen levels are getting increasingly accepted as independent 
risk indicators of cardiovascular disease. This has enhanced the interest in 
identifying agents that can normalize elevated plasma fibrinogen levels. One group 
of agents with this capacity consists of the lipid lowering fibric acid derivatives, e.g. 
ciprofibrate and gemfibrozil. 
We studied the fibrinogen lowering effect of 12-week treatment with ciprofibrate 
(n=48) and gemfibrozil (n=51) in hypercholesterolemic patients. The correlation of 
the decrease in fibrinogen with the lipid lowering effects and the contribution of the 
acute phase and genetic polymorphisms to this decrease were evaluated. 
After 12 weeks treatment the fibrinogen levels were significantly decreased 
(p < 0.0005) with both drugs, although the decrease in the ciprotibrate group (3.4 
pre-treatment to 2.4 giL after 12 weeks) was larger than in the gemtibrozil group 
(3.4 to 3.0 giL ). The lipid lowering effect oi the two drugs was comparable and not 
parallel to the fibrinogen lowering effect. A decrease in the major regulating 
mechanism of plasma fibrinogen levels, the acute phase reaction, was invoked as 
underlying mechanism because the increased pre~treatment fibrinogen levels were 
normalized after treatment. However, pre~treatment C~reactive protein levels were 
not increased and did not change after treatment. No effects of the polymorphisms of 
the BE-fibrinogen chain on the decrease of the plasma tibrinogen levels were 
observed. This suggests that. a new, yet unknown, mechanism is involved in 
fibrinogen lowering by fibrates. 
INTRODUCTION 
An elevated plasma fibrinogen level is an important independent risk indicator for 
the development of cardiovascular disease"'. Prospective studies like the Northwick 
Park Heart Study' and the Framingham Study' have shown that the predictive value 
of elevated plasma fibrinogen levels for developing cardiac events is of the same 
magnitude as that of elevated cholesterol levels. In the PROCAM study' it was 
shown that the highest cardiac risk was present in individuals with both high 
fibrinogen and high cholesterol levels. 
In this respect it is of great interest to study ways to reduce fibrinogen in 
individuals with elevated levels. No agents have yet been identitied that can 
selectively affect fibrinogen, but some drugs have been shown, as an additional 
effect, to decrease plasma fibrinogen levels. For example there are the fibric acid 
derivatives whose main effect is a reduction of triglyceride and cholesterol levels'. 
Increased plasma fibrinogen levels"'" can be decreased by about 20% after treatment 
with bezafibrate and clofibrate"'''. One study with ciprotibrate showed that this drug 
also decreased plasma fibrinogen by 21 % in dyslipidemic patients". Gemfibrozil 
also belongs to the fibric acid derivatives, but reports on its effect on fibrinogen are 
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conflicting 13,17.20. 
The mechanism of the fibrinogen lowering effect of fibtates is still unknown. The 
most important mechanism that regulates the plasma fibrinogen levels is the acute 
phase reaction2I •22 • A role for the acute phase in fibrinogen lowering by fibrates is 
suggested by the results of Pickart et al who describe that clofibrate suppresses the 
acute phase stimulated synthesis of fibrinogen in the rat23 • If the fibrinogen lowering 
effect of fibrates is a result of a diminished acute phase reaction it is expected that 
the plasma levels of other acute phase proteins, like C-reactive protein (CRP), will 
also change. 
Regulation of the fibrinogen level can partly be accounted for by genetic factors. 
Two DNA-polymorphisms (G/A~" and Be/I) of the B3-chain of tibrinogen have 
been reported14.26 , and healthy individuals with the rare A~'~'~ allele have the highest 
plasma fibrinogen leve!s24,27-2!} and the greatest longitudinal variability of these 
fibrinogen levels24 . If we use the longitudinal variation as a Illeasure of the 
sensitivity to factors that regulate the fibrinogen levels, it might be suggested that the 
fibrinogen lowering effect of lipid lowering drugs (e.g. ciprol1brate) in individuals 
with the rare allele will be the largest. 
In this study we documented the relation between plasma I1brinogen levels and 
factors that are known to influence these levels in hypercholesterolemic patients and 
evaluated the fibrinogen lowering effect of ciprot1brate and gemfibrozil and the 
contributions of the aClite phase (re!lected by CRP-Ievels) and of genetic factors. 
PATIENTS AND METHODS 
Patients 
Ninety-nine patients with primary hyperlipidaemia (type lIa and b according to the 
Fredrickson classification) with a total cholesterol level equal to or higher than 6.5 
mmol/L were randomly allocated to treatment with 100 mg/day ciprotlbrate (n ~48) 
or 2 times 600 mg/day gemfibrozil (n~51). 
The study consisted of a dietary washout period and a placebo period of four 
weeks each, foHowed by an active twelve week treatment .period. Five visits took 
place, the first vi~it was prior to the fOLir week dietary period, the second visit took 
place prior to the placebo period. The other three visits were planned for, after 6 
weeks and after 12 weeks of active treatment. 
Age, body mass index (BMI) (weight divided by height'), gender and smoking 
habits of the patients were carefully documented. Smokers were dell ned as 
individuals who had never smoked or who had stopped smoking more than 10 years 
ago. Information on smoking habits, however, could not be obtained from all 
patients; table 1 provides the available data. Basic characteristics are given, for each 
treatment group, in table I. 
Thirty healthy male blood donors, comparable for age (54.0 (SD 6.4) years) were 
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used as a reference group for the pre-treatment fibrinogen and CRP data. 
At visits two, three, four and five blood samples were collected from fasting 
patients in trisodium citrate (tinal concentration II IllmoIlL). The blood samples 
were immediately put into melting ice. After centrifugation (30 min. 3000 g, 4 'C) 
plasma was collected and stored at -80"C. DNA was isolated from the white blood 
cells and stored at 4 "C. 
The study was approved by the Medical Ethical Committee of the Siotervaart 
Hospital, Amsterdam and written consent was obtained from the patients in 
accordance with the Declaration of Helsinki. 
Table 1. Baseline ciHlracteristics of the individuals in the ciprot1hrate and the gemfihrozil group. 
Given are mean (1 SD). 
Gemlihrozil Ciprofibfil!e 
men/women 27/21 32/19 
age (years) 52.4 (12.5) 51.4(11.4) 
smokers/non smokers 17/25 24/16 
EM! 25.6 (3.4) 27.1 (4.4) 
cholesterol (mmollL) 8.9 (1.8) 8.9 (2.0) 
Familial comhined 8 6 
hypercholesterolemia 
Familial hypercholesterolemia 25 33. 
polygenetic hypercholesterolemia 15 12 
BMl is hody mass index (weight in kg divided hy (length in 111)2) 
n.s not significant with p> 0.10 in the x2-test 
p gives the difference between the ciprofihrate and the geml1hrozil group 
Assays 
p 
n.s. 
n.s. 
p~0.07 
n.s. 
n.s. 
n.s. 
n.s. 
n.li. 
Functional plasma fibl'inogen levels were determined according to ClallssJo. 
C-I'eactive protein levels were determined with an enzyme immune assay, using 
rabbit anti-human C-reactive protein (Dako, Copenhagen, Denmark) as the catching 
and the tagging antibody. 
The GI A--m. polymorphism of the B-fibrinogen gene is assessed as described by 
Thomas et al.2.~. Briefly, genomic DNA was amplified by polymerase chain reaction 
(PCR) and digested with the NodH restriction enzyme (Boehringer Mannheim 
GmbH, MannheiIll, Germany). The DNA fragments were then visualized under UV 
light after separation on 2 % agarose gels containing 0.5 ,ug/mL ethidium bromide. 
Due to the small number of individuals in this study that were homozygous for the 
rare A-45S allele we combined the individuals with G/A"'!'·~·~ and A/A-m in one group. 
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Statistical evaluation 
The distribution of the CRP levels was skewed and ther~fore we used logarithmical 
transformation. The fibrinogen levels were normally distributed. The pre-treatment 
fibrinogen and CRP levels were the average of the levels at the first and the second 
visit. The pre-treatment characteristics of the two treatment groups were compared 
with the Chi'-test. The pre-treatment associations between fibrinogen and CRP levels 
with age, BMI, smoking, gender and G/A-4SS-RFLP were evaluated using multiple 
regression analysis. The effects of treatment with ciprofibrate and gcmfibrozil on the 
changes of plasma fibrinogen and CRP levels was tested using the paired Student t-
test. The effects were tested separately in individuals with or without the rare A-m_ 
allele and in men and women. 
The results are given as mean (central 90% range) or mean (l standard deviation), 
The statistical package SOLO was used and p-values less than 0.05 were considered 
significant. 
RESULTS 
Pre-h'eatment data 
In the total patient group the mean (central 90% range) plasma pretreatment 
fibrinogen levels (average of the first two visits) was 3.4 giL (2.7-4.2), whereas in 
the healthy reference group plasma levels of 2.1 giL (1.3-3.1) were found. For 
CRP, levels were 0.98 mglL (0.26-4.2) in the patient group and 2.0 mg/l (0.3-11) in 
the healthy volunteers. The pre-treatment levels of tibrinogen ancl C-reactive protein 
(eRP) were comparable in the ciprofihrate and gemfibrozil treated groups, with a 
Spearman correlation of 0.38 (p<O.OI). 
The pre-treatment plasma fibrinogen levels also revealed an increase of 0.15 gIL 
per 10 years of age (R=0.30, p=0.002). However, no signiticant effects of gender, 
BMI or smoking were observed. When we studied the relation between CRP and 
these variables, however, we found significant correlations with BMI (R=O.39, 
Table 2. Mean (I SD) levels of pre-treatment plasma tlhrino~en levels lin the ,genotypes of the 
G/A45S polymorphism in smokers and non-smokers 
non-smokers 
smokers 
n 
20 
30 
n gives the number of individuals 
3.33 (0.53) 
3.23 (0.47) 
n 
20 
II 
O/A~.\~ and A/A~~.\ 
3.47 (0.62) 
3.88 (0.44) * 
• significant higher (p<0.05) fihrinogen level than in the G/O·m smokers group 
chapter to 155 
p=0.0005) and smoking (0.3 mglL higher in smokers with R=0.23 and p=0.03), 
but not with age and gender. 
The pre-treatment fibrinogen levels in the patients with the rare allele of the 01 A-
m RFLP were not significantly different when we studied the total patient group. 
However, when we studied smokers and non-smokers separately, higher fibrinogen 
levels were observed in smokers who possessed the GI A 455 allele whereas in the 
non-smokers this difference was not found (table 2). The effect of the GlA~ll RFLP 
on the fibrinogen levels was similar in men and women. 
Effecls of cip"ofibrale and gemfibrozil Irealmenl 
After 6 weeks treatmenl with ciprofibrate the fibrinogen levels were already 
significantly reduced, whereas fibrinogen levels in the gemtibrozil group had not 
changed signiticantly (table 3). After 12 weeks of ciprofibrate treatment the 
fibrinogen levels had further decreased (mean total decrease 0.91 giL, p<O.OOOI), 
and now the fibrinogen levels in the patients treated with gemfibrozil were also 
decreased. Although the reduction was smaller (0.41 giL), it was significant 
(p<O.OOOI). In Ihe last six weeks of treatmenl, both treatment groups showed a 
reduction comparable to the first six weeks (0.21 and 0.47 giL, respectively). 
The plasma levels of CRP were reduced after six weeks treatment with ciprofibrale 
(-0.11 mglL, n.s.) and gemfibrozil (-0.29 giL, p=0.002) but the levels had returned 
10 pre-treatment levels after 12 weeks of treatment in both groups (table 3). After 
adjustment for eRP the decrease of the fibrinogen levels after 12 weeks treatment 
with ciprofibrate were 1.21 giL (p<O.OOOI) and with gemfibrozil 0.81 giL 
(p<O.OOOI). 
No associations could be found between the changes in fibrinogen or CRP and the 
changes in lolal, LDL-, HDL-cholesterol or triglycerides (levels of lipid variables 
previously published by Knipscheer et al"). After 12 weeks treatment with 
ciprofibrate the plasma fibrinogen levels in Ihe smokers were 0.30 giL higher than 
in Ihe non-smokers (R=0.35, p=0.03). In the patients treated with gemfibrozil for 
12 weeks, this association was not found. 
A somewhat larger decreasing effect after 12 weeks ciprotlbrate treatment was 
observed in individuals who possessed the rare allele of the O/A~·" 3-fibrinogen 
polymorphism (table 4), though this was not signitican!. When non-smokers and 
smokers were analyzed separately, here too no effect of the RFLP was found, nor 
was any effect of the RFLP found when men and women were analyzed separately. 
Table 3. Mea.~ (central 90% range) of fibrinogen and CRP levels in the ciprofibrate and the gemfibrozil group at the different visits. 
Fibrinogen (giL) C-reactive protein (mg/L) 
gemfibrozil ciprofibrate gemfibrozil ciprofibrate 
mean central mean central 90% geometrical central 90% geometrical central 90% 
90% mean mean 
pre-treatment 3.44 2.27-4.61 3.38 2.19-4.57 0.93 0.13-6.7 1.28 0.15-10.6 
6 weeks 3.24 2.08-4.44 2.89* 1.01-4.77 0.51' 0.02-13.8 0.94 0.04-19.7 
12 weeks 3.01 * 1.75-4.27 2.42* 1.61-3.24 1.25 0.11-14.4 1.32 0.20-8.7 
* p < 0.0005 from the pre-treatment level using the Student-t test 
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Table 4. Mean (1 SD) levels of lihrinogen for the genotypes of the O/AH_I polymorphism of the n1\-
chain of fihrinogen at the pre-treatment visit, after 6 and after 12 weeks (r"'alment with ciprotibnlte or 
gemfibrozil. 
gemfibrozil ciprof1hrate 
GlO·m GlA·455 and AIA-4H G1Gm O/A-45j and A/Am 
pre-treatment 3.42 (0.41) 3.55 (0.71) 3.27 (0.57) 3.62 (0.53) 
6 weeks 3.14 (0.49) 3.33 (0.69) 2.76 (0.56) 3.21 (/.55) 
12 weeks 2.96 (0.72) 3.07 (0.55) 2.39 (0.41) 2.50 (0.42) 
DISCUSSION 
In hyperlipidemic patients we found significantly higher plasma fibrinogen levels 
than in the healthy volunteers. As the acute phase is a main regulatory mechanism of 
the fibrinogen synthesis, increased levels might be a reflection of a low grade 
inflammatory status in these patients. Therefore a relation between the plasma levels 
of fibrinogen and those of CRP was expected. We did observe a significant 
Spearman correlation of 0.38 (p<O.OI). However, we also observed that the pre-
treatment CRP levels in patients with hyperlipidaemia and in healthy controls were 
comparable. This discrepancy between fibrinogen and CRP levels indicates that the 
regulation of the synthesis of fibrinogen is partly, but not entirely the effect of a low 
grade acute phase reaction. 
We documented factors that are known to be associated in healthy volunteers with 
the plasma fibrinogen and eRP levels, e.g. age, gender, BMI and smoki ng l. 32 • In 
our study fibrinogen was only significantly related to age, whereas eRP levels were 
associated with BMI and smoking. This further suggests that plasma fibrinogen and 
CRP-Ievels in these patients are regulated differently. 
To our surprise, no relation existed between smoking and the plasma fibrinogen 
levels. In this study lVe included persons who had stopped smoking less than 10 
years ago in the smoking group, but also when we compared current smokers with 
persons who had never smoked or had stopped smoking more than 10 years ago, we 
found no correlation between smoking and the plasma fibrinogen levels. We 
previously made a similar observation in patients with severe coronary artery 
diseaseH , where we found no association between smoking and plasma fibrinogen 
levels in the patient group, while we observed an association in the healthy control 
group. Also, in the PLAT study, performed on patients with vascular disease, an 
effect of smoking on the plasma tibrinogen levels was absent-ll. This suggests that 
smoking will not give an additional elevation in patients with an increased plasma 
level of fibrinogen, both in patients with vascular disease and with type II 
h yperli pidaemia. 
The relation between the GI A ---t.~.~ polymorphism of the BIl-chain of tihrinogen and 
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the pre-treatment plasma fibrinogen levels was not significant in the total patient 
group. This confirms the reports on other patient groups. No associations could be 
found between the polymorphisms in BB-fibrinogen chain and plasma fibrinogen 
levels in peripheral artery disease patients35 ,J6, cardiovascular disease patientsJ7 or 
thrombosis patients3S . Because an association between this RFLP and fibrinogen 
levels is frequently reported in healthy individuals"·27.29 , it might be suggested that 
this association between B-fibrinogen polymorphisms and plasma fibrinogen levels is 
confined to healthy individuals. However, in the smoking patients we did lind a 
clear relation between the Gf A 455 polymorphism and plasma fibrinogen levels. In the 
non-smoking patients this relation was absent. This confirms the results of Green et 
a123 , who described that in young survivors of myocardial infarction the relation 
between this RFLP in the gene of the fibrinogen BB-chain and plasma fibrinogen 
levels can only be found in smokers. Also in the ECTIM studyJ7, there was an 
association between the Gf A 455 RFLP and plasma librinogen levels but only in 
smokers. 
In this study, we observed that the effect of fib rates on fibrinogen levels is quite 
slow: already after 6 weeks treatment with ciprofibrate, patients had already a 
significant decrease in plasma fibrinogen, but this effect was more pronounced after 
12 weeks. With gemfibrozil no significant decrease was found after six weeks, but 
after twelve weeks the decrease was significant, although much smaller than after 
ciprofibrate treatment. This delayed effect suggests that there is no direct effect of 
the fib rates on the fibrinogen synthesis. Since the fibrinogen levels after 12 weeks 
treatment are lower than those after 6 weeks, a greater fibrinogen decrease might be 
achieved after prolonged treatment. A t1brinogen decrease was also found in the 
study of Avellone et al in patients with primary hypertriglyceridemia19 • 
Unfortunately, this study was not placebo-controlled, which makes it impossible to 
differentiate drug effects from disease-associated changes in fibrinogen levels. Other 
studies with gemfibrozil, however, reported an increase of the fibrinogen levels in 
hypercholesterolemic patients type IIa and lIb" or found no significant effect in 
coronary artery disease patients17,IS,20, 
No associations between the changes in plasma fibrinogen levels and those in 
total, LDL- and HDL-cholesterol were found in either the ciprotibrate or the 
gemfibrozil treated patients. This was anticipated, as the effect of the two drugs on 
fibrinogen was different, while the effect on the lipid parameters was comparable. 
This indicates different mechanisms for the fibrinogen decrease and the lipid changes 
of ciprofibrate and gemfibrozil. 
We studied whether the genetic polymorphism of the BB-librinogen gene might be 
associated with the fibrinogen decrease. Recently, it has been suggested that the BB-
fibrinogen polymorphisms are mainly important in the acute phase regulation of the 
fibrinogen synthesis, because the correlation between librinogen levels and genotype 
was only found in smoking survivors of myocardial infarction2R , In this study we 
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could not confirm that the BB-polymorphisms are associated with acute phase 
induced fibrinogen synthesis. At baseline, the individuals with the rare allele have 
slightly higher fibrinogen levels, though not significantly so. Although there is a 
trend, the decrease of fibrinogen is not signiticantly larger in individuals with the 
rare allele, but the significance might have been missed because the group that was 
homozygous for the rare allele was too small to be studied separately. 
In summary, we have shown in this study that ciprofibrate decreases fibrinogen 
levels significantly, and that the levels that are found after 12 weeks of treatment are 
comparable with those in healthy individuals. Gemfibrozil gave a smaller fibrinogen 
decrease, which was only significant after 12 weeks. In attempts to elucidate the 
mechanism by which ciprofibrate lowers fibrinogen we found that the low grade 
acute phase stimulation of the fibrinogen synthesis contributes only minimally and 
that there mllst be another mechanism. The Btl-fibrinogen 01 A ...t.~.~ polymorphism was 
not associated with the reduction of the fibrinogen level by tibrates. 
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ABSTRACT 
Elevated plasma fibrinogen levels represent an increased risk for cardiovascular 
disease, but the mechanism explaining this association is still not clear. Genetic 
differences of the fibrinogen genes might playa role, since it has been shown that 
individuals who carry the rare alleles of polymorphisms in the gene for the Bll-chain 
(Bell and G/A-455) and the Aa-chain (Taql) of fibrinogen have higher plasma 
fibrinogen levels, and patients with peripheral arterial disease have a higher 
frequency of the rare allele of the Bell polymorphism than healthy controls. We 
studied in Greenland Inuit, a population with a low incidence of ischaemic heart 
disease, the polymorph isms of the fibrinogen gene and their association with the 
plasma fibrinogen level. The group studied has a small age range 00-34), 97% were 
smokers, 62 were men and 71 women. 
We observed differences in the fibrinogen polymorphisms in the Inuit when 
compared to Caucasian populations: firstly, in the Inuit the frequencies of the rare 
alleles of the Bll-chain and the common alleles of the Aex-chain polymorphisms were 
lower than that in other published populations (all Caucasian). Accordingly, these 
distribution patterns give a higher frequency in the Inuit of alleles that are associated 
with lower plasma fibrinogen levels. Secondly, we observed linkage disequilibrium 
between Bll and ACi polymorph isms, which has not been observed in other healthy 
populations. In the Inuit men the rare allele of the Bell and G/A~" fibrinogen 
poJymorphisms was associated with the plasma fibrinogen levels, comparable to the 
association described in Caucasian populations. 'In women, however, we did not find 
a significant association, supporting the desirability of separate analysis in men and 
women of the influence of genetic factors on atherosclerotic disease, 
In conclusion: in the Inuit the association of fibrinogen polymorphisllls with 
fibrinogen levels is comparable to that in Caucasians, but the genes that are 
associated with lower fibrinogen levels are Illore frequent ill the Inuit than in 
Caucasians. 
INTRODUCTION 
In several epidemiological studies it has been shown that an increased plasma 
fibrinogen level is an independent risk indicator for cardiovascular disease l-6 , The 
Northwick Park Heart Study showed that an increase of the fibrinogen level at one 
standard deviation predicted an increase in the risk for cardiovascular events within 
the next 5 years of 84 % '. 
The mechanism of the association of fibrinogen with risk has not yet been 
elucidated, It might be that an increased amount of fibrinogen in the circulation 
gives an increased propensity for thrombosis? or directly contributes to the 
development of the atherosclerotic lesion~. There are also indications that increased 
plasma fibrinogen levels retlect the intlammatory condition of the vascular wall. 
166 fibrinogen poiymorphisms in Inuit 
This theory is supported by the results of the ECAT-angina pectoris study', where 
increased fibrinogen levels and increased C-reactive protein (CRP) levels are both 
risk indicators for cardiac events in patients with angina pectoris. The PROCAM 
study has recently reported comparable results for a healthy population'. Another 
cardiovascular risk factor that is closely linked to inflammation is smoking, which 
increases the levels of fibrinogen and other acute phase reactantslO,l'. It is 
conceivable that smoking contributes to risk also because of its acute phase inducing 
properties. 
Taq-1 801-1 
-y -chain 0( -chain /3 -chain 
Figure 1. The fibrinogen genes of the ct, ij and 'Y chain of fibrinogen with the location of tbe genetic 
poiymorphisms that were applied in tIlis study. The direction of transcription of the genes is 
represented by the arrows under the boxes. 
Genetic variation may also playa role in determining plasma fibrinogen levels. An 
association between polymorph isms in the genes for the Au and Ba chain and 
plasma fibrinogen levels (figure 1) has been described"'''. Recently, Green et al 14 
showed that the association between GI A 455 genotypes and fibrinogen levels was 
observed OI11y' in smokers, suggesting that the increase of fibrinogen as the result of 
a low grade acute phase reaction, e.g. by smoking, might depend on polymorph isms 
of the fibrinogen Ba chain. It has also been reported that the binding of nuclear 
proteins to DNA fragments was influenced by the genotype at the G/A4ss and C/i'48 
polymorphic sites of the Ba-fibrinogen genelS,,,, the last of which is located close to 
the interleukin-6 responsive element of the promoter. If these findings are combined, 
they imply an involvement of the a-fibrinogen polymorph isms in the cytokine 
stimulated regulation of fibrinogen synthesis. 
The association between fibrinogen genotypes and plasma levels has not been 
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confirmed in all studies. There is, however, much diversity in the composition of the 
population samples and in the fibrinogen assays used. One of the variant factors is 
the number of smokers. Since both the ECTIM study" and Green et aP' reported 
that the association between genotypes and fibrinogen levels is stronger in smokers, 
part of the reported difference in the relation between fibrinogen pol ymorphisms and 
fibrinogen levels might be ascribed to this variation. 
A fibrinogen restriction fragment length polymorphism (RFLP) at the 3' end of the 
a-fibrinogen chain has been described (Ta'lI)I'. No significant correlation between 
these polymorph isms and plasma fibrinogen level has been found, but when the 
average excess of GI A -455 and Tat] 1 combined genotype is estimated l8 , the presence 
of functionally distinct genotype combinations is suggested". 
We performed a study of tibrinogen polymorphisms in Greenland Inuit, a 
population with a low incidence of ischaemic heart disease2{1. We determined the 
allele frequencies of the G/ A~", Bell and Taq I polymorphisms and calculated the 
associations between the different polymorphisJl1s. In addition, we estimated the 
association between genotype and plasma tibrinogen levels (functional and 
immunological methods) in Illen and women. 
METHODS 
Population 
One hundred and ninety IIVo Inuit, aged 30-34 years, living in Nanortalik, in the 
southwest of Greenland, were invited to participate in this study. This group was 
studied because in individuals aged 30-34 no selection by coronary heart disease wiB 
be observed. A complete set of data, consisting of blood specimens, a filled-in 
questionnaire and anthropometric measurements was obtained from 133 individuals 
(62 men and 71 women). Upon medical investigation these 133 Inuit appeared to be 
healthy and did not show signs or symptoms indicating the presence of severe 
atherosclerosis. Characteristics of the population have been described elsewhere in 
detail'l. We considered individuals who never smoked (n =4) and those who stopped 
smoking more than lO years ago (11 =2) as non-smokers, and current slllokers and 
those who stopped less than 10 years ago as smokers (n=6, stopped between 3 
months and 3 years before sampling). Of the smokers, 13% smoked less than 5 
cigarettes/day, 60% smoked 5-14 cigarettes/day and 27% smoked more than 15 
cigarettes/day. The Inuit had smoked for 17.5 (SD 3.6) years. There was no 
difference in smoking habits between men and women. 
C-reactive protein and fibrinogen levels were available from all 133 subjects, 
polymorphisms analysis could not be performed in all samples, due to a poor quality 
of some DNA samples (see table I for number of analyzed samples). Body mass 
index (BMI) was calculated as weight/height' (kg/m'). 
Fifty two Danes, comparable for age (30-34 years) and gender (28 men and 24 
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women), were the control group for plasma fibrinogen and CRP-Ievels. Danes were 
chosen as a reference group, because 1) it was not possible to compose a large 
enough group of Greenland inhabitants without Inuit among their ancestors, and 2) 
the way of living, plasma lipid and (apo)lipoprotein levels and apparently lack of 
ischaemic heart disease, and therefore the Danish control population is comparable 
with the Inui!'!. 
Blood sampling 
Blood was collected in sodium citrate (final concentration 14 mmol/L) and 
immediately placed in melting ice. After centrifugation (30 min, 2000 g, 4 'C) the 
plasma was collected and frozen at -70'C. The blood cells were stored at -20'C. 
Polymorphism analysis 
Each 501'1 polymerase chain reaction (PCR) reaction contained 100-400 ng genomic 
DNA, 100 ng of each appropriate primer, 10 mmoIlL Tris/HCI pH=9.0, 1,5 
mmol/L MgCl" 50 mmoIlL KCI, 0.01 (w/v) gelatin, 0.1 % Triton X-IOO, 0.02 
mmol/L dNTP, 0.1 U Taq polymerase (HT Biotechnology LTD, Cambridge, 
England). The reaction components were incubated at 95°C for 5 min, followed by 
30 cycles of 95°C for I min, 55°C for I min, 72°C for 2 min in a DNA thermal 
cycler (perkin Elmer Cetus). 
The primers have been previollsly described (G/A-I·~·~ by Thomas et alY, Bell and 
Taql by Thomas et al"). 10 1'1 of the PCR product was digested with the 
appropriate restriction enzyme. These digestion products were separated by 
electrophoresis through a 2% agarose gel in 44 mmol/L tris-borate I mmol/L EDTA 
containing 0.5 I'g/ml ethidium bromide and visualized under UY-light. The alleles 
with the restriction site and the non-cleavable alleles were designated B I and 82 for 
the Bell polymorphism, G-45.'i and A-US for the G/A-4~~ polymorphism and TI and T2 
for the Taql polymorphism, respectively. 
Plasma protein measurements 
Fibrinogen activity levels were measured with the modi fied Clauss assay2J. The 
within-day and between-day coemcients of variation (CY) were 3.2% and 4.9%, 
respectively. Fibrinogen antigen levels were measured nephelometrically, using 
rabbit polyclonal anti-human fibrinogen (Dako, Denmark) antibodies. The within-day 
and between-day coefficients of variation (CY) were 1.7% and 4.2%, respectively. 
Normal plasma (Nycomed Pharma, Oslo, Norway) was lIsed as calibrator for the 
fibrinogen assays. The ratio of the two fibrinogen assays and its 99% confidence 
interval were calculated. Seven samples were outside this range and omitted. Levels 
of Cwreactive protein were measured with an ElA lIsing rabbit antibodies against 
human C-reactive protein (Dako, Denmark) as catching and tagging antibodies. The 
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within-day and between-day coefficients of variation (CV) were 2.9% and 6.2%, 
respectively. CRP-standard serum (Behringwerke, Marburg, Germany) was used as 
calibrator. 
Statistical analysis 
Deviations of the genotype distributions in the Inuit samples from that expected for a 
population in Hardy-Weinberg equilibrium were analyzed using the x'-test. Genotype 
frequencies in the Inuit and published frequencies were compared with a x'-test. 
Standardised disequilibrium statistics were calculated as described by Chakravarti". 
Allele frequencies in the Inuit were determined by gene counting, 95 % confidence 
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Figure 2. The mean (SEM) of the functional fibrinogen levels in Inuit with the G/G-I5~  and 
G/ A -m (1/1/1/1) genotypes of the GI A -155 restriction fragment length polymorphism (RFLP) of the total 
group, men and women. * indicates a significant difference from the levels in the G/G-I55 group. 
intervals (95 % CI) of the allele frequencies were calculated from sample allele 
frequencies2s , based on the approximation of the binomial and normal distributions 
when n is large. 
With analysis of covariance (ANCOV A) the adjusted fibrinogen levels for each 
genotype were estimated and the significance of genotypes in determining plasma 
fibrinogen levels was eslimated, with BMI, waist-hip ratio and CRP levels as 
covariables. A multiple linear regression model was used to assess the amount of 
variance in plasma fibrinogen levels, explained by BMI, CRP, smoking status and 
genotype in men and women, separately. 
Statistical analysis was performed using the "SOLO" and "Lotusl23" computer 
programmes. Statistical significance was taken as p < 0.05. 
Table 1. Frequency (and 95% confidence intervals) of the rare allele of fibrinogen polymorphisms 
Bell G/A-4-<5 Taql 
n* freq. t 95% CIt n* freq·t 95% CI:j: n* freq. t 95% CI:j: 
Study: 
London12 91 0.25§ 0.19-0.32 91 0.28§ 0.22-0.35 
Norway27 118 0.17§ 0.13-0.23 118 0.27§ 0.22-0.33 
London2S 53 0.16§ 0.10-0.23 53 0.26§ 0.18-0.36 
UK all" 292 0.19§ 0.16-0.22 
UK smokersI3 120 0.20§ 0.15-0.26 
UK non-smokers i3 172 0.19§ 0.15-0.24 
Edinburgh29 126 0.10 0.07-0.15 126 0.25§ 0.14-0.23 
Sweden all '4 86 0.25§ 0.20-0.31 
Sweden smokersl4 57 0.20§ 0.13-0.27 
Sweden non-smokersl4 29 0.34§ 0.22-0.46 
UK and France" 64S 0.21§ 0.19-0.23 
UK" 293 0.15 0.12-0.IS 276 0.27§ 0.24-0.31 
Inuit (This study) 126 0.12 0.09-0.17 131 0.11 0.OS-0.15 121 0.47 0.41-0.53 
n* number of individuals evaluated 
t frequency of the rare allele 
t 95% confidence interval of the rare allele frequency 
§ frequency is significantly different from the Inuit (p < 0.05 in x'-test) 
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RESULTS 
Genetic distribution compal'ed to Caucasian populations 
In the Inuil population the allele distributions of the Bell, G/A455 and Taql 
polymorphisms were in Hardy Weinberg equilibrium, as expected in a general 
population. A different genetic background was indicated for the Inuit when 
compared to Caucasian populations, since the allele frequencies of the rare alleles of 
the G/A455 and Be/I polymorphisms and the frequency of the common allele of the 
Taql polymorphism in the Inuit were significantly lower when compared to most, 
but not all, of the Caucasian populations (table I ".n.22.27.". 
Allelic associations 
In Caucasian popuiations\3,14 there was a strong linkage between the two 
polymorphisms of the fibrinogen BB chain giving a strong association between the 
BI and the G455 allele. However, the linkage was weak between the polymorphism 
of the AOl chain and those of the B3 chain, since there was no signiticant linkage 
between the T2 allele on the one side and the B I and the G4 \j alleles on the other 
(table 2)13,14,)0,31, In the Inuit, the B I allele was in strong allelic association with the 
G-,m allele as in other populations, but, in contrast, there was also a significant 
association with the T1 allele (Table 2). 
Table 2 The allelic association hetween the Ta'll polymorphism of the a-lihrinogen gene and the 
G/A455 and Bell polymorphisms of Ihtl {J-fihrinogen gene. 
Inuit Caucasian 
Beil ~ G/A-455 
G/A-455 _ Taql 
Beil - Taql 
A~ 0.9t, X'~222. p<O.OOt 
.6.=-0,32, X2= 24, p<O,OOI 
.6.=-0.29, X2= 22, p<O.OOI 
A~ 0.85. X'~322. p<O.OOt (22) 
.6.=-0,09, X2= 3 • p>O,1 (22) 
.6.= 0.01, X2= I • 1'>0.1 (22) 
A~·O.G7. p>O.1 (3 t) 
A~ 0.01. p>O,1 (30) 
.6. linkage coefficient 
Genetic cOllfriburion to the plasma jihrinogen levels 
The acute phase markers fibrinogen and CRP were both higher (2.81 giL in the 
functional assay, 2.81 giL for fibrinogen antigen and 2.9 mg/L for CRP) in the Inuit 
than in the Danish control group (2.30 giL in the functional assay, 2.19 giL for 
fibrinogen antigen and below 1.5 mglL for CRP). Adjustment for the acute phase 
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state by adding CRP in ANCOVA still gave a comparable difference between these 
populations (results not shown). 
If all Inuit are studied as a single group, there is no significant association in the 
ANCOV A between either of the three fibrinogen polymorphisms and plasma 
fibrinogen level. However, when the group is divided into men and women, we 
observed only in the men a significant significantly higher plasma librinogen levels 
with the BIB2 or the G/A455 genotype. In women, there was a similar trend, but this 
was not significant (figure 2, table 3). Stratilication by combined a- and 3-
fibrinogen genotype did not reveal any more informative genotype combination (data 
not shown). 
In the Inuit, BMI, CRP, smoking status and genotypes together accounted in the 
men for 25% and in the women for 35% of the variation in plasma fibrinogen 
levels. Removal of the genotype from the regression model reduced the amount of 
variance explained to 16% in men and to 26% in women, suggesting that the 
fibrinogen polymorphism genotypes accounted in both men and women for 9% of 
the variation in fibrinogen levels after adjustment for covariables. Removal of other 
covariates from the regression equations in men and women respectively, suggested 
that CRP levels accounted for 7% and 19% of the variation in plasma tibrinogen 
levels, BMI accounted for 9% and 2% in men and women, respectively. 
DISCUSSION 
The polymorphisms of (X- and R-fihrinogen were studied in the Inuit, a population 
with a low incidence of ischaemic heart disease (20). We observed different allele 
frequencies of the polymorphisms of the fibrinogen chain, with lower frequencies of 
rare A 4" and B2 alleles of the 6-librinogen polymorphisms and higher frequencies 
of the rare T2 allele of the a-fibrinogen polymorphism when the Inuit were 
compared with Caucasian populations. In this study and other studies, the A ~''. B2 
and Tl alleles are associated with higher fibrinogen levels suggesting that their 
lower frequency among the Inuits may explain in part their lower incidence of 
ischaemic heart disease. 
The Inuit are a population with very few genetic influences from other populations. 
This isolation has resulted in some genetic differences in blood groups (ABO, rheslis 
and MN blood group system), HLA system and red cell enzymes (review: 32). it 
might therefore also be possible that the tibrinogen gene locus has developed 
differently from that in Caucasians and has another allelic distribution. To study a 
possible genetic difference of the fibrinogen genes in the Inuit, we assessed the 
linkage disequilibrium between the polymorphisills. The association between Taql 
and the polymorphisms of the {l-tibrinogen gene was different in the Inuit. In the 
Caucasian populations there was no correlation between the Ci- and {l-tibrinogen 
polymorphisms. In the Inuit, however, we found linkage between these 
Table 3 Mean (SEM) of plasma fibrinogen levels (gIL)(functional and immunological methods) in Inuit with different genotypes of 
GI A 455, Bell and Taql fibrinogen polymorphisms. 
A. Functional assay 
WHOLE GROUP MEN WOMEN 
n* mean SEM** n' mean SEM** n* mean SEM*' 
GIA455 GIG455 93 2.69 0.05 44 2.58 0.Q7 49 2.75 0.06 
GIA455 26 2.86 0.10 12 2.93$ 0.13 14 2.95 0.11 
A/A-455 0 0 0 
&1I BIBI 101 2.70 0.05 46 2.63 0.06 55 2.70 0.05 
BIB2 22 2.85 0.11 10 2.94 0.14 12 2.96 0.12 
B2B2 0 0 0 
Taql TITI 25 2.79 0.10 13 2.77 0.14 12 2.77 0.12 
TlTI 71 2.72 0.06 27 2.66 0.10 44 2.78 0.06 
TITI 17 2.59 0.13 8 2.45 0.17 9 2.78 0.14 
B. Immunological assay 
WHOLE GROUP MEN WOMEN 
n' mean SEM** n' mean SEM** n* mean SEM*' 
GIA-455 GIG-455 93 2.78 0.06 44 2.63 0.08 49 2.86 0.08 
G/A-I55 26 2.86 0.12 12 2.98$ 0.14 14 2.92 0.15 
AiA-I55 0 0 0 
&11 BIBI 101 2.79 0.06 46 2.69 0.08 55 2.84 0.08 
BIB2 22 2.86 0.13 10 2.99 0.18 12 2.92 0.16 
B2B2 0 0 0 
Ta'll TITI 25 2.79 0.13 13 2.77 0.17 12 2.79 0.16 
TlTI 71 2.76 0.08 27 2.71 0.12 44 2.80 0.09 
TITI 17 2.90 0.15 8 2.69 0.21 9 3.15 0.19 
n* numbers of individuals evaluated 
** standard error of the mean 
§ levels are significantly different from GIG"",55 (p<0.05 in ANOVA) 
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polymorphisms. 
In the total Inuit group no signiticant relation could be 'found between fibrinogen 
levels and genotypes of the iJ-fibrinogen genes. However, we observed increased 
fibrinogen levels in Inuit men with the BIB2 and GIA455 genotypes, when we 
compare them with the men with genotypes BIBI and G/G~55. In women, no 
significant associations were found, although we found a similar trend. As the 
percentage of smokers in the Inuit was ±97%, Ollf observation that there is a 
correlation between genotype and fibrinogen level in the Inuit might corroborate the 
theory of Green et aJ!' that a low grade stimulation of the fibrinogen synthesis, like 
smoking, is expressed more strongly in men with an A 455 allele. The direct 
involvement of iJ-fibrinogen polymorphisms in regulation of fibrinogen expression is 
suggested by a differential binding of nuclear proteins to DNA with G455 or A~" 
(Green, unpublished data). This study also suggests that the fibrinogen levels are 
regulated differently in men and women. 
OUf results may explain the inconsistency that is found in the literature describing 
the relation between fibrinogen levels and fIbrinogen polymorphismsI2-14.17.27,2~. The 
reported studies vary in a number of factors that are known to have an effect on 
plasma fibrinogen levels, like the men/women ratio and the fraction and definition of 
smokers. Furthermore these studies are also inconsistent in the adjustment for 
gender, BMI, smoking status, acute phase status and age. The importance of 
controlling for such factors that affect the plasma tibrinogen levels is clearly 
illustrated by the present study, and thereby we could show a gender difference in 
the association between genetic polymorphisms and plasma levels of tibrinogen. It 
has been stressed before that men and women should not be studied together in 
atherosclerosis research 3J , a statement which seems to be supported by the results of 
our study. 
The role of the B2 and k'55 alleles of the Bell and GIA~" 6-tibrinogen 
polymorphisms in the regulation of the fibrinogen level under conditions that induce 
a low grade innammation merits further investigation. 
REFERENCES 
Meade TW. Brozovic M. Haines APt hnenson 1D, Mellows S, Miller OJ, Norlh MRS, Slirling 
Y, Thompson SO. Haemoslatic function and ischaemic heart dise,\se: Principal results of the 
Northwick Park Heart Study. Lancd 1986;2:533-538 
2 Yarnell JWG, Baker lA, Swednam PM, Bainton D, O'Brien JR, WhitdH~ad PJ, Elwood PC. 
Fibrinogen, viscosity, and white hlood cell count are ma.ior risk factors li'f ischemic heart 
disease. The Caerphilly ami Speedwell Collaboralive Heart Oist'ase Studies. Circulation 
t99 t;83:836-844 
3 Stone MC, Thorp 1M. Plasma fihrinogen - a Ill~ior risk factor. J R Coil Gen Pmc! 
t985;t2:565-569 
4 Wilhelmsen L, Svardsudd K, Korsun-Dengtsen K, Larsson B, Welin L, Tihhlin G. Fihrinogen 
as a risk factor for stroke amI myocardial infarction. N Engl J Mt'u 1984;311 :50 1-505 
5 Heinrich J, BalJeisen L, Schulte H, Assmann G, Van de Loo J. Fibrinogen and tiICtor VII in 
the prediction of coronury risk: Results from the PROCAM stuuy in he:llthy mt'll. Arterioscler 
Thromb 1994; 14:54-59. 
6 Kannel WB. Wolf PA, Castellini WP, O'Agostino RBD. Fihrinogen and ri.~k of curuiovHscular 
disease: The Framingham Study. J Am Meu Assoc 1987; 258: 1183-1186. 
7 Eber B, Schumacher M. Fihrinogen: lis role in Ihe hemoslatic regUlation in atherosclerosis. 
Semin Thromh Hemostas 1993; 19: 104-107. 
8 Smith EB, Thompson WO. Fibrinogen as a factor in atherogenesis. Thrmnh Res 1994;71: 1- J 9 
chapter 11 175 
9 Haverkate F. Thrombosis and disahilities. Advances in Medical Biology 1994;3:81-103 
to Meade TW, Imeson J, Stirling Y. Eftl!cts of changes in smoking and other characteristics on 
clotting factors and the risk of ischaemic heart disease. Lancet 1987; 1 :986-991 
11 Das I. Raised C·reactive protein levels in serum from smokers. Clin chim Acta 1985;153:9-13 
12 Humphries SE, Cook M. Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the 
fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; I: 1452-1455 
13 Thomas AB, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. 
Variation in the promoter region of the fi fibrinogen gene is associated with plasma fibrinogen 
levels in smokers and non-smokers. Thromb Racmost 1991;65:487-490. 
14 Green F, Hamsten A, Blomback M, Humphries S. The role of {3-fibrinogen genotype in 
detennining plasma fibrinogen levels in young survivors of myocardial infarction and healthy 
controls from Sweden. Haemostasis 1993~70:915-920. 
15 Lane A, Humphries SE, Green FR. Effect on transcription of two common genetic 
polymorphisms adjacent to the promoter region of the B-tlbrinogen gene. Thromb Haemost 
1993;69:962 (Abs. 1516). 
16 Baumann RE, Henschen AH. Genetic variation in human BI\ fihrinogen gene promoter 
influences formation of a specific DNA~protein complex with the interleukin 6 response 
element. Thromh Haemostas 1993;69:961 (abs. 1515) 
17 Scarabin p. Bara L, Ricard S. Poirier 0, Camhou JP, Arveiler D, Luc G, Evans AE, Samama 
MM, Cambien F. Genetic variation at the fi-fihrinogen locus in rdation to plasma fibrinogen 
concentrations and risk of myocardial int~1rction. Arterioscl Thromh 1993; 13:886-891 
18 Templeton AR, Sing CF, Kessling A, Humphries S. A cladistic analysis of phenotype 
associations with haplotypes inferred from restriction endonuclease mapping. n. The analysis of 
natural popUlations. Genetics 1988; 120: I 145-1154 
19 Humphries SE, Green FR, Thomas AE, Kelleher CH, Meade TW. Genelic control of plasma 
fibrinogen levels: an example of gene-environment intemction in the etiology of a multifactorial 
disorder. In: Lindsten J and Petlersson U, Eds. Etiology of human disease at the DNA-level. 
Raven Press Ltd. 1991; pp. 115-128. 
20 Dyerberg J. Bang HO. A hypothesis on the development of acute myocardial infarction in 
Greenlanders. Scand J Clin Lah Invest 1982;42:7-13 
21 De Knijff P, Johansen LG, Rosseneu M, Frants RR, Jespersen J, Havekes LM. Lipoprotein 
profile of a Greenland Inuit population. Arterioscler Thromhos 1992; 12: 1371 -1379 
22 Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilihrium across the fihrinogen 
locus as shown by five genetic polymorphisms, G/Am (HadlI), CIT·14~ (Hil/(flUlAtuI), 
T/G+I(.89 (AmIl). and Be/I (fi-fihrinogen) and Ttlql (a-fihrinogen), and their detection by PCR. 
Human Mutation 1994;3:79-81 
23 Jespersen J, Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of 
plasma fibrinogen. Acta Haematol 1982;67:2·7 
24 Chakravarti A, Buetow KH, Antonarakis SE, Waher PG, Boehm CD, Kazazian HH. 
Nonuniform recombination within the human Il-globin gene cluster. Am J Hum Genet 
1984;36: 1239· 1258 
25 Colton T. Interference on Proportions. In: Statistics in Medicine. Boston, USA: Little Brown 
and Company Inc. 1974; pp. 151-188. 
26 Templeton AR. The general relationship hetween avemge effect and average excess. Genet Res 
Camb 1987;49:69·70 
27 Berg K, Kierulf P. DNA polymorphisms at fihrinogen loci and plasma fihrinogen concentration. 
Clinical Genetics 1989;36:229-235 
28 Wiseman SA, Jaye PD, Powdl JT, Humphries SE, Greenhalgh RM. Frequency of DNA 
polymorphisms of the apolipoprotein Band fihrinogen genes in young patients with peripheral 
arterial disease, in Zilla P, Fasol R, Callow A (eds): Applied Cardiov,t.~cular Biology 1989. 
Basel, Karger 1990;1:118-123 
29 Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype 
and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-696. 
30 Aschbacher A, Buetow K, Chung D, Walsh S, Murray J. Linkage disetluilibrium of RFLP's 
associated with a, fi and 'Y fibrinogen predict gene order on chromosome 4. Am J Hum Genet 
1985;37:186A. 
31 Murray JC, Buetow K, Chung D, Aschhacher A. Linkage disequilihrium of RFLPs at the beta 
176 tlhrinnJ,lcn pnlymul'phi)';l1ls in Inuit 
and gamma fibrinogen loci on chromosome 4. Cytogenet Cell Genet 1985;40:707-708 
32 Eriksson AW, Lehman W, Simpson NE. Genetic stm.lies on circumpolar populations, in Milan 
FA (00): The human biology of circumpolar populations. Camhripge, Camhridge University 
Press 1979, pp 81-168 
33 Sing CF, Haviland MB, Templeton AR, Zerha KE, Reilly SL. Biologic'll complexity and 
strategies for finfing DNA variations responsible for inter-individual variation in risk of a 
common chronic disease, coronary artery disease. Ann Med 1992;24:539*547 
177 
CHAPTER 12 
DNA-POLYMORPHISMS OF FIBRINOGEN IN MEN WITH SYMPTOMATIC 
CORONARY HEART DISEASE, 
M.P.M. de Maat l , B. Groenemeier2, J.J.P. Kastelein 2, H. Jansen3, C. Kluft l , on 
behalf of the REGRESS-study group', 
lGaubius Laboratory TNO-PG, Leiden, 'Dept. Internal Medicine III, 'Centre for 
Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research Center, 
Academic Medical Amsterdam and 4 Interuniversity Cardiology Institute, Utrecht, 
the Netherlands 
178 
chapter 12 179 
ABSTRACT 
Increased plasma fibrinogen levels have been identified as a risk indicator for 
myocardial infarction, stroke and thrombosis. Healthy individuals with the rare allele 
of the GfA455 polymorphism of the fibrinogen Bll-chain have higher plasma 
fibrinogen levels than in individuals without this allele. The frequency of this allele 
has been reported to be higher in patients with peripheral arterial disease than in 
healthy individuals. We determined the distribution of the Gf A 455 genotypes in a 
group of 492 men with symptomatic stable coronary heart disease (CHD) and a. 
reference group of 214 healthy men and also we evaluated whether the allele 
frequencies were different in smoking and non-smoking patients or in patients with 
and without a positive family history of coronary artery disease affected The GfA455 
polymorphism of the fibrinogen Bll chain and the Taql polymorphism of the ACI 
chain were determined and the plasma levels of fibrinogen were measured with an 
enzyme immuno assay, 
In our study, we observed no difference in the allele frequencies or linkage 
disequilibrium of the GfA455 and Taql RFLP in the CHD patients and healthy 
individuals. The allele frequencies were comparable in smoking and non-smoking 
patients, and in patients with and without positive family history of coronary artery 
disease, Plasma fibrinogen levels were similar in patients with the 0/0-455 and O/A' 
455 genotype, while patients with the AI A -455 genotype had significantly higher 
fibrinogen levels. Taql polymorphism was not associated with the fibrinogen levels. 
The results of this study suggest that the GfA455 and Taql fibrinogen polymorphisms 
do not predispose to coronary artery disease. 
INTRODUCTION 
There is growing interest in fibrinogen since several epidemiological studies have 
reported on a clear association between elevated plasma levels of fibrinogen and 
increased risk for myocardial infarction l .9 , stroke lO-12 , thrombotic risk in patients with 
venOliS thrombosis 13 and mortality in stable c1audicantsl4, A direct association 
between fibrinogen and thrombotic events is suggested by several mechanisms by 
which elevated fibrinogen might be deleterious, such as by the effect of fibrinogen 
levels on plasma viscosityl5, the growth l6 and migration17 of smooth muscle celis, 
platelet aggregation 18, thrombus size l9 and formation (lnd growth of atherosclerotic 
lesions10, 
The three chains of fibrinogen are encoded by three different genes that are 
located on the long arm of chromosome 4 in a 50 kb cluster21 , Several DNA 
polymorphisms of the three genes have been described2J.2~ and the restriction 
fragment length polymorph isms (RFLP) of the Bll-chain (Ben and GfA4 ") are 
associated with differences in the plasma levels of fibrinogen'J·". Healthy individuals 
who are homozygous for the rare allele of polymorphisms of the Bn-chain have the 
180 fibrinogen polymorph isms ill cnronury hl'art dist'Hse patienl<; 
highest fibrinogen levels; individuals who are homozygous for the common allele 
have the lowest plasma fibrinogen levels while the fibrinogen levels in heterozygotes 
are intermediate23,28-32. 
The G/ A455 polymorphism is located close to the interleukin-6 responsive element 
in the promoter of the Bn-chain. This might suggest an effect of the RFLP on the 
acute phase induced increase of the fibrinogen synthesis. Indications for this 
mechanism come from studies in survivors of a myocardial infarclionJ',~ where the 
association between genotype of the G/ A ~55 polymorphism and plasma fibrinogen 
levels is much stronger in smokers than in non-smokers. In smokers a low level 
increase of a chonic inflammatory status has been suggested by increased levels of 
fibrinogenomvlew: 35 and other acute phase proteins36-3&. 
Fowkes et al" reported that they observed higher frequencies of the rare allele of 
the G/A455 RFLP in patients with peripheral arterial disease than in a healthy 
reference group (frequencies of 0.197 and 0.097, respectively, p<0.005). This 
might suggest that individuals with the rare A 45> allele have a greater tendency to 
develop peripheral arterial disease. A similar predisposition might exist for other 
arterial diseases} like coronary heart disease. 
To assess a possible contribution of the fibrinogen DNA polymorphisms to the 
prevalence of coronary heart disease we studied the frequency and linkage 
disequilibrium of the G/ A 455 and Taq I genotypes in men with coronary heart disease 
and in healthy volunteers; frequencies were also compared in smoking and non-
smoking patients, and in patients with and without a positive family history of CHD. 
We also documented the association between the fibrinogen polymorphism and ~he 
plasma fibrinogen levels in the CHD patients, taking into account smoking habits 
and the acute phase state. 
PATIENTS AND METHODS 
Study design 
REGRESS is a double blind, placebo controlled, multicentre study to assess the 
effect of a two year treatment with the 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitor pravastatin, on progression and regression of angiographically 
documented coronary atherosclerosis in 885 male patients undergoing coronary cine-
arteriography to assess anginal complaints. The patients were below 70 years of age, 
had normal to moderately raised serum cholesterol levels, i.e. between 4.0 and 8.0 
mmollL, and at least one coronary stenosis ;;, 50% (visually assessed). Baseline and 
follow-up coronary arteriograms were analyzed by quantitative computer analysis. A 
number of substudies were performed in addition to the angiographic main study. 
Substudies include: B-mode ultrasound studies of the carotic and femoral arteries, 
ambulatory electro-cardiographic monitoring, specialized lipid research and DNA 
studies. The study was conducted under the auspices of the Interuniversity 
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Table 1. Baseline cha(acteristics of the p(ltients with coronlifY heart discllse (CHD) and the reference 
group. 
CHD patients reference group 
number 679 214 
age (yea,,)(mean (SD)) 55.6 (8.0) 50.0 (7.6) 
DM! (kglm')(mean (SD)) 26.1 (2.6) 25.0 (2.4) 
non-smokers (%) 27% 43% 
ex-smokers (%) 61% 33% 
smokers (%) 12% 24% 
< to cigarettes/day (%) 12% 34% 
10-20 cigarettes/day (%) 60% 25% 
> 20 cigarettes/day (%) 27% 40% 
positive family history of MI (%) 48% 38% 
Cardiology Institute of the Netherlands (ICIN), Utrecht, the Netherlands. Written 
consent was obtained from the patients and the study was performed in accordance 
with the Declaration of Helsinki. 
Subjects 
In the substudy reported here the baseline data of the above-mentioned patients was 
evaluated. DNA was available from 679 patients and from 492 of these patients also 
plasma were available. Information about smoking and family history of coronary 
heart disease was obtained through a questionnaire. The information about smoking 
consisted of the current smoking status and the number of sigarettes smoked per day. 
The family history was considered positive when one of the parents had had a 
myocardial infarction before the age of 60. As a reference a group of 214 healthy 
Dutch men was selected from the general population of Amsterdam, Doetinchem and 
Maastricht, three of the cities that participated in the multicentre patients study. The 
men in the reference group were without history of coronary artery disease and 
comparable to the patient group with respect to age, BMI, smoking habits and lipid 
levels. The baseline characteristics of the patients and the reference group are given 
in table I. 
Assays 
Plasma fibrinogen levels were determined with an enzyme immuno assay that llses 
a monoclonal antibody against the carboxyl terminal end of the fibrinogen A,,-chain 
as the capture antibody (08), and a monoclonal antibody against the amino-terminal 
end of the A,,-chain (YlS) as the tagging antibody". 
C~l'eactive protein levels were determined with an enzyme immune assay, llsing 
182 11hrinot::en poIYn1orphi.'l11s in coronary heart di~"';l~e patients 
rabbit anti-human C-reactive protein (Dako, Denmark) as the catching and the 
tagging antibody. 
The G/A'''' polymorphism of the 3-fibrinogen gene is assessed as described by 
Thomas et al. 24 • Briefly, genomic DNA was amplified by polymerase chain reaction 
(PCR) and incubated with HaeIII restriction enzyme. The DNA fragments were then 
visualized under UV light after separation on 2 % agarose gels with ethidium 
bromide. The rare allele was called the A"" allele. 
Statistical evaluation. The frequencies of the different alleles was assessed by gene-
counting. Linkage disequilibrium between the B3 and A,,-RFLP was calculated as 
described by Chakravarti". The CRP levels were logarithmically transformed 
because they were positively skewed (skewness 2.3). The fibrinogen levels were also 
a little skewed (skewness 1.03); but because similar resuits were obtained with 
untransformed and logarithmically transformed fibrinogen data, the resuits of the 
untransformed calculations are given. The effect of genetic polymorphisms on 
fibrinogen levels was studied using analysis of covariance with age, BMI and eRP 
as covariables. 
RESULTS 
Genetic polymorph isms 
In the patient group the frequency of the A"" allele of the O/A"" RFLP was 0.21, 
with a 95% confidence interval of 0.19-0.23. The frequency of the T2 allele of the 
Taql RFLP was 0.31, with a 95% confidence interval of 0.28-0.33. There was no 
linkage between the two polymorphisms (LI~0.02, X2~0.51, ns). The frequency of 
the A-4lS and 1'2 allele was similar in the non-, ex- and current smokers. The 
frequency of the rare alleles of the O/A"" and the Tllql RFLP did not differ in the 
patients with and without a family history of ischaemic heart disease. 
In the reference group the frequency of the A"'" allele of the 01 A"" RFLP was 
0.22, with a 95% confidence interval of 0.18-0.27. The frequency of the T2 allele 
of the Taql RFLP was 0.25, 'Vith a 95% confidence interval of 0.21-0.30. No 
linkage the two polymorph isms (LI~0.06, Xb 1.44, ns) was observed. In the 
reference group also no differences in the allele frequencies were observed in non-
smoking and smoking men, and men with and without a positive family history of 
ischaemic heart disease. 
Effects of genetic polymol'phisms on the plasma fibrinogen levels 
The individuals who were homozygous for the common G"t.~·~ allele and the 
heterozygotes had comparable plasma fibrinogen levels, while the homozygotes for 
the rare A"" allele had significantly higher librinogen levels (table 2). When the 
smokers and non-smokers were studied separately, an effect of the polymorphism on 
the plasma fibrinogen level, adjusted for age and BMI, was observed only in 
Table 2. Geometrical mean (95% CI) of fibrinogen levels in the three genotypes of the G/A4 " (a) and Taql (b) fibrinogen 
polymorphisms. Fibrinogen levels are adjusted for age and BMI or for age. BMI and CRP. 
GI A"'" RFLP BB chain Taql RFLP Aa chain 
n adjusted for adjusted for n adjusted for 
age, BMI age, BMI, CRP age, EM! 
total group GIG"" 288 3.15 (3.00-3.30) 3.14 (2.99-3.29) TITI 209 3.13 (2.65-3.70) 
G/A"''' 154 3.12 (2.92-3.33) 3.14 (2.94-3.35) TlTI 179 3.24 (3.05-3.44) 
A/A-4S5 16 3.90' (3.18-4.78) 3.89 (3.1l-4.85) TITI 48 2.97 (2.64-3.35) 
never- plus ex-smokers GIG"''' 217 3.05 (2.89-3.22) 3.05 (2.89-3.22) TITI 154 3.07 (2.88-3.27) 
G/A-m III 3.14 (3.01-3.28) 3.15 (2.92-3.40) TlTI 130 3.18 (2.97-3.41) 
A/A-l.55 Il 3.63 (2.85-4.61) 3.87 (2.97-5.04) TITI 37 2.S7 (2.52-3.27) 
current smokers GIG"''' 71 3.45 (3.12-3.80) 3.40 (3.08-3.75) TITI 55 3.35 (2.97-3.77) 
G/A455 43 3.07 (2.70-3.49) 3.12 (2.75-3.53) TlTI 49 3.42 (2.98-3.84) 
AlA -155 5 4.65* (3.20-6.76) 4.08 (2.72-6.13) TITI II 3.30 (2.50-4.25) 
n gives the number of individuals in the groups 
* the fibrinogen level in this group is significantly higher than in the G/G-455 group 
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smokers (table 2). When the fibrinogen levels were also adjusted for CRP, the effect 
of the polymorphism was no longer significant. The Taql RFLP had no effect on the 
fibrinogen level, although there was a trend towards lower levels in the individuals 
who were homozygous for the rare allele. 
DISCUSSION 
In our study the frequencies of the rare alleles of the tibrinogen DNA 
polymorph isms (G/A4 S5 of the B3 chain and Taql of the AOi chain) were comparable 
in the patient group and in the healthy reference group. The frequencies in our study 
(0.21 for G/A4S5 and 0.31 for Taql in the patients and 0.22 for G/A~" and 0.25 for 
Taql in the reference group) were also similar to frequencies that were reported for 
most healthy Caucasian populations (between 0.19 and 0.25 for G/A~'" and between 
0.25 and 0.28 for Taql)23.16. Fowkes et al)) reported a higher frequency of the Bell 
polymorphism of the 83 gene in patients with peripheral arterial disease (PAD) than 
in a healthy control group (0.197 and 0.097, respectively). In view of our results 
with coronary artery patients, this might be typical for PAD. Also the ECTIM 
Study'" did not find different allele frequencies of B3-chain polymorph isms in 
myocardial infarction patients compared to healthy controls. 
If individuals with the rare allele have a greater risk of vascular diseases, they 
may die at an earlier age and therefore relatively less frequently included in studies 
in older individuals. The age distribution in our group was comparable to that in the 
study of Fowkes", which reduces a selection bias by age, however age-related 
mortality differences in the two diseases remain. 
Subgroup analysis on non-smokers, ex-smokers Of current smokers showed no 
differences in the frequencies of the rare alleles of both the GI A ~.'.' and the Taq I 
polymorphism, indicating that there is no increased predisposition to a 
cardiovascular disease in smokers with the A -455 allele. Such a predisposition has 
been suggested in a study in young survivors of myocardial infarction from Sweden 
where the frequency of the rare allele of the GI A 4" RFLP was somewhat lower in 
the non-smokers3l , Subgroup analysis on patients with or without a positive family 
history of CHD also did not reveal different allele frequencies. 
The linkage disequilibrium between the RFLP on the 83 and Arx chains is 
comparable in our CHD patients and the reference group. The linkage is also 
comparable to that described for healthy Caucasian populations2J.lh. 
The relation between the GI A"55 RFLP and the plasma tibrinogen levels is 
different in this patient group from the relationship that has been described for 
healthy volunteers, where the individuals homozygous for G-m have the lowest, 
those homozygous for A-455 the highest and heterozygotes intermediate plasma 
fibrinogen levels2J,2&~J2. In our patients with CHD the hotllozygotes for the rare allele 
had significantly higher plasma fibrinogen levels, but the heter07,ygotes had levels 
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that were comparable with those in homozygotes for the common allele. This 
observation has recenlly also been made in the LETS SludyLl in patients with 
thrombotic disease. In the ECTIM study" a similar pallern appeared, with 
comparable levels in individuals homozygous for the common allele and 
heterozygotes, while only homozygotes for the rare allele had higher levels. 
Fowkes" found no correlation between Bell RFLP and plasma tibrinogen levels in 
patients with peripheral arterial disease in Scotland, in accordance with Wiseman41 
studying a comparable group in England. 
Patients with CHD consistenlly have higher plasma fibrinogen levels than heallhy 
individualsJ6,42 and in several studies associations were observed between the plasma 
level of tibrinogen and the severily of the vascular disease""""". In CHD patients the 
effects of smoking on the plasma tibrinogen levels were smaller than in heallhy 
individualsJ6,42, suggesting a lower reaction to stimuli when the fibrinogen level is 
already increased. The association between Of A 4jj RFLP and the plasma tibrinogen 
levels in the patients is different from that in heallhy individuals, which further 
illustrates that associations that were found in heallhy individuals can not be simply 
transferred to patients. 
When the fibrinogen levels were adjusted for CRP levels the relation between the 
Of A'" RFLP and the plasma tibrinogen levels was weaker and no longer 
significant. There is also a stronger relation between the genotype and the plasma 
fibrinogen levels in smokers than in non-smokers. Since the location of the Of A 4" 
RFLP is close to the promoter of the Bfi-gene it is therefore suggested that the 
induction of the tibrinogen synthesis by the acute phase reaction is, at least parlly, 
associated with the Of A 4" RFLP. 
In summary, we observed no differences in the frequencies or the linkage 
disequilibrium of the OfA4" or Til'll RFLP in the CHD patients and heallhy 
reference group when the patient group was studied as a whole or when the patients 
were studied in subgroups according to their smoking state and family history. The 
association between G/A4H genotypes and plasma fibrinogen levels in the patient 
group was different from the association reported in healthy reference groups but not 
different from the association in other patient groups with vascular disease. 
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SUMMARY AND GENERAL DISCUSSION 
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Several aspects that are related to the role of fibrinogen as a cardiovascular risk 
indicator were studied for this thesis. 
Measurement of fibrinogen 
First of all, the currently available fibrinogen assays were reviewed with special 
attention to their possible contribution to identifying prethrombotic states. The 
clotting rate assays are the most frequently lIsed methods in routine laboratories; 
they specifically measure the functional levels of fibrinogen and they are sensitive to 
some factors that influence the time that is needed for clotting, such as levels of 
fibrin(ogen) degradation products and proteolytic degradation of the fibrinogen 
molecule. The c/ollable protein assay.\' are independent of the clotting rate but 
spuriously high levels can be obtained in the presence of fibrin monomers or early 
degradation products of fibrinogen, that are still clottable. Measurement of clottable 
protein levels can be based on assessment of the amollnt of protein that can clot or 
can be based on the change in turbidity as the resuit of clot formation. The first type 
of method is not frequently used but the turbidity methods are gaining interest 
because they can be automated and performed in combination with a prothrombin 
time. The immunological methods that use polyclonal antibodies are mainly 
performed when a dysfunctional fibrinogen is sllspected. New immunological 
methods that use monoclonal antibodies may be valuable in measuring specific 
fractions of fibrinogen, for example the fraction with the shortest clotting time. All 
available assays have their own characteristics and their value in risk assessment has 
to be compared in future in clinical and epidemiological studies (CHAPTER I). 
In Chapter 2 we evaluated live methods (clotting rate assays with thrombin, 
reptilase and peptidase, immunological assays with polyclonal and monoclonal 
antibodies) to what extent the heterogeneity of the fibrinogen molecule in plasma 
influenced the results and contributed to the notion of different specificity of the 
methods. Several molecular weight (MW) forms of fibrinogen can be detected in 
plasma: the high MW (HMW) form has both carboxyl-terminal parts of the Acx-
chains intact, the low MW (LMW) form has one AQ'-chain intact and the other 
degraded while in the LMW' form both Aex-chains have been degraded. We 
observed that the three forms were detected equally well in an enzyme imllluno 
assay (E1A) with polyclonal antibodies, indicating that this EIA gives an appropriate 
representation of the molar concentration of fibrinogen. The characteristics of the 
three fibrinogen forms were found to differ in clotting rate assays, with the shortest 
clotting time for the HMW form, independent of whether the clotting was initiated 
by thrombin, reptilase or peptidase. The clotting time of LMW was slightly longer, 
and LMW' needed again somewhat longer to clot. The concentration curves of the 
three fibrinogen forms in the three clotting rate assays were not parallel. In 
monoclonal antibody based EfA for HMW +LMW fibrinogen the sensitivity for the 
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HMW forms of fibrinogen was three times higher than the sensitivity for the LMW 
form while the very low molecular weight (LMW') form was scarcely detected. In 
conclusion, the ErA using polyclonal antibodies gave a good illustration of the molar 
fibrinogen concentration, in the functional fibrinogen assays a complex image was 
observed of the different MW forms of fibrinogen and the HMW + LMW EIA was 
most specific for the HMW forms (CHAPTER 2). 
The diagnostic value of each type of assay should eventually be assessed in 
clinical and epidemiological studies. Comparative studies in epidemiological studies 
are outside the scope of this thesis; we did, however, undertake a comparison of 
methods for application in patients with liver cirrhosis. Three methods for measuring 
plasma fibrinogen levels, namely a clotting rate method (Clauss-method), a total 
clottable protein method and an ErA for HMW + LMW tibrinogen, were evaluated in 
patients with mild, moderate and severe cirrhosis of the liver and in healthy 
controls. With each of the three methods, the fibrinogen levels were normal Of 
slightly increased in patients with mild or moderate cirrhosis, whereas the levels in 
severe cirrhotics were decreased. Although the levels of the tibrin(ogen) degradation 
products were increased in the patients with moderate and severe cirrhosis, the levels 
were not that high that they might have disturbed the Clauss assay. We advise the 
use of the Clauss assay to determine the tibrinogen levels in cirrhotic patients, 
because with the three assays comparable plasma tibrinogen levels were observed 
and because the Clauss assay is very reproducible, quick, cheap and easy to perform 
(CHAPTER 3). 
The acute phase reaction and flbl'inogen 
Fibrinogen is an acute phase protein and in several studies the level of tibrinogen 
has been associated with the degree of atherosclerosis. It has further been postulated 
that atherosclerosis is an inflammatory process of the vascular wall. Taken together, 
it might be suggested that the inflammatory state of the vascular wall is retlected by 
increased levels of fibrinogen in patients with coronary heart disease (CHD). Other 
acute phase proteins, like C-reactive protein (CRP) would then also be expected to 
be increased. 
In chapter 4 cultured hepatocytes were lIsed to study the aClite phase reaction in 
vitro. The study focused on HRG suggested to be a negative acute phase protein 
since decreased HRG plasma levels have been observed in patients with an acute 
phase r~1.ction, Decreased HRG levels have been observed in patients with an acute 
phase reaction which suggests that HRG is a negative acute phase protein. We could 
confirm this in a study in cultured hepatocytes from cynomolgus monkeys. HRG 
secretion was decreased dose-dependently by conditioned medium of LPS-stimulated 
monocytes (CM), tumour necrosis factor" (TNP,,) and interleukin I fi (ILl fi). The 
increase of the HRG mRNA levels by TNF" and ILl fi was higher than the increase 
of the secreted HRG. The HRG secretion and the HRG mRNA levels were not 
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affecled by interleukin 6 (IL6). Evaluation of the positive acute phase proteins 
fibrinogen and CRP in the saille model showed that the secretion of both proteins 
was markedly increased by CM. We further observed a down regulation of 
fibrinogen and CRP by TNPa, while fibrinogen was also decreased by ILiB. Both 
positive acute phase reactants showed a marked increase upon addition of IL6. These 
studies suggest the evaluation of IL6 as an important marker for acute phase 
reactions and they warn for complexity due to differences in the regulation of the 
acute phase proteins (CHAPTER 4). 
This difference in regulation of the acute phase proteins was also observed ill vivo. 
We observed increased fibrinogen levels in patients with CHD, but CRP levels were 
comparable in the patient group and healthy controls, rendering the acute phase 
hypothesis less likely. Smoking is known to increase the plasma levels of both 
fibrinogen and CRP in healthy volunteers. We could confirm this in our study, but 
to our surprise smoking increased fibrinogen only in the healthy controls, while CRP 
was increased by smoking both in the patients and the controls. In conclusion, it is 
suggested that the increased fibrinogen levels in CHD might not be the result of an 
acute phase reaction or that the regulation of the acute phase proteins fibrinogen and 
CRP is not parallel (CHAPTER 5). 
In most cross-sectional and prospective epidemiological studies, the parameters are 
measured only in one blood sample. Since fibrinogen, PAl, CRP and histidine rich 
glycoprotein (HRG) are all acute phase proteins, it might be expected that their 
plasma levels show variation due to aClite phase reactions, which might affect the 
required sample size in epidemiological studies or which might require multiple 
sampling in the assessment of habitual levels of individuals. In a longitudinal study 
the relations between intra- and inter-individual variation of these variables were 
investigated for young healthy volunteers. From those data it was determined that in 
epidemiological studies multiple sampling is not required since a relativel~ small 
increase in the number of participants is necessary to compensate for the biological 
variation. For the assessment of a habitual level single sampling is sufficient for 
HRG and PAl, but fibrinogen and CRP will need duplicate sampling to get the 
within-individual variation below an acceptable 10% of the total variation 
(CHAPTER 6). A small pilot study of the placebo period in the healthy volunteers 
and the CHD patients in the tic10pidine study (described in CHAPTER 9) suggests a 
comparable relation between the intra- and interindividual variation (results not 
shown). 
Modulation of plasma fibrinogen levels by medication 
It has been suggested that N-3 fatty acids, when they are administered in 
combination with the antioxidant vitamin E, affect the synthesis of fibrinogen, CRP 
and PAl-I. In our study on healthy young volunteers, however, no effects of either 
fish oil containing vitamin E or vitamin E alone were observed. However, it might 
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be possible that vitamin E and N-3 fatty acids affect the plasma levels of fibrinogen, 
eRP and PAl activity in patient groups, in older individuals or in smokers, who 
might for instance have a low grade acute phase reaction or higher lipid levels and 
increased fibrinogen levels. We conclude that in healthy young volunteers fish oil 
and vitamin E do not affect fibrinogen, CRP and PAl activity (CHAPTER 7). 
Several drugs have been described that can, in addition to their originally intended 
medical effects, decrease the plasma fibrinogen levels. One example is ticlopidine, a 
drug that inhibits the ADP-induced aggregation of blood platelets. Surgical 
procedures induce an increase of the fibrinogen levels, probably by an acute phase 
reaction. If the effect of ticlopidine on fibrinogen is mediated through modulation of 
the acute phase reaction, it might be expected that the acute post surgical fibrinogen 
levels are lower in the patients that are treated with ticlopidine, compared with the 
patients that received placebo. However, there was no difference in post surgical 
fibrinogen levels, indicating that ticlopidine does not innuence the post surgical 
increase of the plasma fibrinogen levels (CHAPTER 8). 
It has been reported several times that ticlopidine can decrease the plasma 
fibrinogen levels in patients with vascular diseases, but no studies into the 
mechanism have yet been performed. The decrease might be a direct effect on the 
fibrinogen synthesis, in which case effects on tibrinogen levels in healthy volunteers 
would be expected. If, however. the action of ticlopidine is through regulation of the 
chronically stimulated low-grade acute phase or through the fibrin(6gen) degradation 
products induced fibrinogen synthesis. then the effect would be much more 
pronounced in patients than in volunteers or only observed in the patients. In this 
study a 0.20 giL (9%) decrease of the tibrinogen levels in patients and a 0.39 giL 
(II %) decrease in healthy volunteers was observed, which makes a clear distinction 
of the suggested mechanisms impossible. However, ollr results suggest the 
occurrence of a disease independent effect on fibrinogen synthesis. A remarkable 
finding was that the effect was only observed in the clotting rate assay and not in the 
HMW + LMW fibrinogen EIA, suggesting that the effect involves a change in the 
quality rather than quantity of fibrinogen. Further analysis is required to elucidate 
the mechanism by which ticlopidine lowers fibrinogen. Also, a genetic contribution 
had been suggested, but no effects could be observed of the genetic polymorphism of 
the tibrinogen B6-chain (CHAPTER 9). 
Another group of drugs that has been reported to be able to decrease the plasma 
fibrinogen levels are the fibrates. In patients that were treated with these drugs for 
high lipid levels, an additional decrease of the functional fibrinogen levels was 
observed. In an attempt to elucidate the mechanism of this decrease, we evaluated 
the effects of gemfibrozil and ciprofibrate on tibrinogen levels, and studied the 
association of the fibrinogen decrease with the lipid lowering effect, effects on the 
acute phase and a genetic contribution. After 12 weeks of treatillent, we observed a 
decrease of the functional fibrinogen levels with gemtibrozil and a stronger decrease 
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with ciprofibrate. However, no associations with changes in lipids, eRP or genetic 
polymorphisms were observed which suggests that there Illust be an additional 
mechanism for the regulation of tibrinogen levels (CHAPTER 10. 
Genetic poiymol'phisms and fibrinogen 
In patients with peripheral arterial disease a higher frequency was observed of the 
rare B2 allele of the Bell RFLP of the B6-chain of tibrinogen. Furthermore, in 
healthy individuals higher plasma tibrinogen levels are associated with the 
occurrence of the rare allele of the tibrinogen B6-chain polymorphisms. Since 
Greenland Inuit are a population with a low incidence of myocardial infarctions, 
despite a "normaltl atherosclerosis level, it might be interesting to study if there 
might be population differences in the characteristics of tibrinogen RFLP. 
Therefore, we studied the tibrinogen polymorph isms of the AOi- and B6-genes, the 
linkage disequilibrium between them and their associations with the plasma 
tibrinogen levels. We observed that the frequencies of RFLP of genes for the AOi 
and BB chains of tlbrinogen and the linkage disequilibrium between them were 
different in the Inuit group from what has been described for Caucasian populations. 
In the Inuit the relation between polymorphisms of the tibrinogen B6-chain and the 
plasma fibrinogen levels was comparable to the relations that are known for 
Caucasian populations, with the highest levels in the individuals that are hOlllozygous 
for the rare allele of the BIl-chain RFLP. The relation was stronger in men than in 
women. The higher frequencies in Inuit of the alleles that are associated with lower 
fibrinogen when compared to the Caucasian might suggest that they play a role in 
differences in CHD in the Inuit (CHAPTER II). 
The higher frequency of the B2 allele in peripheral arterial disease might suggest a 
possible role for the RFLP in the gene of the tibrinogen B6-chain in other vascular 
diseases. Therefore, the allele frequencies and linkage disequilibriulll of fibrinogen 
polymorphisms were studied in Illen with symptomatic CHD in relation to the 
frequencies in healthy individuals. We found no differences in the frequency of 
alleles or the linkage between RFLP of the AOi and B6-chains of fibrinogen. 
Subgroup analysis according to smoking habits or family history of CHD also 
showed no frequency differences. The plasma fibrinogen levels were comparable in 
patients that were heterozygote or homozygote for the common allele of the BB-
chain RFLP, while patients homozygous for the rare allele had higher fibrinogen 
levels. This effect was only significant in smokers. Therefore we concluded that in 
this study there is no indication for a relation between B6-tibrinogen RFLP and 
CHD (CHAPTER 12). 
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The overall objective of this thesis has been to invcsti~ate different aspects of 
fibrinogen in its role as risk indicator for vascular events. At present, not sufJ1cient 
information is available to definitively decide whether fibrinogen is a risk indicator 
for vascular diseases and vascular events and lor whether it plays a 
pathogenetic/etiological role in the development of disease. It is also conceivable that 
initial elevations in fibrinogen mark the existence of a continued tissue repair process 
and inllammation and that persistence of elevated fibrinogen contributes to 
progression of the disease. It is also possible that the role of elevated fibrinogen is 
different for the different forms of vascular disease such as peripheral arterial 
disease, atherosclerosis and acute thromboembolic events such as myocardial 
infarction. Based, among others, on the results of the ECAT Angina Pectoris Study, 
it has been argued by Haverkate that inflammatory factors, stich as fibrinogen, might 
be a marker for the occurrence of atherosclerotic disease and may at the sallle time 
playa causal role in thromboembolic complications of slIch diseases, 
Assays of fibrinogen: discussion and conclusions 
The first aspect that was considered was the measurement of the plasma fibrinogen 
level. In the last decade, experts have had difficulties in defining what tibrinogen is 
since there is a large heterogeneity in the circulating tibrinogen molecules, with 
estimates of lcr different fibrinogen molecules. This heterogeneity creates a problem 
for the assay methodology. The uncertainty mentioned above about the role of 
fibrinogen in vascular diseases makes it at present impossible to select those aspects 
of fibrinogen that should be assayed for optimal prediction of risk. It is a fact that 
different types of assays have been used in the various epidemiological studies and 
that all showed a predictive value. Until now, only one direct comparison of 
different methods in one study has been reported: in the Caerphilly and Speedwell 
Studies the predictive value of a nephelometric assay was signillcantly larger than 
the Clauss assay (2nd International Symposium on Fibrinogen and Cardiovascular 
disease, November 1994, Edinburgh), Further comparative studies need to be 
performed and such study will inform us firstly about the aspect of tibrinogen that is 
most important and secondly, it will indicate which assay should be lIsed for optimal 
prediction. For such a comparison a selection of a set of assays that each represent 
different aspects of fibrinogen can be proposed. Our analysis of existing methods, 
including a recent assay that uses monoclonal antibodies, revealed more than 
expected differences between assays in the specificity for fractions of fibrinogen. 
If fibrinogen is a risk factor because more tibrinogen gives more substrate to form 
a clot, it is expected that the clottable protein assays will give the data that directly 
represents the cardiac risk. If the clotting rate of fibrinogen is important for cardiac 
risk clotting rate assays are indicated but might also reslilt in choosing the 
HMW + LMW EIA for the assessment of the fibrinogen levels, since this EIA 
mainly detects the HMW form, which has the highest clotting rate, If, however, the 
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plasma fibrinogen level is a risk marker that retlects the chronic intlammatory state 
of the vascular wall, it could be a choice measure the molar fibrinogen 
concentration, for example by using polyclonal antibody-based immunological 
methods or to measure the HMW fraction, which is most probably the form in 
whcih fibrinogen is newly synthesized. The fibrinogen that is synthesized as a result 
of the acute phase is HMW fibrinogen, with a short clotting time. Therefore, using 
functional assays might also provide good marking in inflammatory states. 
Furthermore, also the effect of fibrinogen on the blood viscosity, its stimulating 
effect on smooth muscle celis, its association with platelet aggregation or its role in 
plaque formation might be the mechanism behind the relation between the fibrinogen 
levels and the risk for vascular events. These possible mechanisms would each be 
best represented by a different assay (CHAPTER 1,2,3). 
Next to assays for the molar concentration of total fibrinogen, no assays specific 
for intact or degraded forms of tibrinogen could be evaluated as yet, but are desired. 
It was a surprise that the functional property, the clotting rate, was a complex 
function of the various molecular forms when in mixture and thus should be 
evaluated as such. The importance of assay choice was illustrated further in this 
thesis when effects of ticlopidine on fibrinogen were only observed with a clotting 
rate assay and not with an enzyme immullo assay for HMW plus LMW fibrinogen. 
It is a conclusion from our studies that further 3.ttention should be paid to 
definition of assay specificity and that additional assays for specitic fractions and 
specific functions of fibrinogen are required for research. For each vascular disease 
and clinical question a rationally designed comparison of assays will provide 
information about pathogenetic mechanisms and which assay is the best for 
predictive purposes. Future research in the field of fibrinogen assays might therefore 
concentrate on a) comparison of the different tibrinogen assays in epidemiologicaf 
studies to compare their capacity to predict (venous or arterial) thrombotic risk and 
b) the identification of the mechanism of the association between fibrinogen and 
thrombotic risk will probably make it necessary to develop a new fibrinogen assay, 
since the available methods have a number of restrictions 
Mechanisms of elevation of fibl'inogen 
Only the acute phase reaction and induction of librinogen synthesis by fibrin(ogen) 
degradation products and hormones are biochemically defined regulatory 
mechanisms which might be involved in the elevation of fibrinogen. 
To evaluate the role of these mechanisms we determined in variolls studies the 
acute phase condition extensively (IL6, fLIn, TNF", CRP) or more limited (CRP, 
fibrin(ogen) degradation products) in relation to the effects on the synthesis or 
condition of tibrinogen. We performed cross-sectional patient studies, analyzed 
effects of medication and followed the acute phase reaction during surgery. A 
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general conclusion is that the acute phase reaction and fibrin(ogen) degradation 
products do not seem to explain the changes in the plasma fibrinogen levels or to 
correlate with it, suggesting strongly the occurrence of anbther (as yet unknown and 
speculative) mechanism for elevation of fibrinogen. Observations in cultured primary 
hepatocytes showed a difference in regulation of CRP and fibrinogen by cytokines, 
which reduces the power of conclusions on the role of the acute phase reaction 
concluded on levels and changes in eRP. Also in cross-sectional analysis of patients 
awaiting a PTCA it was observed that differences occurred in relations between 
fibrinogen, eRP and cytokines when non-smoking and smoking patients were 
compared with non-smoking and smoking healthy individuals. Therefore as a first 
approach it is required to further underscore the above conclusion about another 
mechanism, with analysis of cytokines and other acute phase proteins in a number of 
the studies that we have performed and in other patient groups. Next a thorough 
study into the putative new mechanisms that influence the fibrinogen synthesis is 
indicated. From our studies it can be concluded that it is not related to lipid 
metabolism since lipid lowering and tlbrinogen changes were clearly dissociated in 
two of our studies. We observed no difference in the postoperative increase of the 
plasma fibrinogen levels when we compared patients who received placebo with 
those who were treated with ticiopidine, which makes it unlikely that tic\opidine 
regulates the acute phase induced tlbrinogen synthesis (CHAPTER 7). Treatment of 
hyperlipemic patients with fibrates resulted in a decrease of the fibrinogen levels. 
The C-reactive protein levels were normal in these patients, not affected by the 
fibratc treatment and changes in fibrinogen were not related to changes in eRP 
(CHAPTER 10). 
We also observed effects of ticlopidine in healthy volunteers which suggests that 
the baseline plasma fibrinogen levels (or function) were affected. A ciue might be 
found in the fact that the clotting rate of fibrinogen can be changed independently 
from levels of HMW and LMW fibrinogen (see chapter 9) suggesting the possibility 
that an important qualitative/functional change in the fibrinogen moiety is possible. 
Further studies should certainly take the aspect of molecular heterogeneity of 
fibrinogen and related assay methodology into account. Further studies on the 
mechanism of regulation of fibrinogen synthesis needs to concern a) analysis of the 
complexity of the relation between fibrinogen decrease by medication and the aClite 
phase reaction or FDP, for example by the measurement of the cytokines IL6, ILlIl 
and TNFa and b) the other, yet unidentified mechanisms that are involved in the 
regulation of the fibrinogen decrease by medication, for example a direct effect 011 
hepatocytes, possible via effects on signal transduction. 
Genetic studies on fibrinogen 
When elevated fibrinogen levels plays an etiological role in vascular diseases it 
can be expected that also genetically determined elevations might contribute. In this 
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respect, the report of Fowkes et al about a higher frequency in British patients with 
peripheral arterial disease of the rare allele of the G/ A 4\\ fibrinogen B6-chain 
polymorphism is of considerable interest, especially since this A-m allele is 
associated with higher plasma fibrinogen levels. Our analysis of Dutch men with 
anginal complaints and documented coronary artery disease showed no such 
difference at all. This either ind~cates a difference between populations or a 
difference between Ihe type of vascular disease. It strongly suggests to repeat the 
analysis reported by Fowkes et al on Dutch patients with peripheral arterial disease, 
and lor to foclis analysis on well-defined patient groups in order to obtain information 
about the vascular complications/diseases that are "sensitive" of genetically increased 
fibrinogen levels. We confirmed a relationship between genotypes of B6-chain 
fibrinogen polymorphisms and plasma fibrinogen levels in healthy volunteers 
(chapter 6,11). However, relationships between genetic background and fibrinogen 
levels depended upon other fibrinogen determinants, stich as gender and smoking 
habits. Apparently in patients who as a result of their disease have increased 
fibrinogen levels, the effect of the fibrinogen polymorphisms on the plasma 
fibrinogen levels are weakened Of even overruled. 
In conclusion, the characteristics of fibrinogen polymorphisms are different in 
healthy populations with different cardiovascular risks and in healthy volunteers and 
CRD patients, which indicates a desire for further research. Since in the Inuit the 
genetics of the fibrinogen genes are in a direction that might suggest a contribution 
of fibrinogen polymorphisms in the reduced risk of cardiac events, research into 
different populations with different cardiac risks might give further information. In 
CRD patients no effect of genetics is observed, and therefore future research might 
concentrate on other disease populations, e.g. patients with unstable angina that 
either do or do not have complications. 
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Voar dit proefschrift werden verschillende aspecten van de rol van tibrinogeen als 
risicofactor voar hart- en vaatziekten bestudeerd. 
Meting van fibrinogeen 
In HOOFDSTUK I worden de momenteel beschikbare tibrinogeenbepalingen 
besproken, waarbij speciaal de aandacht uitging naar de bijdrage van de 
respectievelijke bepalingen bij het vaststellen van thrombofilie. De slolsnelheids-
bepalillgell worden het meest frequent gebruikt in routine laboratoria; deze 
bepalingen meten specifiek het fUl1ctionele f1brinogeen gehalte en zijn gevoelig voar 
factoren die de stolsnelheid be'invloeden, zoals daar zijn de tibrin(ogeen) afuraak 
produkten en enzymatische atbraak van het tibrinogeen molekuul. De .wolbaar eiwil 
bepalingen zijn onafhankelijk van de snelheid van stoiselvonning, maar te hoge 
gehaltes worden gevonden in de aanwezigheid van I1brine mOilomeren of vroege 
afuraakprodukten van fibrine. De meting van stolbaar eiwit kan geschieden via het 
bepalen van de hoeveelheid eiwit die stolt of gebruikt de veran<lering in turbiditeit 
die optreedt als gevolg van de stolling. Deze eerste methode wordt nauwelijks 
gebruikt maar er komt steeds meer aandacht VOCf de turbiditeitsmctingen omdat deze 
kunnen worden geautomatiseerd en omdat ze kunnen worden gecombineerd met de 
prothrombine-tijd. De il1l111111l0/ogis('/1l' methoden die gebruik maken van polyclonale 
antilichamen worden voornamelijk gcbruikt als er cen disfullctioneel fibrillogeen 
wordt verwacht. De immunologische method en die specil1eke monoclonale 
antilichamen gebruiken kunnen waardevol zijn in het identificeren van specifieke 
fracties van tibrinogeen, bijvoorbeeld de fractie die het snelst stolt. De verschillende 
methoden hebben ieder hun eigen karakteristieken en waarde in risico-vaststelling en 
de waarde van de verschillende methoden moet worden bestudeerd in 
epidemiologische studies. 
In HOOFDSTUK 2 werden van vijl' method en (stolsnelheids-bepalingen met 
thrombine, reptilase en peptidase, iml11ullologische bepalingcn met poly- en 
Illolloclonale antilichamen) geevalueerd in welke mate de heterogeniteit van het 
ftbrinogeenmoiecuui bijdroeg aan de speciticiteit van de verschillende bepalingen. In 
plasma kunnen fihrinogeen moleculen met verschillend moleculair gewicht worden 
waargenomen: de hoog moleculair gelVicht (HMW) VDrm met beide carboxyl einden 
van de Aa-keten intact, de laag MW (LMW) VDrm met een Aa-keten intact en de 
andere afgebroken terwijl bij de LMW' vorm beide Aa-ketens zijn gedegradeerd. 
We constateerden dat de drie vormen even goed werden gemeten met een enzyme 
immuno assay (EIA) die gebruik maakte van poJyclonale antilichamen, hetgeen doet 
vermoeden dat deze EIA een goede weerspiegeling vorml van de molaire fibrinogeen 
concentratie. De drie fibrinogeen vonnen hadden verschillende stoitijden, waarbij de 
HMW vorm de kortste stoltijd gal', onatllankelijk van het enzym dat de stolling in 
gang zette: thrombine, reptilase of peptidase. De stoltijd van LMW wat iets langer 
terwiji LMW' weer wat meer tijd nodig had om Ie stollen. De concentralie curven 
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van de drie fihrinogeen vormen in de dde stoisnelheids-bepalingen waren niet 
parallel. 
In de EIA met monoclonale antilichamen voor de HMW en LMW vormell van 
fibrinogeen was de gevoeligheid waarmee HMW werd gemeten drie keer zo haag als 
die waarmee LMW werd gemeten, lerwijl de test nauwelijks gevoelig was voor 
LMW'. We concludeerden dat de EIA met polyclonale antilichamen een goede 
afspiegeling gaf van de molaire fibrinogeen concentratie, dat' de functionele 
bepatingen met de verschillende MW vormen een complex ileeld te zien gaven en 
dat de HMW + LMW EIA het meest specifiek was voor de HMW vorm, 
De diagnostische betekenis van elk type bepaling dient uileindelijk te worden 
vastgesteld in klinische en epidemioiogische studies. Vergelijkende studies binnen 
epidemiologische onderzoeken Iiggen buiten het bereik van dit proefschrift; we 
hebben wei fibrinogeen methoden vergeleken in patienten met Illilde, gematigde of 
ernstige cirrhose van de lever. In HOOFDSTUK 3 worden drie methoden voor het 
melen van fihrinogeen geevaiueerd, namelijk een stolsnelheids bepaling (Clauss), 
meting van de hoeveelheid stolbaar eiwil en een EIA voor HMW + LMW 
fibrinogeen. Met elk van de drie methoden was het fibrinogeen gehaUe normaal of 
Heht verhoogd in patienten met milde of gematigde eirrhose, terwijl de gehaltes in 
ernstige cirrhose verlaagd waren. Hoewel de gehaUes van tibrin(ogeen) afuraak 
produkten verhoogd waren in patienten met matige en ernstige cirrhose, was deze 
verhoging oiet zodanig, dat hel de Clauss bepaling zou be'invloeden. Wij adviseerden 
om de Clauss methode te gebruikeo bij het meten van tibrinogeen gehaJtes in 
patienten met cirrhose, omdat de drie methoden vergelijkbare fibrinogeen levels gaf 
en omdat de Clauss methode reprodllceerbaar, snel, goedkoop en makkelijk lIit te 
voeren is. 
De acute fase reactic en fibl'inogeen 
Fibrinogeen is een aeute fase eiwit en in verschillende studies is het gchalte van 
fibrinogeen in verband gebracht met de mate van atherosclerose. Verder is 
gesuggereerd (Ross) dat atherosclerose een ontstekingsproces van de vaatwand is. 
Hieruit zou kunnen volgen da! de verhoogde fibrinogeen gehaltes by paticnten met 
coronaire hartziekten (eHD) een weerspiegeling vormen van de ontstekingstoestand 
van de vaatwand. Als da! zo zou zijn, dan is het ook de verwachting dat andere 
acute fase eilVilten, zoals C-reactief eiwit (CRP) verhoogd zal zijn. 
In HOOFDSTUK 4 werden hepatocyten in kweek gebracht om de acute fase 
rcactie in vitro te bestuderen. De studie was gericht op het bestuderen van het 
negatieve acute fase karakter van histidine-rijk glycoproteine (HRG), dat in de 
Iiteratuur werd gesuggereerd door verlaagde plasma HRG gehaUes by patienten met 
een acute fase reaclie. Wij konden di! negatieve acute Hlse gedrag bevestigen in 
gekweekte hepatocyten van makaak apen. De uitscheiding van HRG in het 
kweekmedium werd dosis atllankelijk vedaagd door geconditioneerd medium van 
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LPS-gestimuleerde monocyten (CM), tumor necrosis factor-a (TNFa) en 
interleukine-lG (lUG). De verlaging van de hoeveelheid HRG mRNA was sterker 
dan de verlaging van het nitgescheiden eiwit. De uitscheiding van HRG en de 
hoeveelheid HRG mRNA werden niet beInvloed door interleukine 6 (lL6). Bij 
evaluatie van de positieve acute fase eiwitlen fihrinogeen en CRP in hetzelfde model 
bleek dat de uitscheiding van beide eiwillen duidelijk werd verhoogd door CM. 
Verder werd bemerkt dat fibrinogeen en CRP werden verlaagd door TNFa, waarbij 
fibrinogeen oak werd verlaagd door lUG. De secretie van beide positieve aClite fase 
reactanten werden sterk verhoogd door IL6. Deze studies doen vermoeden dat IL6 
een belangdjke marker is VODr acute fase reacties en ze waarschuwen voar de 
compiexiciteit in de verschillen van de regulatie van aClite fase eiwitten. 
Bij patienten met CHD werden verhoogde fibrinogeen gehaltes gevonden, maar de 
CRP gehaltes waren vergelijkbaar in de patientengroep en de gezonde vrijwilligers, 
hetgecn cen verschil in acute fase tussell deze groepen onwaarschijnlijk maakt. Het 
is bekend dat roken in gezonde vrijwilligers het plasma gehalte van zowel 
fibrinogeen als CRP verhoogd. Wij konden dit bevestigen in deze stud ie, maar lot 
ollze verrassing verhoogde roken het fihrinogeen gehaltc aileen in de vrijwilligers, 
terwijl CRP in beide groepen werd verhoogd. Wij concludeerden daarom dat 
waarschijnlijk de verhoogde fibrinogeen gehaltes bij CHD niet het resultaat zijn van 
cen aClite fase reactie of dat de regulatie van de aClIte fase eiwitten fibrinogeen en 
CRP verschillend is (HOOFDSTUK 5). 
In cen groat deel van de cross-sectionele en prospec;tieve epidemiologische studies 
worden de parameters in slechts een monster gemeten. Omdat fibrinogeen, PAl, 
CRP en HRG acute fase eiwitten zijn zou het kunnen worden verwacht dat hun 
plasma gehaltes variatie vertonen als gevolg van acute fase reacties. Dit ZOli dan 
weer de grootte van de studiepopulatie in epidemiologische studies bei'nvloeden of 
het zou meervoudige bloedafname nodig maken bij het vaststellen van het basale 
gehaUe van een individu. In een longitudinale studie werden de relaties tussen intra-
en interindividuele variatie van deze variabelen bestudeerd in gezonde, jonge 
vrijwilligers. Vit de verkregen gegevens werd geconcludeerd dat in epidemiologische 
studies mcervoudige afname geen duidelijke voordelen biedt daar cen relatief kleine 
vergroting van de studiegroep nodig is om voor de biologische variatie te 
compenseren. Voor de bepaling van de basale level van een individu is eenmalige 
afname valdoende voor de bepaling van HRG en PAl, maar voor fibrinogeen en 
CRP zal meervoudige afname nodig zijn om de intra-individuele variatie binnen een 
acceptabele 10% van de totale variatie te houden (HOOFDSTUK 6). Een kleine pilot 
studie van de placebo peri ode in de gezonde vrijwilligers en de CHD patit!nten in de 
ticlopidine stuclie sLiggereert cen vergelijkbare relatie tussen de intra- en 
interindividuele variatie (resultaten worden niet gegeven). 
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Modulatie van plasma fibl'inogeen gelmltes dOQl' medicatie 
Het is beschreven dat N-3 vetzuren, wanfleer ze worden toegediend in combinatie 
met het antioxidant vitamine-E, de synthese van tibrinogeen, CRP en PAI-i kunnen 
be'invloeden. In onze studie bij gezonde, jonge vrijwilligers werd geen effect van 
vitamine E bevattende vi solie of vitamine E geconstateerd. Dit ZOli kUl1ncn worden 
verklaard door de keuze van de studie-populatie. Het effect zou mogelijk kunnen 
verwacht in individue.n met cen laag niveau ontstekingsreactie, vcrhoogde Iipid-
gehaItes en verhoogde fibrinogeen gehaItes, zoals patienten, oudere mensen of 
rakers. Wij concJuderen dat in gezonde, jonge vrijwilligers vi solie en vitamine E 
geen invloed hebben op fibrinogeen en CRP (HOOFDSTUK 7). 
Van verschillende stoffen is het beschreven dat ze, naast hun belangrijkste 
effecten, oak de plasma fibrinogeen gehaltes verlagen. Een voorbeeld is ticiopidine, 
een medicijn dat de ADP-ge'induceerde aggregatie van bloedplaatjes rem!. Operaties 
zargeo voor eeo verhoging van de fibrinogeen gehaites, mogelijk door. een acute fase 
reactie. Indien aangenomen wordt dat het effect van ticiopidine op fibrinogeen wordt 
geschiedt door modulatie van de acute fase reactie, ZOli worden verwacht dat de 
post-operationele fibrinogeen gehaltes lager zouden zijn in patienten die worden 
vergeleken met ticlopidine dan in patienten die placebo krijgen, In ollze studie was 
er geeo verschil in posl-operationele fibrinogeen gehaites, hetgeen suggereert dat 
ticlopidine geen invloed heeft op de post-operationele stijging van fibrinogeen 
(CHAPTER 8). 
In verschillende studies is gebleken dat ticlopidine de plasma librinogeen gehalies 
verlaagd in patienten met vaatziekten, maar er zijn nog geen studies verricilt naar het 
mechanisme. Het is mogelijk dat de verlaging een direct effect is op de librinogeen 
synthese, hetgeen ertoe zal leiden dal ticlopidine de tibrinogeen gehaJtes van 
patienten en oak van gezonde vrijwilligers ZOU verlagen, Indien ticlopidine de 
regulatie van fibrinogeen synthese door de acute t:1se of de TDP-pradukten 
be'invloed, zou het effect sterker zijn in patienten dan in vrijwilligers, In onze studie 
werd fibrinogeen 0.20 giL (9%) verlaagd in de gezonde vrijwilligers en 0.39 giL 
(11 %) in gezonde vrijwilligers, hetgeen een duidelijk onderscheid van de 
gesuggereerde mechanismen ollmogelijk maakt. Onze resuitaten sllggereren een 
ziekte-onafhankelijk effect op de librinogeen-synthese. Een opmerkelijke bevinding 
was dal hel effect aileen werd waargenomen met de Clallss-bepaling en nie! met de 
HMW + LMW fibrinogeen ElA, hetgeen suggereert dat het effect een verandering in 
de kwaliteit in plaats van de hoeveelheid zou kunnen zijll. Verdere analyse is nodig 
am dit Ie bestuderen. Verder ZOti een genetische bijdrage een ral kunnen speien, 
maar in deze studie werden geen effecten van het genetische polymorlisme van de 
librinogeen Bfl-keten (HOOFDSTUK 9). 
De fibraten vormen andere groep medicijnen waarvan bekend is dat ze tibrinogeen 
verlagen, In patienten die werden behandeld met deze me<licijnen omdat ze hoge 
lipid gehaltes hadden, werd een verlaging van de functionele nbrinogeen gehaltes 
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waargenomen. In een paging 0111 het mechanisme van deze verlaging op te helderen, 
werd het effect van gemfibrozil en ciprofibraat of fibrinogeen gehaltes bestudeerd. 
De associatie tussen de fibrinogeen verlaging en de lipid verlaging. het effect op de 
acute fase en een genetische bijdrage werden geevalueerd. Na een 
behandelingsperiode van 12 weken was het functionele fibrinogeen gehalte gedaald 
met beide medicijnen. maar het was sterker gedaald met ciprofibraat dan met 
gemfibrozil. Geen associatie werd gevonden met veranderingen in lipiden, CRP of 
genetische polymorfismen, hetgeen sllggereert dat een ander mechanisme het 
fibrinogeen reguleert (HOOFDSTUK 10). 
Genetische polymorfismcn en fibl'inogecn 
In patienten met perifeer vaatlijden werd een hogere frequentie waargenomen van 
het zeldzame B2 a11e1 van het Bell polymorfisme van de BB keten van fibrinogeen. 
Ook werden in gezonde vrijwi11igers hogere plasma fibrinogeen gehaltes 
waargenomen in individuen met het zeldzame allel van de fibrinogeen BB keten 
pOlymorfismen. Daar Groenlandse Inuit een lage incidentie hebben van myocard 
infarcten, ondanks cen "normaal" atherosclerose gehaite, waren wij ge'interesseerd 
naar de populatie verschillen van de fibrinogeen polymorfismen. Daartoe 
bestudeerden wij de frequenties en de relatie met het fibrinogeen gehalte van de 
polymorfisrnen van de Act en de BIl ketens van fibrinogeen. In de Inuit waren er 
verschillen in de frequentie van de RFLP en de l,inkage wanneer ze werden 
vergeleken met Caucasische populaties. De relatie tussen de RFLP en de plasma 
gehaltes was hetzelfde in de Inuit en in de Caucasiers. met de hoogste gehaltes in 
degenen die het zeldzame a11el van de BB-keten polymorfismen bezitten. Deze relatie 
was sterker in mannen dan in vrouwen. De hogere frequentie in de Inuit an de 
allelen die worden geassocieerd met een lager fibrinogeen zou kunnen suggereren 
dat ze een ral spelen in de verschillen in CHD in de Inuit (CHAPTER 11). 
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Toft, Else Bladjberg, Liddy Larsen: Ihanks for the discussions and Ihe collaboralion 
in Ihe Inuil Sludy, especially for Ihe help wilh Ihe Danish com puler programs and 
questionnaires. 
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Alf Arnold, de andere cardioiogen en de medewerkers van het Medisch Centrum 
Alkmaar, de cardiologen van het AZR en de medewe(kers van de Bloedbank in 
Rotterdam voor hun gastvrijheid tijdens het Ticlopidine-onderzoek. 
De samenwerking met Haye Knipscheer, Bjorn Groenemeier, Paul Reimer, John 
Kastelein en Hans Jansen in de Cipro studie en in de Regress studie was erg prettig 
hoewel ik nog steeds weinig van lipid en afweet (en jullic van fibrinogeen vermoed 
ik). 
Anneke Pietersma, Wim Sluiter en Marcel Kofflard bedankt voor de bijdrage aan de 
PTCA-studie. 
Arie Timmerman, Jan Staal en hun collega's van het RIVM VOOf het isoleren van de 
apelevers en Hans Princen, Allard Kaptein en Elly de Wit bedankt voor de 
samenwerking met de hepatocyten-isolaties en het gezelschap tijdens de hepatocyten-
weekenden. 
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CURRICULUM VITAE 
De schrijfsler van dit proefschrift is geboren op 14 mei 1960 Ie Rosmalen. Na hel 
doorlopen van hel AIheneum-B Ie Vlaardingen werd de HBO-B opleiding 101 
chemisch medisch analisl gevolgd van 1978 tot 1981 aan het Van 't Hoff Institnut te 
Rotterdam. In jnni 1981 werd een aallSteliing als research analist verkregen bij de 
afdeling Hematologie van het Dijkzigt Ziekenhuis Ie Rotterdam (Hoofd: Prof. J. 
Abels). In 1986 werd overgestapl naar de afdeling Inwendige Geneesknnde II 
(Hoofd: Prof. J.H.P. Wilson). Van 1987 tot 1991 werd de deeltijdopleiding Chemie 
gevolgd aan de Rijksnniversiteit te Utrecht. Het hoofdvak werd verricht bij de 
vakgroep Enzymologie en Protein Engineering (prof. G. H. de Haas) en werd 
praklisch nitgevoerd op het Ganbins Institnnt TNO, te Leiden. Na het behalen van 
hel doctoraalexamen volgde een aanstelling als wetenschappelijk medewerking bij de 
afdeling Inwendige Geneeskunde II van de Erasmus Universiteit Rotterdam. Tijdens 
de studie chemie werd aangevangen met het onderzoek dat in dit proefschrift is 
beschreven en dat voar het grootste deel werd uitgevoerd in het Gaubius 
Laboratorium TNO-PG. Vallaf 1 januari 1994 is de schrijfster tevens verbonden aan 
het Instituut for Thrombosis Research van het South Jutland University Center in 
Esbjerg, Denemarken. 



